

Exhibit B

US010227648B2

(12) **United States Patent**
Hindson et al.(10) **Patent No.:** **US 10,227,648 B2**
(45) **Date of Patent:** **Mar. 12, 2019**

- (54) **METHODS AND SYSTEMS FOR PROCESSING POLYNUCLEOTIDES**
- (71) Applicant: **10X GENOMICS, INC.**, Pleasanton, CA (US)
- (72) Inventors: **Benjamin Hindson**, Pleasanton, CA (US); **Serge Saxonov**, Oakland, CA (US); **Kevin Ness**, Pleasanton, CA (US); **Paul Hardenbol**, San Francisco, CA (US)
- (73) Assignee: **10X GENOMICS, INC.**, Pleasanton, CA (US)
- (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 48 days.

(21) Appl. No.: **15/392,557**(22) Filed: **Dec. 28, 2016**(65) **Prior Publication Data**

US 2017/0335385 A1 Nov. 23, 2017

Related U.S. Application Data

(63) Continuation of application No. 14/104,650, filed on Dec. 12, 2013, now Pat. No. 9,567,631.

(60) Provisional application No. 61/737,374, filed on Dec. 14, 2012.

(51) **Int. Cl.****C12Q 1/68** (2018.01)**C12Q 1/6874** (2018.01)**C12Q 1/6806** (2018.01)**C12Q 1/683** (2018.01)(52) **U.S. Cl.**CPC **C12Q 1/6874** (2013.01); **C12Q 1/683** (2013.01); **C12Q 1/6806** (2013.01)(58) **Field of Classification Search**

CPC C12Q 1/6806; C12Q 1/6874; C12Q 2563/149

See application file for complete search history.

(56) **References Cited****U.S. PATENT DOCUMENTS**

2,797,149 A 6/1957 Skeggs
 3,047,367 A 7/1962 Kessler
 3,479,141 A 11/1969 William et al.
 4,124,638 A 11/1978 Hansen
 4,253,846 A 3/1981 Smythe et al.
 4,582,802 A 4/1986 Zimmerman et al.
 5,137,829 A 8/1992 Nag et al.
 5,149,625 A 9/1992 Church et al.
 5,185,099 A 2/1993 Delpuech et al.
 5,202,231 A 4/1993 Drmanac et al.
 5,270,183 A 12/1993 Corbett et al.
 5,413,924 A 5/1995 Kosak et al.
 5,418,149 A 5/1995 Gelfand et al.
 5,436,130 A 7/1995 Mathies et al.
 5,478,893 A 12/1995 Ghosh et al.
 5,489,523 A 2/1996 Mathur
 5,512,131 A 4/1996 Kumar et al.
 5,558,071 A 9/1996 Ward et al.
 5,585,069 A 12/1996 Zanzucchi et al.
 5,587,128 A 12/1996 Wilding et al.
 5,605,793 A 2/1997 Stemmer
 5,618,711 A 4/1997 Gelfand et al.

5,695,940 A 12/1997 Drmanac et al.
 5,700,642 A 12/1997 Monforte et al.
 5,705,628 A 1/1998 Hawkins
 5,708,153 A 1/1998 Dower et al.
 5,736,330 A 4/1998 Fulton
 5,739,036 A 4/1998 Parris
 5,744,311 A 4/1998 Fraiser et al.
 5,756,334 A 5/1998 Perler et al.
 5,834,197 A 11/1998 Parton
 5,842,787 A 12/1998 Kopf-Sill et al.
 5,846,719 A 12/1998 Brenner et al.
 5,846,727 A 12/1998 Soper et al.
 5,851,769 A 12/1998 Gray et al.
 5,856,174 A 1/1999 Lipshutz et al.
 5,872,010 A 2/1999 Karger et al.
 5,897,783 A 4/1999 Howe et al.
 5,900,481 A 5/1999 Lough et al.
 5,942,609 A 8/1999 Hunkapiller et al.
 5,958,703 A 9/1999 Dower et al.
 5,965,443 A 10/1999 Reznikoff et al.
 5,994,056 A 11/1999 Higuchi
 5,997,636 A 12/1999 Gamarnik et al.
 6,033,880 A 3/2000 Haff et al.
 6,046,003 A 4/2000 Mandecki
 6,051,377 A 4/2000 Mandecki
 6,057,107 A 5/2000 Fulton
 6,057,149 A 5/2000 Burns et al.
 6,103,537 A 8/2000 Ullman et al.
 6,133,436 A 10/2000 Koester et al.
 6,143,496 A 11/2000 Brown et al.
 6,159,717 A 12/2000 Savakis et al.
 6,171,850 B1 1/2001 Nagle et al.
 6,172,218 B1 1/2001 Brenner
 6,207,384 B1 3/2001 Mekalanos et al.
 6,258,571 B1 7/2001 Chumakov et al.
 6,265,552 B1 7/2001 Schatz
 6,291,243 B1 9/2001 Fogarty et al.
 6,294,385 B1 9/2001 Goryshin et al.
 6,296,020 B1 10/2001 McNeely et al.
 6,297,006 B1 10/2001 Drmanac et al.
 6,297,017 B1 10/2001 Schmidt et al.
 6,303,343 B1 10/2001 Kopf-Sill
 6,306,590 B1 10/2001 Mehta et al.
 6,327,410 B1 12/2001 Walt et al.

(Continued)

FOREIGN PATENT DOCUMENTS

CN 102292455 A 12/2011
 CN 103202812 A 7/2013

(Continued)

OTHER PUBLICATIONS

Co-pending U.S. Appl. No. 15/933,299, filed Mar. 22, 2018.

(Continued)

Primary Examiner — David C Thomas(74) *Attorney, Agent, or Firm* — Wilson Sonsini Goodrich & Rosati(57) **ABSTRACT**

The present disclosure provides compositions, methods, systems, and devices for polynucleotide processing. Such polynucleotide processing may be useful for a variety of applications, including polynucleotide sequencing.

47 Claims, 8 Drawing Sheets**Specification includes a Sequence Listing.**

US 10,227,648 B2

Page 2

(56)

References Cited

U.S. PATENT DOCUMENTS

6,355,198 B1	3/2002	Kim et al.	8,133,719 B2	3/2012	Drmanac et al.
6,361,950 B1	3/2002	Mandecki	8,137,563 B2	3/2012	Ma et al.
6,372,813 B1	4/2002	Johnson et al.	8,168,385 B2	5/2012	Brenner
6,379,929 B1	4/2002	Burns et al.	8,252,539 B2	8/2012	Quake et al.
6,406,848 B1	6/2002	Bridgham et al.	8,268,564 B2	9/2012	Roth et al.
6,409,832 B2	6/2002	Weigl et al.	8,273,573 B2	9/2012	Ismagilov et al.
6,432,290 B1	8/2002	Harrison et al.	8,278,071 B2	10/2012	Brown et al.
6,432,360 B1	8/2002	Church	8,298,767 B2	10/2012	Brenner et al.
6,485,944 B1	11/2002	Church et al.	8,304,193 B2	11/2012	Ismagilov et al.
6,492,118 B1	12/2002	Abrams et al.	8,318,433 B2	11/2012	Brenner
6,511,803 B1	1/2003	Church et al.	8,318,460 B2	11/2012	Cantor et al.
6,524,456 B1	2/2003	Ramsey et al.	8,329,407 B2	12/2012	Ismagilov et al.
6,569,631 B1	5/2003	Pantoliano et al.	8,337,778 B2	12/2012	Stone et al.
6,579,851 B2	6/2003	Goeke et al.	8,361,299 B2	1/2013	Sabin et al.
6,586,176 B1	7/2003	Trnovsky et al.	8,420,386 B2	4/2013	Ivics et al.
6,593,113 B1	7/2003	Tenkanen et al.	8,461,129 B2	6/2013	Bolduc et al.
6,613,752 B2	9/2003	Kay et al.	8,563,274 B2	10/2013	Brenner et al.
6,632,606 B1	10/2003	Ullman et al.	8,592,150 B2	11/2013	Drmanac et al.
6,632,655 B1	10/2003	Mehta et al.	8,598,328 B2	12/2013	Koga et al.
6,670,133 B2	12/2003	Knapp et al.	8,603,749 B2	12/2013	Gillevet
6,723,513 B2	4/2004	Lexow	8,679,756 B1	3/2014	Brenner et al.
6,767,731 B2	7/2004	Hannah	8,748,094 B2	6/2014	Weitz et al.
6,800,298 B1	10/2004	Burdick et al.	8,748,102 B2	6/2014	Berka et al.
6,806,052 B2	10/2004	Bridgham et al.	8,765,380 B2	7/2014	Berka et al.
6,806,058 B2	10/2004	Jespersion et al.	8,822,148 B2	9/2014	Ismagilov et al.
6,859,570 B2	2/2005	Walt et al.	8,829,171 B2	9/2014	Steeners et al.
6,880,576 B2	4/2005	Karp et al.	8,835,358 B2	9/2014	Fodor et al.
6,884,788 B2	4/2005	Bulpitt et al.	8,871,444 B2	10/2014	Griffiths et al.
6,913,935 B1	7/2005	Thomas	8,889,083 B2	11/2014	Ismagilov et al.
6,929,859 B2	8/2005	Chandler et al.	8,927,218 B2	1/2015	Forsyth
6,969,488 B2	11/2005	Bridgham et al.	8,975,302 B2	3/2015	Light et al.
6,974,669 B2	12/2005	Mirkin et al.	8,986,286 B2	3/2015	Tanghoj et al.
7,041,481 B2	5/2006	Anderson et al.	9,005,935 B2	4/2015	Belyaev
7,115,400 B1	10/2006	Adessi et al.	9,012,390 B2	4/2015	Holtze et al.
7,129,091 B2	10/2006	Ismagilov et al.	9,017,948 B2	4/2015	Agresti et al.
7,138,267 B1	11/2006	Jendrisak et al.	9,029,083 B2	5/2015	Griffiths et al.
7,211,654 B2	5/2007	Gao et al.	9,029,085 B2	5/2015	Agresti et al.
7,268,167 B2	9/2007	Higuchi et al.	9,068,210 B2	6/2015	Agresti et al.
7,282,370 B2	10/2007	Bridgham et al.	9,074,251 B2	7/2015	Steeners et al.
7,294,503 B2	11/2007	Quake et al.	9,080,211 B2	7/2015	Grunenwald et al.
7,297,485 B2	11/2007	Bornarth et al.	9,102,980 B2	8/2015	Brenner et al.
7,316,903 B2	1/2008	Yanagihara et al.	9,150,916 B2	10/2015	Christen et al.
7,323,305 B2	1/2008	Leamon et al.	9,175,295 B2	11/2015	Kaminaka et al.
7,329,493 B2	2/2008	Chou et al.	9,238,671 B2	1/2016	Goryshin et al.
7,425,431 B2	9/2008	Church et al.	9,249,460 B2	2/2016	Pushkarev et al.
7,536,928 B2	5/2009	Kazuno	9,273,349 B2	3/2016	Nguyen et al.
7,544,473 B2	6/2009	Brenner	9,290,808 B2	3/2016	Fodor et al.
7,604,938 B2	10/2009	Takahashi et al.	9,328,382 B2	5/2016	Drmanac et al.
7,608,434 B2	10/2009	Reznikoff et al.	9,347,059 B2	5/2016	Saxonov
7,608,451 B2	10/2009	Cooper et al.	9,388,465 B2	7/2016	Hindson et al.
7,622,280 B2	11/2009	Holliger et al.	9,410,201 B2	8/2016	Hindson et al.
7,638,276 B2	12/2009	Griffiths et al.	9,567,631 B2	2/2017	Hindson et al.
7,645,596 B2	1/2010	Williams et al.	9,574,226 B2	2/2017	Gormley et al.
7,666,664 B2	2/2010	Sarofim et al.	9,637,799 B2	5/2017	Fan et al.
7,700,325 B2	4/2010	Cantor et al.	9,644,204 B2	5/2017	Hindson et al.
7,708,949 B2	5/2010	Stone et al.	9,689,024 B2	6/2017	Hindson et al.
7,709,197 B2	5/2010	Drmanac	9,694,361 B2	7/2017	Bharadwaj et al.
7,745,178 B2	6/2010	Dong	9,695,468 B2	7/2017	Hindson et al.
7,745,218 B2	6/2010	Kim et al.	9,701,998 B2	7/2017	Hindson et al.
7,776,927 B2	8/2010	Chu et al.	9,856,530 B2	1/2018	Hindson et al.
RE41,780 E	9/2010	Anderson et al.	9,951,386 B2	4/2018	Hindson et al.
7,799,553 B2	9/2010	Mathies et al.	9,957,558 B2	5/2018	Leamon et al.
7,842,457 B2	11/2010	Berka et al.	1,001,187 A1	7/2018	Belgrader et al.
7,901,891 B2	3/2011	Drmanac	1,003,026 A1	7/2018	Hindson et al.
7,910,354 B2	3/2011	Drmanac et al.	1,004,111 A1	8/2018	Hindson et al.
7,947,477 B2	5/2011	Schroeder et al.	1,005,372 A1	8/2018	Hindson et al.
7,960,104 B2	6/2011	Drmanac et al.	1,005,998 A1	8/2018	Giresi et al.
7,968,287 B2	6/2011	Griffiths et al.	1,007,137 A1	9/2018	Bharadwaj et al.
7,972,778 B2	7/2011	Brown et al.	1,013,744 A1	11/2018	Bharadwaj et al.
8,003,312 B2	8/2011	Krutzik et al.	1,015,099 A1	12/2018	Giresi et al.
8,008,018 B2	8/2011	Quake et al.	2001/0020588 A1	9/2001	Adourian et al.
8,053,192 B2	11/2011	Bignell et al.	2001/0036669 A1	11/2001	Jedrzejewski et al.
8,067,159 B2	11/2011	Brown et al.	2001/0041357 A1	11/2001	Fouillet et al.
8,101,346 B2	1/2012	Takahama	2001/0044109 A1	11/2001	Mandecki
8,124,404 B2	2/2012	Alphey	2001/0048900 A1	12/2001	Bardell et al.
			2001/0053519 A1	12/2001	Fodor et al.
			2002/0001856 A1	1/2002	Chow et al.
			2002/0005354 A1	1/2002	Spence et al.
			2002/0034737 A1	3/2002	Drmanac

US 10,227,648 B2

Page 3

(56)

References Cited

U.S. PATENT DOCUMENTS

2002/0043463	A1	4/2002	Shenderov	2006/0275782	A1	12/2006	Gunderson et al.
2002/0051971	A1	5/2002	Stuelpnagel et al.	2006/0286570	A1	12/2006	Rowlen et al.
2002/0051992	A1	5/2002	Bridgham et al.	2006/0292583	A1	12/2006	Schneider et al.
2002/0058332	A1	5/2002	Quake et al.	2007/0003442	A1	1/2007	Link et al.
2002/0065609	A1	5/2002	Ashby et al.	2007/0020617	A1	1/2007	Trnovsky et al.
2002/0068278	A1	6/2002	Giese et al.	2007/0020640	A1	1/2007	McCloskey et al.
2002/0089100	A1	7/2002	Kawasaki	2007/0031829	A1	2/2007	Yasuno et al.
2002/0092767	A1	7/2002	Bjornson et al.	2007/0042400	A1	2/2007	Choi et al.
2002/0113009	A1	8/2002	O'Connor et al.	2007/0042419	A1	2/2007	Barany et al.
2002/0119455	A1	8/2002	Chan et al.	2007/0054119	A1	3/2007	Garstecki et al.
2002/0119536	A1	8/2002	Stern	2007/0072208	A1	3/2007	Drmanac
2002/0131147	A1	9/2002	Paolini et al.	2007/0077572	A1	4/2007	Tawfik et al.
2002/0160518	A1	10/2002	Hayenga et al.	2007/0092914	A1	4/2007	Griffiths et al.
2002/0164820	A1	11/2002	Brown	2007/0099208	A1	5/2007	Drmanac et al.
2002/0166582	A1	11/2002	O'Connor et al.	2007/0134277	A1	6/2007	Chen et al.
2002/0172965	A1	11/2002	Kamb et al.	2007/0154903	A1	7/2007	Marla et al.
2002/0175079	A1	11/2002	Christel et al.	2007/0160503	A1	7/2007	Sethu et al.
2002/0179849	A1	12/2002	Maier et al.	2007/0172873	A1	7/2007	Brenner et al.
2003/0005967	A1	1/2003	Karp	2007/0190543	A1	8/2007	Livak
2003/0007898	A1	1/2003	Bohm et al.	2007/0195127	A1	8/2007	Ahn et al.
2003/0008285	A1	1/2003	Fischer	2007/0207060	A1	9/2007	Zou et al.
2003/0008323	A1	1/2003	Ravkin et al.	2007/0228588	A1	10/2007	Noritomi et al.
2003/0022231	A1	1/2003	Wangh et al.	2007/0231823	A1	10/2007	McKernan et al.
2003/0027214	A1	2/2003	Kamb	2007/0238113	A1	10/2007	Kanda et al.
2003/0027221	A1	2/2003	Scott et al.	2007/0259357	A1	11/2007	Brenner
2003/0028981	A1	2/2003	Chandler et al.	2007/0264320	A1	11/2007	Lee et al.
2003/0032141	A1	2/2003	Nguyen et al.	2008/0003142	A1	1/2008	Link et al.
2003/0036206	A1	2/2003	Chien et al.	2008/0004436	A1	1/2008	Tawfik et al.
2003/0039978	A1	2/2003	Hannah	2008/0014589	A1	1/2008	Link et al.
2003/0044777	A1	3/2003	Beattie	2008/0124726	A1	5/2008	Monforte
2003/0044836	A1	3/2003	Levine et al.	2008/0138878	A1	6/2008	Kubu et al.
2003/0075446	A1	4/2003	Culbertson et al.	2008/0213766	A1	9/2008	Brown et al.
2003/0082587	A1	5/2003	Seul et al.	2008/0228268	A1	9/2008	Shannon et al.
2003/0089605	A1	5/2003	Timperman	2008/0241820	A1	10/2008	Krutzik et al.
2003/0104466	A1	6/2003	Knapp et al.	2008/0242560	A1	10/2008	Gunderson et al.
2003/0108897	A1	6/2003	Drmanac	2008/0268431	A1	10/2008	Choy et al.
2003/0124509	A1	7/2003	Kenis et al.	2008/0268450	A1	10/2008	Nam et al.
2003/0149307	A1	8/2003	Hai et al.	2009/0005252	A1	1/2009	Drmanac et al.
2003/0170698	A1	9/2003	Gascoyne et al.	2009/0011943	A1	1/2009	Drmanac et al.
2003/0182068	A1	9/2003	Battersby et al.	2009/0012187	A1	1/2009	Chu et al.
2003/0207260	A1	11/2003	Trnovsky et al.	2009/0025277	A1	1/2009	Takanashi
2003/0215862	A1	11/2003	Parce et al.	2009/0035770	A1	2/2009	Mathies et al.
2004/0063138	A1	4/2004	McGinnis et al.	2009/0048124	A1	2/2009	Leamon et al.
2004/0081962	A1	4/2004	Chen et al.	2009/0053169	A1	2/2009	Castillo et al.
2004/0101680	A1	5/2004	Barber et al.	2009/0068170	A1	3/2009	Weitz et al.
2004/0101880	A1	5/2004	Rozwadowski et al.	2009/0098555	A1	4/2009	Roth et al.
2004/0132122	A1	7/2004	Banerjee et al.	2009/0099041	A1	4/2009	Church et al.
2004/0224331	A1	11/2004	Cantor et al.	2009/0105959	A1	4/2009	Braverman et al.
2004/0258701	A1	12/2004	Dominowski et al.	2009/0118488	A1	5/2009	Drmanac et al.
2005/0019839	A1	1/2005	Jespersen et al.	2009/0134027	A1	5/2009	Jary
2005/0042625	A1	2/2005	Schmidt et al.	2009/0137404	A1	5/2009	Drmanac et al.
2005/0079510	A1	4/2005	Berka et al.	2009/0137414	A1	5/2009	Drmanac et al.
2005/0130188	A1	6/2005	Walt et al.	2009/0143244	A1	6/2009	Bridgham et al.
2005/0172476	A1	8/2005	Stone et al.	2009/0148961	A1	6/2009	Luchini et al.
2005/0181379	A1	8/2005	Su et al.	2009/0155780	A1	6/2009	Xiao et al.
2005/0202429	A1	9/2005	Trau et al.	2009/0155781	A1	6/2009	Drmanac et al.
2005/0202489	A1	9/2005	Cho et al.	2009/0197248	A1	8/2009	Griffiths et al.
2005/0221339	A1	10/2005	Griffiths et al.	2009/0197772	A1	8/2009	Griffiths et al.
2005/0244850	A1	11/2005	Huang et al.	2009/0202984	A1	8/2009	Cantor
2005/0272159	A1	12/2005	Ismagilov et al.	2009/0203531	A1	8/2009	Kurn
2005/0287572	A1	12/2005	Mathies et al.	2009/0264299	A1	10/2009	Drmanac et al.
2006/0002890	A1	1/2006	Hersel et al.	2009/0286687	A1	11/2009	Dressman et al.
2006/0008799	A1	1/2006	Cai et al.	2010/0021973	A1	1/2010	Makarov et al.
2006/0020371	A1	1/2006	Ham et al.	2010/0021984	A1	1/2010	Edd et al.
2006/0040382	A1	2/2006	Heffron et al.	2010/0022414	A1	1/2010	Link et al.
2006/0073487	A1	4/2006	Oliver et al.	2010/0035254	A1	2/2010	Williams
2006/0078888	A1	4/2006	Griffiths et al.	2010/0062494	A1	3/2010	Church et al.
2006/0153924	A1	7/2006	Griffiths et al.	2010/0069263	A1	3/2010	Shendure et al.
2006/0163385	A1	7/2006	Link et al.	2010/0086914	A1	4/2010	Bentley et al.
2006/0177832	A1	8/2006	Brenner	2010/0105112	A1	4/2010	Holtze et al.
2006/0177833	A1	8/2006	Brenner	2010/0113296	A1	5/2010	Myerson
2006/0199193	A1	9/2006	Koo et al.	2010/0120098	A1	5/2010	Grunenwald et al.
2006/0240506	A1	10/2006	Kushmaro et al.	2010/0120369	A1	5/2010	Shenderov et al.
2006/0257893	A1	11/2006	Takahashi et al.	2010/0136544	A1	6/2010	Agresti et al.
2006/0263888	A1	11/2006	Fritz et al.	2010/0137163	A1	6/2010	Link et al.
				2010/0173394	A1	7/2010	Colston, Jr. et al.
				2010/0187705	A1	7/2010	Lee et al.
				2010/0210479	A1	8/2010	Griffiths et al.
				2010/0248237	A1	9/2010	Froehlich et al.

US 10,227,648 B2

Page 4

(56)	References Cited			2013/0203675	A1	8/2013	Desimone et al.	
	U.S. PATENT DOCUMENTS			2013/0210639	A1	8/2013	Link et al.	
				2013/0210991	A1	8/2013	Fonnum et al.	
				2013/0211055	A1	8/2013	Raines et al.	
				2013/0225418	A1	8/2013	Watson	
	2010/0248991	A1	9/2010	Roesler et al.	2013/0225623	A1	8/2013	Buxbaum et al.
	2010/0304982	A1	12/2010	Hinz et al.	2013/0274117	A1	10/2013	Church et al.
	2011/0000560	A1	1/2011	Miller et al.	2013/0296173	A1	11/2013	Callow et al.
	2011/0008775	A1	1/2011	Gao et al.	2013/0343317	A1	12/2013	Etemad et al.
	2011/0028412	A1	2/2011	Cappello et al.	2014/0030350	A1	1/2014	Ashrafi et al.
	2011/0033548	A1	2/2011	Lai et al.	2014/0037514	A1	2/2014	Stone et al.
	2011/0033854	A1	2/2011	Drmanac et al.	2014/0038178	A1	2/2014	Otto et al.
	2011/0053798	A1	3/2011	Hindson et al.	2014/0057799	A1	2/2014	Johnson et al.
	2011/0059556	A1	3/2011	Strey et al.	2014/0065234	A1	3/2014	Shum et al.
	2011/0071053	A1	3/2011	Drmanac et al.	2014/0093916	A1	4/2014	Belyaev et al.
	2011/0086780	A1	4/2011	Colston, Jr. et al.	2014/0120529	A1	5/2014	Andersen et al.
	2011/0092376	A1	4/2011	Colston, Jr. et al.	2014/0155274	A1	6/2014	Xie et al.
	2011/0092392	A1	4/2011	Colston, Jr. et al.	2014/0155295	A1	6/2014	Hindson et al.
	2011/0160078	A1	6/2011	Fodor et al.	2014/0194323	A1	7/2014	Gillevet
	2011/0195496	A1	8/2011	Muraguchi et al.	2014/0199730	A1	7/2014	Agresti et al.
	2011/0201526	A1	8/2011	Berka et al.	2014/0199731	A1	7/2014	Agresti et al.
	2011/0217736	A1	9/2011	Hindson	2014/0206554	A1	7/2014	Hindson et al.
	2011/0218123	A1	9/2011	Weitz et al.	2014/0227684	A1	8/2014	Hindson et al.
	2011/0263457	A1	10/2011	Krutzik et al.	2014/0227706	A1	8/2014	Kato et al.
	2011/0267457	A1	11/2011	Weitz et al.	2014/0228255	A1	8/2014	Hindson et al.
	2011/0281736	A1	11/2011	Drmanac et al.	2014/0235506	A1	8/2014	Hindson et al.
	2011/0281738	A1	11/2011	Drmanac et al.	2014/0242664	A1	8/2014	Zhang et al.
	2011/0287435	A1	11/2011	Grunenwald et al.	2014/0274740	A1	9/2014	Srinivasan et al.
	2011/0305761	A1	12/2011	Shum et al.	2014/0287963	A1	9/2014	Hindson et al.
	2011/0306141	A1	12/2011	Bronchetti et al.	2014/0302503	A1	10/2014	Lowe et al.
	2011/0319281	A1	12/2011	Drmanac	2014/0315725	A1	10/2014	Faham et al.
	2012/0000777	A1	1/2012	Garrell et al.	2014/0315755	A1	10/2014	Chen et al.
	2012/0003657	A1	1/2012	Myllykangas et al.	2014/0357500	A1	12/2014	Vigneault et al.
	2012/0010091	A1	1/2012	Linnarson et al.	2014/0378322	A1	12/2014	Hindson et al.
	2012/0010098	A1	1/2012	Griffiths et al.	2014/0378345	A1	12/2014	Hindson et al.
	2012/0010107	A1	1/2012	Griffiths et al.	2014/0378349	A1	12/2014	Hindson et al.
	2012/0014977	A1	1/2012	Furihata et al.	2014/0378350	A1	12/2014	Hindson et al.
	2012/0015382	A1	1/2012	Weitz et al.	2015/0005188	A1	1/2015	Levner et al.
	2012/0015822	A1	1/2012	Weitz et al.	2015/0005199	A1	1/2015	Hindson et al.
	2012/0071331	A1	3/2012	Casbon et al.	2015/0005200	A1	1/2015	Hindson et al.
	2012/0121481	A1	5/2012	Romanowsky et al.	2015/0011430	A1	1/2015	Saxonov
	2012/0132288	A1	5/2012	Weitz et al.	2015/0011432	A1	1/2015	Saxonov
	2012/0135893	A1	5/2012	Drmanac et al.	2015/0057163	A1	2/2015	Rotem et al.
	2012/0165219	A1	6/2012	Van Der Zaag et al.	2015/0072899	A1	3/2015	Ward et al.
	2012/0172259	A1	7/2012	Rigatti et al.	2015/0111256	A1	4/2015	Church et al.
	2012/0190032	A1	7/2012	Ness et al.	2015/0111788	A1	4/2015	Fernandez et al.
	2012/0190037	A1	7/2012	Durin et al.	2015/0119280	A1	4/2015	Srinivas et al.
	2012/0196288	A1	8/2012	Beer et al.	2015/0218633	A1	8/2015	Hindson et al.
	2012/0208705	A1	8/2012	Steemers et al.	2015/0224466	A1	8/2015	Hindson et al.
	2012/0208724	A1	8/2012	Steemers et al.	2015/0225777	A1	8/2015	Hindson et al.
	2012/0211084	A1	8/2012	Weitz et al.	2015/0225778	A1	8/2015	Hindson et al.
	2012/0220494	A1	8/2012	Samuels et al.	2015/0259736	A1	9/2015	Steemers et al.
	2012/0220497	A1	8/2012	Jacobson et al.	2015/0267191	A1	9/2015	Steelman et al.
	2012/0222748	A1	9/2012	Weitz et al.	2015/0291942	A1	10/2015	Gloeckner et al.
	2012/0231972	A1	9/2012	Golyshin et al.	2015/0292988	A1	10/2015	Bharadwaj et al.
	2012/0252012	A1	10/2012	Armougom et al.	2015/0298091	A1	10/2015	Weitz et al.
2012/0253689	A1	10/2012	Rogan et al.	2015/0299772	A1	10/2015	Zhang	
2012/0297493	A1	11/2012	Cooper et al.	2015/0299784	A1	10/2015	Fan et al.	
2012/0309002	A1	12/2012	Link	2015/0329891	A1	11/2015	Tan et al.	
2012/0316074	A1	12/2012	Saxonov	2015/0337298	A1	11/2015	Xi et al.	
2013/0017978	A1	1/2013	Kavanagh et al.	2015/0353999	A1	12/2015	Agresti et al.	
2013/0018970	A1	1/2013	Woundy et al.	2015/0361418	A1	12/2015	Reed et al.	
2013/0022682	A1	1/2013	Lee et al.	2015/0368638	A1	12/2015	Steemers et al.	
2013/0028812	A1	1/2013	Prieto et al.	2015/0376605	A1	12/2015	Jarosz et al.	
2013/0041004	A1	2/2013	Drager et al.	2015/0376608	A1	12/2015	Kaper et al.	
2013/0046030	A1	2/2013	Rotem et al.	2015/0376609	A1	12/2015	Hindson et al.	
2013/0059310	A1	3/2013	Brenner et al.	2015/0376700	A1	12/2015	Schnall-Levin et al.	
2013/0078638	A1	3/2013	Berka et al.	2015/0379196	A1	12/2015	Schnall-Levin et al.	
2013/0079231	A1	3/2013	Pushkarev et al.	2016/0024558	A1	1/2016	Hardenbol	
2013/0084243	A1	4/2013	Goetsch et al.	2016/0032282	A1	2/2016	Vigneault et al.	
2013/0096073	A1	4/2013	Sidelman	2016/0053253	A1	2/2016	Salathia et al.	
2013/0109575	A1	5/2013	Kleinschmidt et al.	2016/0060621	A1	3/2016	Agresti et al.	
2013/0109576	A1	5/2013	Shuber et al.	2016/0060691	A1	3/2016	Giresi et al.	
2013/0121893	A1	5/2013	Delamarche et al.	2016/0115474	A1	4/2016	Jelinek et al.	
2013/0130919	A1	5/2013	Chen et al.	2016/0122753	A1	5/2016	Mikkelsen et al.	
2013/0157870	A1	6/2013	Pushkarev et al.	2016/0122817	A1	5/2016	Jarosz et al.	
2013/0157899	A1	6/2013	Adler, Jr. et al.	2016/0153005	A1	6/2016	Zhang et al.	
2013/0178368	A1	7/2013	Griffiths et al.	2016/0160235	A1	6/2016	Solodushko et al.	
2013/0189700	A1	7/2013	So et al.	2016/0177359	A1	6/2016	Ukanis et al.	
2013/0203605	A1	8/2013	Shendure et al.					

US 10,227,648 B2

Page 5

(56)	References Cited			GB	2097692	B	5/1985
	U.S. PATENT DOCUMENTS			GB	2485850	A	5/2012
				JP	S5949832	A	3/1984
				JP	S60227826	A	11/1985
2016/0208323	A1	7/2016	Bernstein et al.	JP	2006507921	A	3/2006
2016/0231324	A1	8/2016	Zhao et al.	JP	2006289250	A	10/2006
2016/0244742	A1	8/2016	Linnarsson et al.	JP	2007015990	A	1/2007
2016/0244809	A1	8/2016	Belgrader et al.	JP	2007268350	A	10/2007
2016/0244825	A1	8/2016	Vigneault et al.	JP	2009513948	A	4/2009
2016/0257984	A1	9/2016	Hardenbol et al.	JP	2009208074	A	9/2009
2016/0281160	A1	9/2016	Jarosch et al.	JP	2012131798	A	7/2012
2016/0289769	A1	10/2016	Schwartz et al.	WO	WO-8402000	A1	5/1984
2016/0304860	A1	10/2016	Hindson et al.	WO	WO-9418218	A1	8/1994
2016/0326583	A1	11/2016	Johnson et al.	WO	WO-9419101	A1	9/1994
2016/0348093	A1	12/2016	Price et al.	WO	WO-9423699	A1	10/1994
2016/0376663	A1	12/2016	Brown	WO	WO-9530782	A1	11/1995
2017/0009274	A1	1/2017	Abate et al.	WO	WO-9629629	A2	9/1996
2017/0016041	A1	1/2017	Greenfield et al.	WO	WO-9641011	A1	12/1996
2017/0114390	A1	4/2017	Hindson et al.	WO	WO-9802237	A1	1/1998
2017/0145476	A1	5/2017	Ryvkin et al.	WO	WO-9852691	A1	11/1998
2017/0183701	A1	6/2017	Agresti et al.	WO	WO-9909217	A1	2/1999
2017/0247757	A1	8/2017	Hindson et al.	WO	WO-9952708	A1	10/1999
2017/0260584	A1	9/2017	Zheng et al.	WO	WO-0008212	A1	2/2000
2017/0268056	A1	9/2017	Vigneault et al.	WO	WO-0023181	A1	4/2000
2017/0321252	A1	11/2017	Hindson et al.	WO	WO-0026412	A1	5/2000
2017/0342404	A1	11/2017	Hindson et al.	WO	WO-0043766	A1	7/2000
2017/0343545	A1	11/2017	Hadrup et al.	WO	WO-0070095	A2	11/2000
2017/0348691	A1	12/2017	Bharadwaj et al.	WO	WO-0102850	A1	1/2001
2017/0356027	A1	12/2017	Hindson et al.	WO	WO-0114589	A2	3/2001
2017/0362587	A1	12/2017	Hindson et al.	WO	WO-0189787	A2	11/2001
2018/0008984	A1	1/2018	Bharadwaj et al.	WO	WO-0190418	A1	11/2001
2018/0015472	A1	1/2018	Bharadwaj et al.	WO	WO-0127610	A3	3/2002
2018/0015473	A1	1/2018	Bharadwaj et al.	WO	WO-0231203	A2	4/2002
2018/0016634	A1	1/2018	Hindson et al.	WO	WO-02086148	A1	10/2002
2018/0030512	A1	2/2018	Hindson et al.	WO	WO-0218949	A3	1/2003
2018/0030515	A1	2/2018	Regev et al.	WO	WO-03062462	A2	7/2003
2018/0057868	A1	3/2018	Walder et al.	WO	WO-2004002627	A2	1/2004
2018/0087050	A1	3/2018	Zheng et al.	WO	WO-2004010106	A2	1/2004
2018/0088112	A1	3/2018	Fan et al.	WO	WO-2004061083	A2	7/2004
2018/0094312	A1	4/2018	Hindson et al.	WO	WO-2004065617	A2	8/2004
2018/0094314	A1	4/2018	Hindson et al.	WO	WO-2004069849	A2	8/2004
2018/0094315	A1	4/2018	Hindson et al.	WO	WO-2004091763	A2	10/2004
2018/0112253	A1	4/2018	Hindson et al.	WO	WO-2004102204	A1	11/2004
2018/0179580	A1	6/2018	Hindson et al.	WO	WO-2004103565	A2	12/2004
2018/0195112	A1	7/2018	Lebofsky et al.	WO	WO-2004105734	A1	12/2004
2018/0216162	A1	8/2018	Belhocine et al.	WO	WO-2005002730	A1	1/2005
2018/0258466	A1	9/2018	Hindson et al.	WO	WO-2005021151	A1	3/2005
2018/0258482	A1	9/2018	Hindson et al.	WO	WO-2005023331	A2	3/2005
2018/0265928	A1	9/2018	Schnall-Levin et al.	WO	WO-2005040406	A1	5/2005
2018/0267036	A1	9/2018	Fan et al.	WO	WO-2005049787	A2	6/2005
2018/0274027	A1	9/2018	Hindson et al.	WO	WO-2005082098	A2	9/2005
2018/0282804	A1	10/2018	Hindson et al.	WO	WO-2006030993	A1	3/2006
2018/0327839	A1	11/2018	Hindson et al.	WO	WO-2006078841	A1	7/2006
2018/0340169	A1	11/2018	Belhocine et al.	WO	WO-2006096571	A2	9/2006
2018/0340170	A1	11/2018	Belhocine et al.	WO	WO-2007001448	A2	1/2007
2018/0340171	A1	11/2018	Belhocine et al.	WO	WO-2007002490	A2	1/2007
2018/0340172	A1	11/2018	Belhocine et al.	WO	WO-2007012638	A1	2/2007
2018/0346979	A1	12/2018	Hindson et al.	WO	WO-2007018601	A1	2/2007
				WO	WO-2007024840	A2	3/2007
				WO	WO-2007081385	A2	7/2007
				WO	WO-2007081387	A1	7/2007
				WO	WO-2007084192	A2	7/2007
EP	0249007	A2	12/1987	WO	WO-2007089541	A2	8/2007
EP	0271281	A2	6/1988	WO	WO-2007093819	A2	8/2007
EP	0637996	B1	7/1997	WO	WO-2007111937	A1	10/2007
EP	1019496	B1	9/2004	WO	WO-2007114794	A1	10/2007
EP	1672064	A1	6/2006	WO	WO-2007121489	A2	10/2007
EP	1482036	B1	10/2007	WO	WO-2007133710	A2	11/2007
EP	1841879	A2	10/2007	WO	WO-2007138178	A2	12/2007
EP	1944368	A1	7/2008	WO	WO-2007139766	A2	12/2007
EP	1594980	B1	11/2009	WO	WO-2007140015	A2	12/2007
EP	1967592	B1	4/2010	WO	WO-2007147079	A2	12/2007
EP	2258846	A2	12/2010	WO	WO-2007149432	A2	12/2007
EP	2145955	B1	2/2012	WO	WO-2008021123	A1	2/2008
EP	1905828	B1	8/2012	WO	WO-2008091792	A2	7/2008
EP	2136786	B1	10/2012	WO	WO-2008102057	A1	8/2008
EP	1908832	B1	12/2012	WO	WO-2008109176	A2	9/2008
EP	2540389	A1	1/2013	WO	WO-2008121342	A2	10/2008
EP	2635679	A1	9/2013	WO	WO-2008061193	A3	11/2008
EP	2752664	A1	7/2014	WO			

FOREIGN PATENT DOCUMENTS

US 10,227,648 B2

Page 6

(56) References Cited

FOREIGN PATENT DOCUMENTS

WO WO-2008134153 A1 11/2008
 WO WO-2008150432 A1 12/2008
 WO WO-2009005680 A1 1/2009
 WO WO-2009011808 A1 1/2009
 WO WO-2009015296 A1 1/2009
 WO WO-2009048532 A2 4/2009
 WO WO-2009061372 A1 5/2009
 WO WO-2009085215 A1 7/2009
 WO WO-2009147386 A1 12/2009
 WO WO-2010004018 A2 1/2010
 WO WO-2010033200 A2 3/2010
 WO WO-2010048605 A1 4/2010
 WO WO-2010104604 A1 9/2010
 WO WO-2010115154 A1 10/2010
 WO WO-2010148039 A2 12/2010
 WO WO-2010151776 A2 12/2010
 WO WO-2010117620 A3 2/2011
 WO WO-2011028539 A1 3/2011
 WO WO-2011047870 A1 4/2011
 WO WO-2011056546 A1 5/2011
 WO WO-2011066476 A1 6/2011
 WO WO-2011074960 A1 6/2011
 WO WO-2011140627 A1 11/2011
 WO WO-2012012037 A1 1/2012
 WO WO-2012047889 A2 4/2012
 WO WO-2012048340 A2 4/2012
 WO WO-2012048341 A1 4/2012
 WO WO-2012061832 A1 5/2012
 WO WO-2012083225 A2 6/2012
 WO WO-2012106546 A2 8/2012
 WO WO-2012112804 A1 8/2012
 WO WO-2012112970 A2 8/2012
 WO WO-2012136734 A1 10/2012
 WO WO-2012142611 A2 10/2012
 WO WO-2012148497 A2 11/2012
 WO WO-2012149042 A2 11/2012
 WO WO-2012166425 A2 12/2012
 WO WO-2013019751 A1 2/2013
 WO WO-2013036929 A1 3/2013
 WO WO-2013055955 A1 4/2013
 WO WO-2013096643 A1 6/2013
 WO WO-2013122996 A1 8/2013
 WO WO-2013123125 A1 8/2013
 WO WO-2013126741 A1 8/2013
 WO WO-2013134261 A1 9/2013
 WO WO-2013150083 A1 10/2013
 WO WO-2013177220 A1 11/2013
 WO WO-2013188872 A1 12/2013
 WO WO-2014028537 A1 2/2014
 WO WO-2014053854 A1 4/2014
 WO WO-2014071361 A1 5/2014
 WO WO-2014074611 A1 5/2014
 WO WO-2014093676 A1 6/2014
 WO WO-2014108810 A2 7/2014
 WO WO-2014140309 A1 9/2014
 WO WO-2014144495 A1 9/2014
 WO WO-2014150931 A1 9/2014
 WO WO-2014182835 A1 11/2014
 WO WO-2014189957 A2 11/2014
 WO WO-2014210353 A2 12/2014
 WO WO-2015031691 A1 3/2015
 WO WO-2015044428 A1 4/2015
 WO WO-2015164212 A1 10/2015
 WO WO-2016040476 A1 3/2016
 WO WO-2016061517 A2 4/2016
 WO WO-2016126871 A2 8/2016
 WO WO-2016187717 A1 12/2016
 WO WO-2016191618 A1 12/2016
 WO WO-2016207647 A1 12/2016
 WO WO-2016207653 A1 12/2016
 WO WO-2016207661 A1 12/2016
 WO WO-2017015075 A1 1/2017
 WO WO-2017025594 A1 2/2017
 WO WO-2017053905 A1 3/2017

WO WO-2017075265 A1 5/2017
 WO WO-2017156336 A1 9/2017
 WO WO-2018045186 A1 3/2018

OTHER PUBLICATIONS

Co-pending U.S. Appl. No. 15/975,468, filed May 9, 2018.
 Co-pending U.S. Appl. No. 15/980,473, filed May 15, 2018.
 Co-pending U.S. Appl. No. 15/985,388, filed May 21, 2018.
 Co-pending U.S. Appl. No. 16/000,803, filed Jun. 5, 2018.
 Depristo et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. *Nature Genet* 43:491-498 (2011).
 Han, SW et al. "Targeted Sequencing of Cancer-Related Genes in Colorectal Cancer Using Next-Generation Sequencing" *PLOS One* (2013) 8(5):e64271.
 Lander, et al. Initial sequencing and analysis of the human genome. *Nature*, 409 (Feb. 15, 2001): 860-921.
 Shaikh, et al. A modular microfluidic architecture for integrated biochemical analysis. *Proc Natl Acad Sci U S A*. Jul. 12, 2005;102(28):9745-50. Epub Jun. 28, 2005.
 Holmberg, et al. The biotin-streptavidin interaction can be reversibly broken using water at elevated temperatures. Feb. 2, 2005. *Electrophoresis*, 26:501-510.
 Invitrogen Dynal. Dynabeads M-280 Streptavidin 2006 product sheet.
 Morton. Parameters of the human genome. Apr. 23, 1991. *Proceedings of the National Academy of Sciences of the United States of America*, 88: 7474-7476.
 National Human Genome Research Institute (NHGRI). The Human Genome Project Completion: Frequently Asked Questions. Last Updated: Oct. 30, 2010.
 Qiagen. Omniscript Reverse Transcription Handbook. Oct. 2010.
 Seifert, et al. Microfluidic fabrication of smart microgels from macromolecular precursors. 2010. *Polymer*.
 Wong, et al. Multiplexed Barcoded CRISPR-CAS9 Screening Enabled by CombiGEM. *PNAS*. Mar. 1, 2016, vol. 113, pp. 2544-2549.
 Zhu, et al. Reverse transcriptase template switching: a SMART approach for full-length cDNA library construction. *Biotechniques*. Apr. 2001;30(4):892-7.
 Baret, et al. Fluorescence-activated droplet sorting (FADS): efficient microfluidic cell sorting based on enzymatic activity. *Lab Chip*. Jul. 7 2009;9(13):1850-8. doi: 10.1039/b902504a. Epub Apr. 23, 2009.
 BD. BD Rhapsody™ Single-Cell Analysis System: Analyze hundreds of genes across tens of thousands of single cells in parallel. BD, Becton, Dickinson and Company. BDGM1012 Rev. 1. 2017. 8 pages.
 Buchman GW, et al. Selective RNA amplification: a novel method using dUMP-containing primers and uracil DNA glycosylase. *PCR Methods Appl*. Aug. 1993; 3(1):28-31.
 Co-pending U.S. Appl. No. 15/687,357, filed Aug. 25, 2017.
 Co-pending U.S. Appl. No. 15/687,856, filed Aug. 28, 2017.
 Co-pending U.S. Appl. No. 15/717,840, filed Sep. 27, 2017.
 Co-pending U.S. Appl. No. 15/717,847, filed Sep. 27, 2017.
 Co-pending U.S. Appl. No. 15/717,871, filed Sep. 27, 2017.
 Co-pending U.S. Appl. No. 15/718,764, filed Sep. 28, 2017.
 Co-pending U.S. Appl. No. 15/718,893, filed Sep. 28, 2017.
 Co-pending U.S. Appl. No. 15/719,459, filed Sep. 28, 2017.
 Co-pending U.S. Appl. No. 15/720,085, filed Sep. 29, 2017.
 Dressman et al. Supplementary Information pp. 1-2 of article published 2003, *PNAS* 100(15):8817-22).
 Hosono S, et al. Unbiased whole-genome amplification directly from clinical samples. *Genome Res*. May 2003; 13(5):954-64. Epub Apr. 14, 2003.
 Kamperman, et al. Centering Single Cells in Microgels via Delayed Crosslinking Supports Long-Term 3D Culture by Preventing Cell Escape. *Small*. Jun. 2017;13(22). doi: 10.1002/smll.201603711. Epub Apr. 28, 2017.
 Lienemann, et al. Single cell-laden protease-sensitive microneedles for long-term culture in 3D. *Lab Chip*. Feb. 14, 2017;17(4):727-737. doi: 10.1039/c6lc01444e.

US 10,227,648 B2

Page 7

(56)

References Cited

OTHER PUBLICATIONS

- Lo, et al. On the design of clone-based haplotyping. *Genome Biol.* 2013;14(9):R100.
- Maricic T, et al. Optimization of 454 sequencing library preparation from small amounts of DNA permits sequence determination of both DNA strands. *Biotechniques.* Jan. 2009; 46(1):51-2, 54-7.
- Perrott, Jimmy. Optimization and Improvement of Emulsion PCR for the Ion Torrent Next-Generation Sequencing Platform. (2011) Thesis.
- Shahi, et al. Abseq: Ultrahigh-throughput single cell protein profiling with droplet microfluidic barcoding. *Sci Rep.* 2017; 7: 44447. Published online Mar. 14, 2017. doi: 10.1038/srep44447.
- Skerra A. Phosphorothioate primers improve the amplification of DNA sequences by DNA polymerases with proofreading activity. *Nucleic Acids Res.* Jul. 25, 1992; 20(14):3551-4.
- Stoeckius, et al. Simultaneous epitope and transcriptome measurement in single cells. *Nature methods.* Jul. 31, 2017. Supplemental Materials.
- Co-pending U.S. Appl. No. 15/693,374, filed Aug. 31, 2017.
- 10X Genomics. 10x Genomics Chromium™ Single Cell 3' Solution Utilized for Perturb-seq Approach. Press Release. Dec. 19, 2016. Retrieved from <https://www.10xgenomics.com/news/10x-genomics-chromium-single-cell-3-solution-utilized-perturb-seq-approach/>.
- Adamson, et al. A Multiplexed Single-Cell Crispr Screening Platform Enables Systematic Dissection of the Unfolded Protein Response. *Cell.* Dec. 15, 2016;167(7):1867-1882.e21. doi: 10.1016/j.cell.2016.11.048.
- Adamson et al., "Production of arrays of chemically distinct nanolitre plugs via repeated splitting in microfluidic devices", *Lab Chip* 6(9): 1178-1186 (Sep. 2006).
- Adey, et al. Rapid, low-input, low-bias construction of shotgun fragment libraries by high-density in vitro transposition. *Genome Biology* 11:R119 (2010).
- Brenner, et al. In vitro cloning of complex mixtures of DNA on microbeads: physical separation of differentially expressed cDNAs. *Proc Natl Acad Sci U S A.* Feb. 15, 2000;97(4):1665-70.
- Buenrostro, et al. ATAC-seq: A Method for Assaying Chromatin Accessibility Genome-Wide. *Curr Protoc Mol Biol.*; 109: 21.29.1-21.29.9. doi:10.1002/0471142727.mb2129s109.
- Buenrostro, et al. Single-cell chromatin accessibility reveals principles of regulatory variation. *Nature.* Jul. 23, 2015;523(7561):486-90. doi: 10.1038/nature14590. Epub Jun. 17, 2015.
- Buenrostro, et al. "Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position." *Nat Methods.* Dec. 2013;10(12):1213-8. doi: 10.1038/nmeth.2688. Epub Oct. 6, 2013.
- Caruccio N., Preparation of Next-Generation Sequencing Libraries Using Nextera Technology: Simultaneous DNA Fragmentation and Adaptor Tagging by In Vitro Transposition. Ch. 17 *Methods in Microbiology* 733:241 (2011).
- Chang et al. Droplet-based microfluidic platform platform for heterogeneous enzymatic assays, 2013, *Lab Chip*, 13, 1817-1822 (Year: 2013).
- Clark, et al. Single-cell epigenomics: powerful new methods for understanding gene regulation and cell identity. *Genome Biol.* Apr. 18, 2016;17:72. doi: 10.1186/s13059-016-0944-x.
- Co-pending U.S. Appl. No. 15/825,740, filed Nov. 29, 2017.
- Co-pending U.S. Appl. No. 15/842,550, filed Dec. 14, 2017.
- Co-pending U.S. Appl. No. 15/842,687, filed Dec. 14, 2017.
- Co-pending U.S. Appl. No. 15/842,713, filed Dec. 14, 2017.
- Co-pending U.S. Appl. No. 15/847,659, filed Dec. 19, 2017.
- Co-pending U.S. Appl. No. 15/847,752, filed Dec. 19, 2017.
- Co-pending U.S. Appl. No. 15/848,714, filed Dec. 20, 2017.
- Co-pending U.S. Appl. No. 15/850,241, filed Dec. 21, 2017.
- Co-pending U.S. Appl. No. 15/872,499, filed Jan. 16, 2018.
- Co-pending U.S. Appl. No. 15/875,899, filed Jan. 19, 2018.
- Co-pending U.S. Appl. No. 15/887,711, filed Feb. 2, 2018.
- Co-pending U.S. Appl. No. 15/887,947, filed Feb. 2, 2018.
- Cusanovich; et al., "Multiplex single-cell profiling of chromatin accessibility by combinatorial cellular indexing. *Scienceexpress*, May 7, 2014, p. 1-9."
- Cusanovich, et al. Supplementary materials for Multiplex single-cell profiling of chromatin accessibility by combinatorial cellular indexing. *Science.* May 22, 2015;348(6237):910-4. doi: 10.1126/science.aab1601. Epub May 7, 2015.
- Dey, et al. Integrated genome and transcriptome sequencing of the same cell. Dey, Siddharth S. et al. "Integrated Genome and Transcriptome Sequencing from the Same Cell." *Nature biotechnology* 33.3 (2015): 285-289. PMC. Web. Dec. 18, 2017.
- Dixit, et al. Perturb-Seq: Dissecting Molecular Circuits with Scalable Single-Cell RNA Profiling of Pooled Genetic Screens. *Cell.* Dec. 15, 2016;167(7):1853-1866.e17. doi: 10.1016/j.cell.2016.11.038.
- JPK "Determining the elastic modulus of biological samples using atomic force microscopy" (<https://www.jpk.com/app-technotes-img/AFM/pdf/jpk-app-elastic-modulus.14-1.pdf>) 2009, pp. 1-9 (Year: 2009).
- Kolodziejczyk et al., "The technology and biology of single-cell RNA sequencing", *Molecular Cell*, vol. 58 (May 21, 2015).
- Lake, et al. "Integrative Single-Cell Analysis by Transcriptional and Epigenetic States in Human Adult Brain". Apr. 19, 2017. doi: <https://doi.org/10.1101/128520>.
- Lasken, et al. (1996) Archaeobacterial DNA Polymerases Tightly Bind Uracil-containing DNA. *The Journal of Biological Chemistry*, 271(30):17692-17696 (Year: 1996).
- Lee et al. Alginate: Properties and biomedical applications. *Prog Polym Sci* 37(1):106-126 (2012).
- Lennon; et al., "Lennon et al. A scalable, fully automated process for construction of sequence-ready barcoded libraries for 454. *Genome Biology* 11:R15 (2010)."
- Macaulay; et al., "G&T-seq: parallel sequencing of single-cell genomes and transcriptomes. *Nature Methods*, 2015, p. 1-7."
- Macaulay, et al. Single-Cell Multiomics: Multiple Measurements from Single Cells. *Trends in Genetics* 33.2 (2017): 155-168. PMC. Web. Dec. 18, 2017.
- Miller-Stephenson Chemicals 157 FS Series catalog, www.miller-stephenon.com.
- Morimoto, et al. Monodisperse semi-permeable microcapsules for continuous observation of cells. 2009. *Lab Chip* 9(15):2217-2223.
- Narayanan, J. et al. "Determination of agarose gel pore size: Absorbance measurements vis a vis other techniques" *Journal of Physics: Conference Series* 28 (2006) 83-86 (Year: 2006).
- Pott, et al. Single-cell ATAC-seq: strength in numbers. *Genome Biol.* Aug. 21, 2015;16:172. doi: 10.1186/s13059-015-0737-7.
- Preissl, et al. Single nucleus analysis of the chromatin landscape in mouse forebrain development. Posted Jul. 4, 2017. *bioRxiv* 159137; doi: <https://doi.org/10.1101/159137>.
- Sakaguchi, et al. (1996) Cautionary Note on the Use of dUMP-Containing PCR Primers with Pfu and VentR. *Biotechniques*, 21(3): 369-370 (Year: 1996).
- Spormann Laboratory, Polymerase Chain Reaction (PCR), Alfred Spormann Laboratory, 2009, 1-3. (Year: 2009).
- Syed, et al. Next-generation sequencing library preparation: simultaneous fragmentation and tagging using in vitro transposition. *Nature Methods* 2 pgs (Nov. 2009).
- ThermoFisher, Protocols, M-270 Streptavidin, ThermoFisherScientific, 2007, 1-5. (Year: 2007).
- Xia and Whitesides, Soft Lithography, *Angew. Chem. Int. Ed.* 37:550-575 (1998).
- Zhou, Y. et al. "Development of an enzyme activity screening system for p-glucosidase-displaying yeasts using calcium alginate micro-beads and flow sorting" *Appl Microbiol Biotechnol* (2009) 84:375-382 (Year: 2009).
- Abate, et al. Beating Poisson encapsulation statistics using close-packed ordering. *Lab Chip.* Sep. 21, 2009;9(18):2628-31. doi: 10.1039/b909386a. Epub Jul. 28, 2009.
- Abate, et al. High-throughput injection with microfluidics using picoinjectors. *Proc Natl Acad Sci U S A.* Nov. 9, 2010;107(45):19163-6. doi: 10.1073/pnas.1006888107. Epub Oct. 20, 2010.
- Abate et al., Valve-based flow focusing for drug formation. *Appl Phys Lett.* 2009;94. 3 pages.

US 10,227,648 B2

Page 8

(56)

References Cited

OTHER PUBLICATIONS

- Agresti, et al. Selection of ribozymes that catalyze multiple-turnover Diels-Alder cycloadditions by using in vitro compartmentalization. *Proc Natl Acad Sci U S A*. Nov. 8, 2005;102(45):16170-5. Epub Oct. 31, 2005.
- Akselband, "Enrichment of slow-growing marine microorganisms from mixed cultures using gel microdrop (GMD) growth assay and fluorescence-activated cell sorting", *J. Exp. Marine Biol.*, 329: 196-205 (2006).
- Akselband, "Rapid mycobacteria drug susceptibility testing using gel microdrop (GMD) growth assay and flow cytometry", *J. Microbiol. Methods*, 62:181-197 (2005).
- Altamos et al., "Genomic Characterization of Large Heterochromatic Gaps in the Human Genome Assembly," *PLOS Computational Biology*, May 15, 2014, vol. 10, Issue 5, 14 pages.
- Amini, S. et al. "Haplotype-resolved whole-genome sequencing by contiguity-preserving transposition and combinatorial indexing" *Nature Genetics* (2014) 46:1343-1349 doi:10.1038/ng.3119.
- Anna, S.L., et al., "Formation of dispersions using "flow focusing" in microchannels," *Applied Physics Letters*, vol. 82, No. 3, pp. 364-366 (2003).
- Anonymous, "Oligo(dT)25 cellulose beads" NEB (2012) Retrieved from the Internet: <https://www.neb.com/~media/Catalog/All-Products/286CA51268E24DE1B06F1CB2886981354/Datacards%20-%20or%20Manuals/S1408Datasheet-Lot0011205.pdf>.
- Anonymous, "Oligotex Handbook" Qiagen (2012) XP055314680. Retrieved from the Internet: URL: <http://www.qiagen.com/de/resources/download.aspx?id=f9fald98-d54d-47e7-a20b-8b0cb8975009&lang=en>.
- Anonymous: "Viscosity-Basic concepts" (2004) XP055314117. Retrieved from the Internet: URL: [http://lhtc.epfl.ch/webdav/site/lhtc/shared/import/migration/2 VISCOSITY.pdf](http://lhtc.epfl.ch/webdav/site/lhtc/shared/import/migration/2%20VISCOSITY.pdf).
- Attia, et al. Micro-injection moulding of polymer microfluidic devices. *Microfluidics and nanofluidics*. 2009; 7(1):1-28.
- Bodi, K. et al. "Comparison of Commercially Available Target Enrichment Methods for Next-Generation Sequencing" *J Biomolecular Techniques* (2013) 24:73-86.
- Boone, et al. Plastic advances microfluidic devices. The devices debuted in silicon and glass, but plastic fabrication may make them hugely successful in biotechnology application. *Analytical Chemistry*. Feb. 2002; 78A:86A.
- Braeckmans et al., Scanning the Code. *Modern Drug Discovery*. 2003:28-32.
- Bransky, et al. A microfluidic droplet generator based on a piezo-electric actuator. *Lab Chip*. Feb. 21, 2009;9(4):516-20. doi: 10.1039/b814810d. Epub Nov. 20, 2008.
- Brouzes, et al. Droplet microfluidic technology for single-cell high-throughput screening. *Proc Natl Acad Sci U S A*. Aug. 25, 2009;106(34):14195-200. doi: 10.1073/pnas.0903542106. Epub Jul. 15, 2009.
- Carroll, "The selection of high-producing cell lines using flow cytometry and cell sorting", *Exp. Op. Bioi. Therp.*, 4:11 1821-1829 (2004).
- Chaudhary "A rapid method of cloning functional variable-region antibody genes in *Escherichia coli* as single-chain immunotoxins" *Proc. Natl. Acad. Sci USA* 87: 1066-1070 (Feb. 1990).
- Chechetkin et al., Sequencing by hybridization with the generic 6-mer oligonucleotide microarray: an advanced scheme for data processing. *J Biomol Struct Dyn*. Aug. 2000;18(1):83-101.
- Chen, et al. Chemical transfection of cells in picoliter aqueous droplets in fluorocarbon oil. *Anal Chem*. Nov. 15, 2011;83(22):8816-20. doi: 10.1021/ac2022794. Epub Oct. 17, 2011.
- Chokkalingam, et al. Probing cellular heterogeneity in cytokine-secreting immune cells using droplet-based microfluidics. *Lab Chip*. Dec. 21, 2013;13(24):4740-4. doi: 10.1039/c3lc50945a.
- Chou, et al. Disposable Microdevices for DNA Analysis and Cell Sorting. *Proc. Solid-State Sensor and Actuator Workshop*, Hilton Head, SC. Jun. 8-11, 1998; 11-14.
- Christiansen et al. "The Covalent Eukaryotic Topoisomerase I-DNA Intermediate Catalyzes pH-dependent Hydrolysis and Alcoholysis" *J Biot Chem* (Apr. 14, 1994) 269(15):11367-11373.
- Chu, et al. Controllable monodisperse multiple emulsions. *Angew Chem Int Ed Engl*. 2007;46(47):8970-4.
- Clausell-Tormos et al., "Droplet-based microfluidic platforms for the encapsulation and screening of mammalian cells and multicellular organisms", *Chem. Biol*. 15:427-437 (2008).
- Coufal, et al. L1 retrotransposition in human neural progenitor cells. *Nature*. Aug. 27, 2009;460(7259):1127-31. doi: 10.1038/nature08248. Epub Aug. 5, 2009.
- De Bruin et al., UBS Investment Research. Q-Series®: DNA Sequencing. UBS Securities LLC. Jul. 12, 2007. 15 pages.
- Demirci, et al. Single cell epitaxy by acoustic picolitre droplets. *Lab Chip*. Sep. 2007;7(9):1139-45. Epub Jul. 10, 2007.
- Doerr, "The smallest bioreactor", *Nature Methods*, 2:5 326 (2005).
- Doshi, et al. Red blood cell-mimicking synthetic biomaterial particles. *Proceedings of the National Academy of Sciences* 106.51 (2009): 21495-21499.
- Dowding, et al. Oil core/polymer shell microcapsules by interfacial phase separation from emulsion droplets. II: controlling the release profile of active molecules. *Langmuir*. Jun. 7, 2005;21(12):5278-84.
- Draper, et al. Compartmentalization of electrophoretically separated analytes in a multiphase microfluidic platform. *Anal Chem*. Jul. 3, 2012;84(13):5801-8. doi: 10.1021/ac301141x. Epub Jun. 13, 2012.
- Dressler, et al. Droplet-based microfluidics enabling impact on drug discovery. *J Biomol Screen*. Apr. 2014;19(4):483-96. doi: 10.1177/1087057113510401. Epub Nov. 15, 2013.
- Drmanac et al., Sequencing by hybridization (SBH): advantages, achievements, and opportunities. *Adv Biochem Eng Biotechnol*. 2002;77 :75-101.
- Droplet Based Sequencing (slides) dated (Mar. 12, 2008).
- "Eastburn, et al. Ultrahigh-throughput mammalian single-cell reverse-transcriptase polymerase chain reaction in microfluidic droplets. *Anal Chem*. Aug. 20, 2013;85(16):8016-21. doi: 10.1021/ac402057q. Epub Aug. 8, 2013."
- Esser-Kahn, et al. Triggered release from polymer capsules. *Macromolecules*. 2011; 44:5539-5553.
- Fan, et al. Noninvasive diagnosis of fetal aneuploidy by shotgun sequencing DNA from maternal blood. *Proc Natl Acad Sci U S A*. Oct. 21, 2008;105(42):16266-71. doi: 10.1073/pnas.0808319105. Epub Oct. 6, 2008.
- Fang, et al. Fluoride-cleavable biotinylation phosphoramidite for 5'-end-labeling and affinity purification of synthetic oligonucleotides. *Nucleic Acids Res*. Jan. 15, 2003;31(2):708-15.
- Fisher, et al. A scalable, fully automated process for construction of sequence-ready human exome targeted capture libraries. *Genome Biol*. 2011;12(1):R1. doi: 10.1186/gb-2011-12-1-r1. Epub Jan. 4, 2011.
- Frampton, G.M. et al. "Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing" *Nature Biotechnology* (2013) 31(11):1023-1031. doi:10.1038/nbr.2696.
- Fredrickson, et al. Macro-to-micro interfaces for microfluidic devices. *Lab Chip*. Dec. 2004;4(6):526-33. Epub Nov. 10, 2004.
- Freiberg, et al. Polymer microspheres for controlled drug release. *Int J Pharm*. Sep. 10, 2004;282(1-2):1-18.
- Wang, et al. Digital karyotyping. *Proc Natl Acad Sci U S A*. Dec. 10, 2002;99(25):16156-61. Epub Dec. 2, 2002.
- Fu, A.Y., et al., "A microfabricated fluorescence-activated cell sorter," *Nature Biotechnology*, vol. 17, pp. 1109-1111 (1999).
- Fulton et al., Advanced multiplexed analysis with the FlowMetrix system. *Clin Chem*. Sep. 1997;43(9): 1749-56.
- Garstecki, et al. Formation of monodisperse bubbles in a microfluidic flow-focusing device. *Applied Physics Letters*. 2004; 85(13):2649-2651. DOI: 10.1063/1.1796526.
- Gartner, et al. The Microfluidic Toolbox—examples for fluidic interfaces and standardization concepts. *Proc. SPIE 4982, Microfluidics, BioMEMS, and Medical Microsystems*, (Jan. 17, 2003); doi: 10.1117/12.479566.
- Gericke, et al. Functional cellulose beads: preparation, characterization, and applications. *Chemical reviews* 113.7 (2013): 4812-4836.

US 10,227,648 B2

Page 9

(56)

References Cited

OTHER PUBLICATIONS

- Ghadessy, et al. Directed evolution of polymerase function by compartmentalized self-replication. *Proc Natl Acad Sci U S A*. Apr. 10, 2001;98(8):4552-7. Epub Mar. 27, 2001.
- Granieri, Lucia. Droplet-based microfluidics and engineering of tissue plasminogen activator for biomedical applications. Ph.D. Thesis, Nov. 13, 2009 (131 pages).
- Grasland-Mongrain, et al. Droplet coalescence in microfluidic devices. *Jan.-Jul. 2003*. 31 pages. <http://www.eleves.ens.fr/home/grasland/rapports/stage4.pdf>.
- Guo, et al. Droplet microfluidics for high-throughput biological assays. *Lab Chip*. Jun. 21, 2012;12(12):2146-55. doi: 10.1039/c2lc21147e. Epub Feb. 9, 2012.
- Gyarmati, et al. Reversible disulphide formation in polymer networks: a versatile functional group from synthesis to applications. *European Polymer Journal*. 2013; 49:1268-1286.
- Hashimshony, et al. CEL-Seq: Single-Cell RNA-Seq by Multiplexed Linear Amplification. *Cell Rep*. Sep. 27, 2012;2(3):666-73. doi: 10.1016/j.celrep.2012.08.003. Epub Aug. 30, 2012.
- He "Selective Encapsulation of Single Cells and Subcellular Organelles into Picoliter- and Femtoliter-Volume Droplets" *ANAL. CHEM.* 77: 1539-1544 (2005).
- He, J. et al. "Genotyping-by-sequencing (GBS), an ultimate marker-assisted selections (MAS) tool to accelerate plant breeding" *Frontiers in Plant Sci* (Sep. 30, 2014) 5:1-8.
- Hjerten, et al. General methods to render macroporous stationary phases nonporous and deformable, exemplified with agarose and silica beads and their use in high-performance ion-exchange and hydrophobic-interaction chromatography of proteins. *Chromatographia* 31.1-2 (1991): 85-94.
- Holtze, et al. Biocompatible surfactants for water-in-fluorocarbon emulsions. *Lab Chip*. Oct. 2008;8(10):1632-9. doi: 10.1039/b806706f. Epub Sep. 2, 2008.
- Huebner, "Quantitative detection of protein expression in single cells using droplet microfluidics", *Chem. Commun.* 1218-1220 (2007).
- Hug, et al. Measurement of the number of molecules of a single mRNA species in a complex mRNA preparation. *J Theor Biol.* Apr. 21, 2003;221(4):615-24.
- Ioannidis, N. Manufacturing of Agarose-Based Chromatographic Adsorbents With Controlled Pore and Particle Sizes. A thesis submitted to the University of Birmingham for the degree of Doctor of Philosophy. 2009.
- Jena, et al. Cyclic olefin copolymer based microfluidic devices for biochip applications: Ultraviolet surface grafting using 2-methacryloyloxyethyl phosphorylcholine. *Biomicrofluidics*. Mar. 2012;6(1):12822-1282212. doi: 10.1063/1.3682098. Epub Mar. 15, 2012.
- Jung, et al. Micro machining of injection mold inserts for fluidic channel of polymeric biochips. *Sensors*. 2007; 7(8):1643-1654.
- Khomiakov A et al., [Analysis of perfect and mismatched DNA duplexes by a generic hexanucleotide microchip]. *Mol Bioi (Mosk)*. Jul.-Aug. 2003;37(4):726-41. Russian. Abstract only.
- Kim et al., Albumin loaded microsphere of amphiphilic poly(ethylene glycol)/poly(a-ester) multiblock copolymer. *Eu. J. Pharm. Sci.* 2004;23:245-51. Available online Sep. 27, 2004.
- Kim, et al. Fabrication of monodisperse gel shells and functional microgels in microfluidic devices. *Angew Chem Int Ed Engl*. 2007;46(11):1819-22.
- Kim, et al. Rapid prototyping of microfluidic systems using a PDMS/polymer tape composite. *Lab Chip*. May 7, 2009;9(9):1290-3. doi: 10.1039/b818389a. Epub Feb. 10, 2009.
- Klein, et al. Droplet barcoding for single-cell transcriptomics applied to embryonic stem cells. *Cell*. May 21, 2015;161(5):1187-201. doi: 10.1016/j.cell.2015.04.044.
- Koster et al., "Drop-based microfluidic devices for encapsulation of single cells", *Lab on a Chip the Royal Soc. of Chem.* 8: 1110-1115 (2008).
- Kutyavin, et al. Oligonucleotides containing 2-aminoadenine and 2-thiothymine act as selectively binding complementary agents. *Biochemistry*. Aug. 27, 1996;35(34):11170-6.
- Lagus, et al. A review of the theory, methods and recent applications of high-throughput single-cell droplet microfluidics. *J. Phys. D: Appl. Phys.* (2013) 46:114005. (21 pages).
- Lee, J.-H. et al. "Fluorescent in situ sequencing (FISSEQ) of RNA for gene expression profiling in intact cells and tissues" *Nature Protocols* (Feb. 12, 2015) 10(3):442-458.
- Li, Y., et al., "PEGylated PLGA Nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats," *JourNal of Controlled Release*, vol. 71, pp. 203-211 (2001).
- Liu, et al. Preparation of uniform-sized PLA microcapsules by combining Shirasu porous glass membrane emulsification technique and multiple emulsion—solvent evaporation method. *J Control Release*. Mar. 2, 2005;103(1):31-43. Epub Dec. 21, 2004.
- Liu, et al. Smart thermo-triggered squirting capsules for Nanoparticle delivery. *Soft Matter*. 2010; 6(16):3759-3763.
- Loscertales, I.G., et al., "Micro/Nano Encapsulation via Electrified Coaxial Liquid Jets," *Science*, vol. 295, pp. 1695-1698 (2002).
- Love, "A microengraving method for rapid selection of single cells producing antigen-specific antibodies", *Nature Biotech.* 24:6 703 (Jun. 2006).
- Lowe, Adam J. Norbornenes and [n]polynorbornanes as molecular scaffolds for anion recognition. Ph.D. Thesis (May 2010). (361 pages).
- Macosko, et al. Highly Parallel Genome-wide Expression Profiling of Individual Cells Using Nanoliter Droplets. *Cell*. May 21, 2015;161(5):1202-14. doi: 10.1016/j.cell.2015.05.002.
- Mair, et al. Injection molded microfluidic chips featuring integrated interconnects. *Lab Chip*. Oct. 2006;6(10):1346-54. Epub Jul. 31, 2006.
- Makino, et al. Preparation of hydrogel microcapsules: Effects of preparation conditions upon membrane properties. *Colloids and Surfaces B: Biointerfaces*. Nov. 1998; 12(2), 97-104.
- Marcus. Gene method offers diagnostic hope. *The Wall Street JourNal*. Jul. 11, 2012.
- Matochko, et al. Uniform amplification of phage display libraries in monodisperse emulsions. *Methods*. Sep. 2012;58(1):18-27. doi: 10.1016/j.jymeth.2012.07.012. Epub Jul. 20, 2012.
- Mazutis, et al. Selective droplet coalescence using microfluidic systems. *Lab Chip*. Apr. 24, 2012;12(10):1800-6. doi: 10.1039/c2lc40121e. Epub Mar. 27, 2012.
- Merriman, et al. Progress in ion torrent semiconductor chip based sequencing. *Electrophoresis*. Dec. 2012;33(23):3397-417. doi: 10.1002/elps.201200424.
- Microfluidic ChipShop. Microfluidic product catalogue. Mar. 2005.
- Microfluidic ChipShop. Microfluidic product catalogue. Oct. 2009.
- Mirzabekov, "DNA Sequencing by Hybridization—a Megasequencing Method and A Diagnostic Tool?" *Trends in Biotechnology* 12(1): 27-32 (1994).
- Moore, et al. Behavior of capillary valves in centrifugal microfluidic devices prepared by three-dimensional printing. *Microfluidics and Nanofluidics*. 2011; 10(4):877-888.
- Morgan, et al. Chapter 12: Human microbiome analysis. *PLoS Comput Biol*. 2012;8(12):e1002808. doi: 10.1371/journal.pcbi.1002808. Epub Dec. 27, 2012.
- Mouritzen et al., Single nucleotide polymorphism genotyping using locked nucleic acid (LNA). *Expert Rev Mol Diagn.* Jan. 2003;3(1):27-38.
- Mozhanova, A.A. et al. "Local elastic properties of biological materials studied by SFM" (2003) XP055314108, Retrieved from the Internet: URL:http://www.ntmdt.com/data/media/files/publications/2003/08.08_a.a.mozhanova_n.i.n_english.pdf.
- Muotri, et al. L1 retrotransposition in neurons is modulated by MeCP2. *Nature*. Nov. 18, 2010;468(7322):443-6. doi: 10.1038/nature09544.
- Nagashima, et al. Preparation of monodisperse poly (acrylamide-co-acrylic acid) hydrogel microspheres by a membrane emulsification technique and their size-dependent surface properties. *Colloids and Surfaces B: Biointerfaces*. Jun. 15, 1998; 11(1-2), 47-56.

US 10,227,648 B2

Page 10

(56)

References Cited

OTHER PUBLICATIONS

- Navin. The first five years of single-cell cancer genomics and beyond. *Genome Res.* Oct. 2015;25(10):1499-507. doi: 10.1101/gr.191098.115.
- Nguyen, et al. In situ hybridization to chromosomes stabilized in gel microdrops. *Cytometry.* 1995; 21:111-119.
- Novak, et al. Single cell multiplex gene detection and sequencing using microfluidically generated agarose emulsions. *Angew Chem Int Ed Engl.* Jan. 10, 2011;50(2):390-5. doi: 10.1002/anie.201006089.
- Oberholzer, et al. Polymerase chain reaction in liposomes. *Chem Biol.* 1995 Oct;2(10):677-82.
- Ogawa, et al. Production and characterization of O/W emulsions containing cationic droplets stabilized by lecithin-chitosan membranes. *J Agric Food Chem.* Apr. 23, 2003;51(9):2806-12.
- Okushima, S., et al., "Controlled Production of Monodisperse Double Emulsions by Two-Step Droplet Breakup in Microfluidic Devices," *Langmuir*, vol. 20, pp. 9905-9908 (2004).
- Oligotex Handbook. For purification of poly A+ RNA from total RNA and directly from cultured cells or tissues as well as purification of polyadenylated in vitro transcripts. Jun. 2012.
- Pantel, et al. Detection methods of circulating tumor cells. *J Thorac Dis.* Oct. 2012;4(5):446-7. doi: 10.3978/j.issn.2072-1439.2012.08.15.
- Patel, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. *Science.* Jun. 20, 2014;344(6190):1396-401. doi: 10.1126/science.1254257. Epub Jun. 12, 2014.
- Perez, C., et al., "Poly(lactic acid)-poly(ethylene glycol) Nanoparticles as new carriers for the delivery of plasmid DNA," *JourNal of Controlled Release*, vol. 75, pp. 211-224 (2001).
- Peters, et al. Accurate whole-genome sequencing and haplotyping from 10 to 20 human cells. *Nature.* Jul. 11, 2012;487(7406):190-5. doi: 10.1038/Nature11236.
- Picot, J. et al. "A biomimetic microfluidic chip to study the circulation and mechanical retention of red blood cells in the spleen" *Am J Hematology* (Jan. 12, 2015) 90(4):339-345.
- Plunkett, et al. Chymotrypsin responsive hydrogel: application of a disulfide exchange protocol for the preparation of methacrylamide containing peptides. *Biomacromolecules.* Mar.-Apr. 2005;6(2):632-7.
- Ram, et al. Strategy for microbiome analysis using 16S rRNA gene sequence analysis on the Illumina sequencing platform. *Syst Biol Reprod Med.* Jun. 2011;57(3):162-70. doi: 10.3109/19396368.2011.555598. Epub Mar. 1, 2011.
- Richardson, et al. Novel inhibition of archaeal family-D DNA polymerase by uracil. *Nucleic acids research* 41.7 (2013): 4207-4218.
- Rogozin, et al. A highly conserved family of inactivated archaeal B family DNA polymerases. *Biol Direct.* Aug. 6, 2008;3:32. doi: 10.1186/1745-6150-3-32.
- Rotem, et al. High-Throughput Single-Cell Labeling (Hi-SCL) for RNA-Seq Using Drop-Based Microfluidics. *PLoS One.* May 22, 2015;10(5):e0116328. doi: 10.1371/journal.pone.0116328. eCollection 2015.
- Rotem, et al. Single Cell Chip-Seq Using Drop-Based Microfluidics. Abstract #50. *Frontiers of Single Cell Analysis*, Stanford University Sep. 5-7, 2013.
- Ryan, "Rapid assay for mycobacterial growth and antibiotic susceptibility using gel microdrop and encapsulation", *J. Clinical Microbial.*, 33:7 1720-1726 (1995).
- Schirinzii et al., Combinatorial sequencing-by-hybridization: aNalysis of the NFI gene. *Genet Test.* 2006 Spring;10(1):8-17.
- Schneider, et al. Fast identification and removal of sequence contamination from genomic and metagenomic datasets. *PLoS One.* Mar. 9, 2011;6(3):e17288. doi: 10.1371/journal.pone.0017288.
- Schmitt, "Bead-based multiplex genotyping of human papillomaviruses", *J. Clinical Microbial.*, 44:2 504-512 (2006).
- Seiffert, et al. Smart microgel capsules from macromolecular precursors. *J Am Chem Soc.* May 12, 2010;132(18):6606-9. doi: 10.1021/ja102156h.
- Shah, "Fabrication of mono disperse thermosensitive microgels and gel capsules in micro fluidic devices", *Soft Matter*, 4:2303-2309 (2008).
- Shimkus, et al. A chemically cleavable biotinylated nucleotide: usefulness in the recovery of protein-DNA complexes from avidin affinity columns. *Proc Natl Acad Sci U S A.* May 1985;82(9):2593-7.
- Shuttleworth, et al. Recognition of the pro-mutagenic base uracil by family B DNA polymerases from archaea. *J Mol Biol. Mar.* 26, 2004;337(3):621-34.
- Simeonov et al., Single nucleotide polymorphism genotyping using short, fluorescently labeled locked nucleic acid (LNA) probes and fluorescence polarization detection. *Nucleic Acids Res.* Sep. 1, 2002;30(17):e91.
- Sorokin et al., DiscrimiNation between perfect and mismatched duplexes with oligonucleotide gel microchips: role of thermodynamic and kinetic effects during hybridization. *J Biomol Struct Dyn.* Jun. 2005;22(6):725-34.
- Su, et al., Microfluidics-Based Biochips: Technology Issues, Implementation Platforms, and Design-Automation Challenges. *IEEE Transactions on Computer-Aided Design of Integrated Circuits and Systems.* 2006;25(2):211-23. (Feb. 2006).
- Sun et al., Progress in research and application of liquid-phase chip technology. *Chinese JourNal Experimental Surgery.* May 2005;22(5):639-40.
- Tawfik, D.S., et al., "Man-made cell-like compartments for molecular evolution," *Nature Biotechnology*, vol. 16, pp. 652-656 (1998).
- Tayyab, S. et al. "Size exclusion chromatography and size exclusion HPLC of proteins" *Biochem Ed, Pergamon*, (1991) 19(3):149-152.
- Tewhey, et al. Microdroplet-based PCR enrichment for large-scale targeted sequencing. *Nat Biotechnol.* Nov. 2009;27(11):1025-31. doi: 10.1038/nbt.1583. Epub Nov. 1, 2009.
- Theberge, et al. Microdroplets in microfluidics: an evolving platform for discoveries in chemistry and biology. *Angew Chem Int Ed Engl.* Aug. 9, 2010;49(34):5846-68. doi: 10.1002/anie.200906653.
- Tonelli, et al. Perfluoropolyether functional oligomers: unusual reactivity in organic chemistry. *Journal of fluorine chemistry.* 2002; 118(1):107-121.
- Tubeleviciute, et al. Compartmentalized self-replication (CSR) selection of *Thermococcus litoralis* Sh1B DNA polymerase for diminished uracil binding. *Protein Eng Des Sel.* Aug. 2010;23(8):589-97. doi: 10.1093/protein/gzq032. Epub May 31, 2010.
- Turner, et al. Methods for genomic partitioning. *Annu Rev Genomics Hum Genet.* 2009;10:263-84. doi: 10.1146/annurev-genom-082908-150112. Review.
- Wagner, et al. Biocompatible fluorinated polyglycerols for droplet microfluidics as an alternative to PEG-based copolymer surfactants. *Lab Chip.* Jan. 7, 2016;16(1):65-9. doi: 10.1039/c5lc00823a. Epub Dec. 2, 2015.
- Wang, et al. A novel thermo-induced self-bursting microcapsule with magnetic-targeting property. *Chemphyschem.* Oct. 5, 2009;10(14):2405-9.
- Wang et al., Single nucleotide polymorphism discrimiNation assisted by improved base stacking hybridization using oligonucleotide microarrays. *Biotechniques.* 2003;35:300-08.
- Weaver, "Rapid clonal growth measurements at the single-cell level: gel microdroplets and flow cytometry", *Biotechnology*, 9:873-877 (1991).
- Whitesides, "Soft lithography in biology and biochemistry", *Annual Review of Biomedical Engineering*, 3:335-373 (2001).
- Williams et al., Amplification of complex gene libraries by emulsion PCR, *Nature Methods* 3(7):545-550 (2006).
- Woo, et al. G/C-modified oligodeoxynucleotides with selective complementarity: synthesis and hybridization properties. *Nucleic Acids Res.* Jul. 1, 1996;24(13):2470-5.
- Xia and Whitesides, *Soft Lithography*, *Ann. Rev. Mat. Sci.* 28:153-184 (1998).
- Yamamoto, et al. Chemical modification of Ce(IV)/EDTA-base artificial restriction DNA cutter for versatile manipulation of double-stranded DNA. *Nucleic Acids Research.* 2007; 35(7):e53.
- Zhang, "Combinatorial marking of cells and organelles with reconstituted fluorescent proteins", *Cell*, 119:137-144 (Oct. 1, 2004).

US 10,227,648 B2

Page 11

(56)

References Cited

OTHER PUBLICATIONS

- Zhang, et al. Degradable disulfide core-cross-linked micelles as a drug delivery system prepared from vinyl functionalized nucleosides via the RAFT process. *Biomacromolecules*. Nov. 2008;9(11):3321-31. doi: 10.1021/bm800867n. Epub Oct. 9, 2008.
- Zhao, J., et al., "Preparation of hemoglobin-loaded Nano-sized particles with porous structure as oxygen carriers," *Biomaterials*, vol. 28, pp. 1414-1422 (2007).
- Zheng, X.Y. et al. "Haplotyping germline and cancer genomes with high-throughput linked-read sequencing" *Nature Biotech* (Feb. 1, 2016) 34(3):303-311.
- Zhu, et al. Synthesis and self-assembly of highly incompatible polybutadiene-poly(hexafluoropropylene oxide) diblock copolymers. *Journal of Polymer Science Part B: Polymer Physics*. 2005; 43(24):3685-3694.
- Zimmermann et al., Microscale production of hybridomas by hypotonic electrofusion. *Hum Antibodies Hybridomas*. Jan. 1992; 3(1): 14-8.
- Zong, et al. Genome-wide detection of single-nucleotide and copy-number variations of a single human cell. *Science*. Dec. 21, 2012;338(6114):1622-6. doi: 10.1126/science.1229164.
- Aitman, et al. Copy number polymorphism in *Fcgr3* predisposes to glomerulonephritis in rats and humans. *Nature*. Feb. 16, 2006;439(7078):851-5.
- Balikova, et al. Autosomal-dominant microtia linked to five tandem copies of a copy-number-variable region at chromosome 4p16. *Am J Hum Genet*. Jan. 2008;82(1):181-7. doi: 10.1016/j.ajhg.2007.08.001.
- Browning, et al. Haplotype phasing: existing methods and new developments. *Nat Rev Genet*. Sep. 16, 2011;12(10):703-14. doi: 10.1038/nrg3054. Review.
- Cappuzzo, et al. Increased *HER2* gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. *J Clin Oncol*. Aug. 1, 2005;23(22):5007-18.
- Choi, et al. Identification of novel isoforms of the *EML4-ALK* transforming gene in non-small cell lung cancer. *Cancer Res*. Jul. 1, 2008;68(13):4971-6. doi: 10.1158/0008-5472.CAN-07-6158.
- Cook, et al. Copy-number variations associated with neuropsychiatric conditions. *Nature*. Oct. 16, 2008;455(7215):919-23. doi: 10.1038/nature07458.
- Fabi, et al. Correlation of efficacy between *EGFR* gene copy number and lapatinib/capecitabine therapy in *HER2*-positive metastatic breast cancer. *J. Clin. Oncol*. 2010; 28:15S. 2010 ASCO Meeting abstract Jun. 14, 2010:1059.
- Gonzalez, et al. The influence of *CCL3L1* gene-containing segmental duplications on HIV-1/AIDS susceptibility. *Science*. Mar. 4, 2005;307(5714):1434-40. Epub Jan. 6, 2005.
- Kitzman, et al. Noninvasive whole-genome sequencing of a human fetus. *Sci Transl Med*. Jun. 6, 2012;4(137):137ra76. doi: 10.1126/scitranslmed.3004323.
- Knight, et al. Subtle chromosomal rearrangements in children with unexplained mental retardation. *Lancet*. Nov. 13, 1999;354(9191):1676-81.
- Lupski. Genomic rearrangements and sporadic disease. *Nat Genet*. Jul. 2007;39(7 Suppl):S43-7.
- Pinto, et al. Functional impact of global rare copy number variation in autism spectrum disorders. *Nature*. Jul. 15, 2010;466(7304):368-72. doi: 10.1038/nature09146. Epub Jun. 9, 2010.
- Ropers. New perspectives for the elucidation of genetic disorders. *Am J Hum Genet*. Aug. 2007;81(2):199-207. Epub Jun. 29, 2007.
- Sebat, et al. Strong association of de novo copy number mutations with autism. *Science*. Apr. 20, 2007;316(5823):445-9. Epub Mar. 15, 2007.
- Shlien, et al. Copy number variations and cancer. *Genome Med*. Jun. 16, 2009;1(6):62. doi: 10.1186/gm62.
- Shlien, et al. Excessive genomic DNA copy number variation in the Li-Fraumeni cancer predisposition syndrome. *Proc Natl Acad Sci U S A*. Aug. 12, 2008;105(32):11264-9. doi: 10.1073/pnas.0802970105. Epub Aug. 6, 2008.
- Co-pending U.S. Appl. No. 15/831,847, filed Dec. 5, 2017.
- Hamilton, A.J. "microRNA in erythrocytes" *Biochem. Soc. Trans.* (2010) 38, 229-231.
- MiRNA (<http://www.exiqon.com/what-are-microRNAs>) accessed Oct. 19, 2017.
- Orakdogan, N. "Novel responsive poly(N,N-dimethylaminoethyl methacrylate) gel beads: preparation, mechanical properties and pH-dependent swelling behavior" *J Polym Res* (2012) 19:9914.
- "Portable Water Filters" (<http://www.portablewaterfilters.org/water-filter-guide/particle-contaminant-size-chart-microns/>) 2015, accessed Oct. 19, 2017.
- Ahern, "Biochemical, Reagents Kits Offer Scientists Good Return on Investment" *The Scientist* (1995) 9(15):1-7.
- Bentzen, et al. Large-scale detection of antigen-specific T cells using peptide-MHC-I multimers labeled with DNA barcodes. *Nat Biotechnol*. Oct. 2016;34(10):1037-1045. doi: 10.1038/nbt.3662. Epub Aug. 29, 2016.
- Berkum, et al. Hi-C: a method to study the three-dimensional architecture of genomes. *J Vis Exp*. May 6, 2010;(39). pii: 1869. doi: 10.3791/1869.
- Biles et al., *Nucl. Acids Res*. 32(22):e176 2004.
- Boulanger, et al. "Massively parallel haplotyping on microscopic beads for the high-throughput phase analysis of single molecules", *PLoS One*, vol. 7:1-10, 2012.
- Briggs, et al. "Tumor-infiltrating immune repertoires captures by single-cell barcoding in emulsion" with Supplementary material. *bioRxiv* 134841; doi: <https://doi.org/10.1101/134841>. Posted May 5, 2017.
- Brown, K., Targeted Sequencing Using Droplet-Based Microfluidics, RainDance Technologies, 2009, 1-18.
- Burns, et al. An Integrated Nanoliter DNA Analysis Device. *Science*. Oct. 16, 1998;282(5388):484-7.
- Burns, et al. Microfabricated structures for integrated DNA analysis. *Proc Natl Acad Sci U S A*. May 28, 1996; 93(11): 5556-5561.
- Burns, et al. The intensification of rapid reactions in multiphase systems using slug flow in capillaries. *Lab Chip*. Sep. 2001;1(1):10-5. Epub Aug. 9, 2001.
- Casbon, et al. "Reflex: intramolecular barcoding of long-range PCR products for sequencing multiple pooled DNAs", *Nucleic Acids Res.*, pp. 1-6, 2013.
- Christian M, et al. Targeting DNA double-strand breaks with TAL effector nucleases. *Genetics*. 2010;186:757-761.
- Chung, et al. Structural and molecular interrogation of intact biological systems. *Nature*. May 16, 2013;497(7449):332-7. doi: 10.1038/nature12107. Epub Apr. 10, 2013.
- Cong, et al. Multiplex genome engineering using CRISPR/CAS systems. *Science*. Feb. 15, 2013;339(6121):819-23. doi: 10.1126/science.1231143. Epub Jan. 3, 2013.
- Co-pending U.S. Appl. No. 15/392,557, filed Dec. 28, 2016.
- Co-pending U.S. Appl. No. 15/430,298, filed Feb. 10, 2017.
- Co-pending U.S. Appl. No. 15/440,772, filed Feb. 23, 2017.
- Co-pending U.S. Appl. No. 15/449,741, filed Mar. 3, 2017.
- Co-pending U.S. Appl. No. 15/470,814, filed Mar. 27, 2017.
- Co-pending U.S. Appl. No. 15/588,519, filed May 5, 2017.
- Co-pending U.S. Appl. No. 15/596,754, filed May 16, 2017.
- Co-pending U.S. Appl. No. 15/598,898, filed May 18, 2017.
- Curcio. Improved Techniques for High-Throughput Molecular Diagnostics. PhD Thesis. 2002.
- Damean, et al. Simultaneous measurement of reactions in microdroplets filled by concentration gradients. *Lab Chip*. Jun. 21, 2009;9(12):1707-13. doi: 10.1039/b821021g. Epub Mar. 19, 2009.
- Dekker, et al. Capturing chromosome conformation. *Science*. Feb. 15, 2002;295(5558):1306-11.
- Dressman et al. Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. *Proc. Natl. Acad. Sci*. 2003. 100(15):8817-8822.
- Fan, et al. Whole-genome molecular haplotyping of single cells. *Nature Biotechnology*, vol. 29, No. 1. Jan. 1, 2011. pp. 51-57.
- Han, X. et al. "CRISPR-Cas9 delivery to hard-to-transfect cells via membrane deformation" *Science Advances* (2015) 1(7): E1500454 (8 pages).

US 10,227,648 B2

Page 12

(56)

References Cited

OTHER PUBLICATIONS

- Hiatt, et al. Parallel, tag-directed assembly of locally derived short sequence reads. *Nat Methods*. Feb. 2010;7(2):119-22. doi: 10.1038/nmeth.1416. Epub Jan. 17, 2010.
- Hirsch et al. (2002) "Easily reversible desthiobiotin binding to streptavidin, avidin, and other biotin-binding proteins: uses for protein labeling, detection, and isolation." *Analytical of Biochemistry* 308(2):343-357.
- Hosokawa, et al. Massively parallel whole genome amplification for single-cell sequencing using droplet microfluidics. *Scientific Reports* 7, Article No. 5199 (2017).
- Sigma. Streptavidin-agarose (S1638) product information sheet. www.sigma-aldrich.com.
- Illumina Nextera Enrichment Sample Preparation Guide. Feb. 2013.
- Illumina TruSeq Custom Enrichment Kit Data Sheet. (c) 2014.
- Imburgio, et al. "Studies of promoter recognition and start site selection by T7 RNA polymerase using a comprehensive collection of promoter variants", *Biochemistry*, 39:10419-30, 2000.
- Kaper, et al. Supporting Information for "Whole-genome haplotyping by dilution, amplification, and sequencing." *Proc Natl Acad Sci U S A*. Apr. 2, 2013;110(14):5552-7. doi: 10.1073/pnas.1218696110. Epub Mar. 18, 2013.
- Kaper, et al. Whole-genome haplotyping by dilution, amplification, and sequencing. *Proc Natl Acad Sci U S A*. Apr. 2, 2013;110(14):5552-7. doi: 10.1073/pnas.1218696110. Epub Mar. 18, 2013.
- Karmakar, et al. Organocatalytic removal of formaldehyde adducts from RNA and DNA bases. *Nat Chem*. Sep. 2015;7(9):752-8. doi: 10.1038/nchem.2307. Epub Aug. 3, 2015.
- Katsura, et al. Indirect micromanipulation of single molecules in water-in-oil emulsion. *Electrophoresis*. Jan. 2001;22(2):289-93.
- Kebschull, et al. High-Throughput Mapping of Single-Neuron Projections by Sequencing of Barcoded RNA. *Neuron*. Sep. 7, 2016;91(5):975-87. doi: 10.1016/j.neuron.2016.07.036. Epub Aug. 18, 2016.
- Kenis, et al. Microfabrication Inside Capillaries Using Multiphase Laminar Flow Patterning. *Science*. Jul. 2, 1999;285(5424):83-5.
- Kirkness et al. "Sequencing of isolated sperm cells for direct haplotyping of a human genome," *Genome Res* (2013) 23:826-832.
- Kitzman et al. "Haplotype-resolved genome sequencing of a Gujarati Indian individual." *Nat Biotechnol* (2011) 29:59-63.
- Kivioja, et al., "Counting Absolute Numbers of Molecules Using Unique Molecular Identifiers", *Nature Methods* 9, 72-74 (2012).
- Kozarewa, et al., "96-plex molecular barcoding for the Illumina Genome Analyzer", *Methods Mol Biol.*, 733:279-98, 2011.
- Korlach et al., *Methods in Enzymology, Real-Time DNA Sequencing from Single Polymerase Molecules*, (2010) 472:431-455.
- Kozarewa, et al. "Amplification-free Illumina sequencing-library preparation facilitates improved mapping and assembly of GC-biased genomes", *Nat Methods.*, 6: 291-5, 2009.
- Kwok, et al., "Single-molecule analysis for molecular haplotyping", *Hum Mutat.*, 23:442-6, 2004.
- Lagally, et al. Single-Molecular DNA Amplification and Analysis in an Integrated Microfluidic Device. *Anal Chem*. Feb. 1, 2001;73(3):565-70.
- Laird et al. Hairpin-bisulfite PCR: Assessing epigenetic methylation patterns on complementary strands of individual DNA molecules, 2004, *PNAS*, 101, 204-209.
- Lan, et al. "Single-cell genome sequencing at ultra-high-throughput with microfluidic droplet barcoding" with Supplementary Material. *Nat Biotechnol*. May 29, 2017. doi: 10.1038/nbt.3880. [Epub ahead of print].
- Lee, et al. ACT-PRESTO: Rapid and consistent tissue clearing and labeling method for 3-dimensional (3D) imaging. *Sci Rep*. Jan. 11, 2016;6:18631. doi: 10.1038/srep18631.
- Lee, et al., "Highly multiplexed subcellular RNA sequencing in situ. *Science*. Mar. 21, 2014;343(6177):1360-3. doi: 10.1126/science.1250212. Epub Feb. 27, 2014."
- Li, et al. A single-cell-based platform for copy number variation profiling through digital counting of amplified genomic DNA fragments. *ACS Appl Mater Interfaces*. Mar. 24, 2017. doi: 10.1021/acsami.7b03146. [Epub ahead of print].
- Linch, et al. Bone marrow processing and cryopreservation. *Journal of Clinical Pathology*; Feb. 1982, vol. 35, No. 2; pp. 186-190.
- Lundin, et al., "Hierarchical molecular tagging to resolve long continuous sequences by massively parallel sequencing", *Sci Rep.*, 3:1186, 2003.
- Man. Monolithic Structures for Integrated Microfluidic Analysis. PhD Thesis. 2001.
- Miller JC, et al. An improved zinc-finger nuclease architecture for highly specific genome editing. *Nat. Biotechnol.* 2007;25:778-785.
- Myllykangas et al., Targeted Sequencing Library Preparation by Genomic DNA Circularization, *Bmc Biotechnology*, 2011, 11(122), 1-12.
- Nagano, et al. Single-cell Hi-C reveals cell-to-cell variability in chromosome structure. *Nature*. Oct. 3, 2013;502(7469):59-64. doi: 10.1038/nature12593. Epub Sep. 25, 2013.
- Nisisako, et al. Droplet formation in a microchannel network. *Lab Chip*. Feb. 2002;2(1):24-6. Epub Jan. 18, 2002.
- Nisisako, T. et al. "Droplet Formation in a Microchannel on PMMA Plate" Abstract. 2001 Kluwer Academic Publishers. p. 137-138.
- Oyola, et al., "Optimizing Illumina next-generation sequencing library preparation for extremely AT-biased genomes", *BMC Genomics*. 13:1, 2012.
- PCT/IB2010/002243, International Search Report and Written Opinion, dated Feb. 9, 2011, 13pgs.
- Porteus MH, Baltimore D. Chimeric nucleases stimulate gene targeting in human cells. *Science*. 2003;300:763.
- Rakaszewska, A. et al. "One drop at a time: toward droplet microfluidics as a versatile tool for single-cell analysis" *NPG Asia Materials* (2014) 6(10):e133 (12 pages).
- Ramsey, J.M. "The burgeoning power of the shrinking laboratory" *Nature Biotech* (1999) 17:1061-1062.
- Ramskold et al. (2012) "Full-length mRNA-Seq from single-cell levels of RNA and individual circulating tumor cells" *Nature Biotechnology* 30(8):777-782.
- Ran, et al., Genome Engineering Using the CRISPR-Cas9 System, *Nature Protocol*, (2013), 8(11):2281-2308.
- Reis, A. et al. "CRISPR/Cas9 and Targeted Genome Editing: A New Era in Molecular Biology" (2014) XP002766825: URL:<https://www.neb.com/tools-and-resources/feature-articles/crispr-cas9-and-targeted-genome-editing-a-new-era-in-molecular-biology>.
- Reisner, et al., "Single-molecule denaturation mapping of DNA in nanofluidic channels", *Proc Natl Acad Sci U.S.A.*, 107: 13294-9, 2010.
- Repp et al. "Genotyping by Multiplex Polymerase Chain Reaction for Detection of Endemic Hepatitis B Virus Transmission" *J Clinical Microbiology* (1993) 31:1095-1102.
- Roche. Using Multiplex Identifier (MID) Adaptors for the GS FLX Titanium Chemistry Basic MID Set Genome Sequencer FLX System, Technical Bulletin 004-2009, (Apr. 1 2009) pp. 1-7. URL:<http://454.com/downloads/my454/documentation/technical-bulletins/TCB-09004 Using MultiplexIdentifierAdaptorsForTheGSFLXTitaniumSeriesChemistry-BasicMIDSet.pdf>.
- Roche. Using Multiplex Identifier (MID) Adaptors for the GS FLX Titanium Chemistry Extended MID Set Genome Sequencer FLX System, Technical Bulletin 005-2009, (Apr. 1, 2009) pp. 1-7. URL:<http://454.com/downloads/my454/documentation/technical-bulletins/TCB-09005 Using MultiplexIdentifierAdaptorsForTheGSFLXTitaniumChemistry-ExtendedMIDSet.pdf>.
- Rodrigue, S. et al. "Whole genome amplification and de novo assembly of single bacterial cells" *PLoS One*. Sep. 2, 2009;4(9):e6864. doi: 10.1371/journal.pone.0006864.
- Rotem, et al. Single-cell ChIP-seq reveals cell subpopulations defined by chromatin state. *Nat Biotechnol*. Nov. 2015;33(11):1165-72. doi: 10.1038/nbt.3383. Epub Oct. 12, 2015.
- Sander JD, et al. Selection-free zinc-finger-nuclease engineering by context-dependent assembly (CoDA). *Nat. Methods*. 2011;8:67-69.
- Schubert, et al. Microemulsifying fluorinated oils with mixtures of fluorinated and hydrogenated surfactants. *Colloids and Surfaces A; Physicochemical and Engineering Aspects*, 84(1994) 97-106.

US 10,227,648 B2

Page 13

(56)

References Cited

OTHER PUBLICATIONS

- Schwartz, et al., "Capturing native long-range contiguity by in situ library construction and optical sequencing", PNAS (Nov. 2012), 109(46):18749-18754.
- Song, et al. Reactions in droplets in microfluidic channels. *Angew Chem Int Ed Engl.* Nov. 13, 2006;45(44):7336-56.
- Stoeckius, et al. Large-scale simultaneous measurement of epitopes and transcriptomes in single cells. *bioRxiv* 113068; doi: <https://doi.org/10.1101/113068>.
- Susaki, et al. Whole-brain imaging with single-cell resolution using chemical cocktails and computational analysis. *Cell.* Apr. 24, 2014;157(3):726-39. doi: 10.1016/j.cell.2014.03.042. Epub Apr. 17, 2014.
- Tewhey et al., Supplementary Materials, *Nature Biotechnology*, 2009, 27(11), 1-22.
- Thorsen, et al. Dynamic pattern formation in a vesicle-generating microfluidic device. *Physical Review Letters. American Physical Society.* 2001; 86(18):4163-4166.
- Tomer, et al. Advanced Clarity for rapid and high-resolution imaging of intact tissues. *Nat Protoc.* Jul. 2014;9(7):1682-97. doi: 10.1038/nprot.2014.123. Epub Jun. 19, 2014.
- Turner, et al. Assaying chromosomal inversions by single-molecule haplotyping. *Nat Methods.* Jun. 2006;3(6):439-45.
- Turner, et al., "High-throughput haplotype determination over long distances by haplotype fusion PCR and ligation haplotyping", *Nat Protoc.*, 4:1771-83, 2009.
- Ushijima et al. Detection and interpretation of altered methylation patterns in cancer cells, 2005, *Nature reviews*, 5, 223-231.
- Van Nieuwerburgh, et al., "Illumina mate-paired DNA sequencing-library preparation using Cre-Lox recombination", *Nucleic Acids Res.*, 40:1-8, 2012.
- Wang, et al., "Self-Formed Adaptor PCR: a Simple and Efficient Method for Chromosome Walking", *Applied and Environmental Microbiology* (Aug. 2007), 73(15):5048-5051.
- Ward, et al. Microfluidic flow focusing: Drop size and scaling in pressure versus flow-rate-driven pumping. *Electrophoresis.* Oct. 2005;26(19):3716-24.
- Weigl, et al. Microfluidic Diffusion-Based Separation and Detection. *Science.* 1999; pp. 346-347.
- Wesolowska, et al. Cost-effective multiplexing before capture allows screening of 25 000 clinically relevant SNPs in childhood acute lymphoblastic leukemia. *Leukemia.* Jun. 2011;25(6):1001-6. doi: 10.1038/leu.2011.32. Epub Mar. 18, 2011.
- Wiseman, R.W. et al. "Major histocompatibility complex genotyping with massively parallel pyrosequencing" *Nature Medicine* (Oct. 11, 2009) 15(11):1322-1326.
- Wood AJ, et al. Targeted genome editing across species using ZFNs and TALENs. *Science.* 2011;333:307.
- Xiao, et al., "Determination of haplotypes from single DNA molecules: a method for single-molecule barcoding", *Hum Mutat.*, 28:913-21, 2007.
- Yan, Pu et al. "Rapid one-step construction of hairpin RNA" *Biochem and Biophys Res Comm* (Jun. 12, 2009) 383(4):464-468.
- Zeng, et al. High-performance single cell genetic analysis using microfluidic emulsion generator arrays. *Anal Chem.* Apr. 15, 2010;82(8):3183-90. doi: 10.1021/ac902683t.
- Zhang F, et al. Efficient construction of sequence-specific TAL effectors for modulating mammalian transcription. *Nat. Biotechnol.* 2011;29:149-153.
- Zhang. Genomics of inherited bone marrow failure and myelodysplasia. Dissertation [online]. University of Washington. 2015 [Retrieved on May 3, 2017].
- Zheng, et al. Massively parallel digital transcriptional profiling of single cells. *Nat Commun.* Jan. 16, 2017;8:14049. doi: 10.1038/ncomms14049.
- Zhu et al. Hydrogel Droplet Microfluidics for High-Throughput Single Molecule/Cell Analysis. *Accounts of Chemical Research* Article ASAP. DOI: 10.1021/acs.accounts.6b00370.
- Xi, et al. New library construction method for single-cell genomes. *PLoS One.* Jul. 19, 2017;12(7):e0181163. doi: 10.1371/journal.pone.0181163. eCollection 2017.
- Adey, et al., "Ultra-low-input, tagmentation-based whole-genome bisulfite sequencing", *Genome Research*, 2012, 22 (6): 1139-1143.
- Ason et al. DNA sequence bias during Tn5 transposition. *Journal of molecular biology* 335.5 (2004): 1213-1225.
- Bjornsson et al., Intra-individual change over time in DNA methylation with familial clustering, *JAMA*, Jun. 25, 2008, vol. 299 No. 24, pp. 2877-2883.
- Boyle, et al. "High-resolution genome-wide in vivo footprinting of diverse transcription factors in human cells", *Genome Res.* Mar. 2011;21(3):456-64.
- Buenrostro, et al., "Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position", *Nature Methods*, 2013, 10(12): 1213-1218.
- Co-pending U.S. Appl. No. 16/052,431, filed Aug. 1, 2018.
- Co-pending U.S. Appl. No. 16/052,486, filed Aug. 1, 2018.
- Co-pending U.S. Appl. No. 16/056,231, filed Aug. 6, 2018.
- Gangadharan et al., DNA transposon Hermes insert into DNA in nucleosome-free regions in vivo, *Proc nat Ad Sci*, Dec. 21, 2010, vol. 107, No. 51, pp. 1966-1972.
- Green et al. Insertion site preference of Mu, Tn5, and Tn7 transposons. *Mobile DNA* 3.1 (2012): 3.
- Haring, et al. Chromatin immunoprecipitation: optimization, quantitative analysis and data normalization. *Plant Methods.* 2007; 3: 11.
- Joneja, et al. Linear nicking endonuclease-mediated strand-displacement DNA amplification. *Anal Biochem.* Jul. 1, 2011;414(1):58-69. doi: 10.1016/j.ab.2011.02.025. Epub Feb. 20, 2011.
- Knapp, et al. Generating barcoded libraries for multiplex high-throughput sequencing. *Methods Mol Biol.* 2012;840:155-70. doi: 10.1007/978-1-61779-516-9_19.
- Lai; et al., "Characterization and Use of Laser-Based Lysis for Cell Analysis On-Chip", *Journal of the Royal Society, Interface*, vol. 5, Supplement 2, pp. S113-S121, Oct. 2008, (Year:2008)", *Journal of the Royal Society, Interface*, Oct. 2008, vol. 5, Supplement 2, S113-S121.
- Park. ChIP-seq: advantages and challenges of a maturing technology. *Nature Reviews Genetics* vol. 10, pp. 669-680 (2009).
- "U.S. App. No. 61/982,001, filed Apr. 21, 2014 (Year:2014)".
- Simon, et al., "Using formaldehyde-assisted isolation of regulatory elements (FAIRE) to isolate active regulatory DNA", *Nature Protocols*, 2012, 7(2): 256-267.
- Smith, et al. Highly-multiplexed barcode sequencing: an efficient method for parallel analysis of pooled samples. *Nucleic Acids Research*, 38(13): e142 (2010).
- Song, et al., "DNase-seq: A High-Resolution Technique for Mapping Active Gene Regulatory Elements across the Genome from Mammalian Cells", Cold Spring Harbor Laboratory Press, 2010, 2010(2), doi:10.1101/pdb.prot5384.
- Zentner, et al. Surveying the epigenomic landscape, one base at a time. *Genome Biol.* Oct. 22, 2012;13(10):250. doi: 10.1186/gb4051.
- Anonymous: "TCEP=HCl" Thermo Scientific, Dec. 31, 2013 (Dec. 31, 2013), XP055508461, Retrieved from the Internet: URL:https://assets.thermofisher.com/TFS-Assets/LSG/manuals/MAN0011306_TCEP_HCl_UG.pdf.
- Caruccio, et al. Nextera Technology for NGS DNA Library Preparation: Simultaneous Fragmentation and Tagging by In Vitro Transposition, Nextera Technology, 2009, 16-3, 1-3. (Year: 2009).
- Co-pending U.S. Appl. No. 16/033,065, filed Jul. 11, 2018.
- Co-pending U.S. Appl. No. 16/043,874, filed Jul. 24, 2018.
- Co-pending U.S. Appl. No. 16/044,374, filed Jul. 24, 2018.
- Co-pending U.S. Appl. No. 16/107,685, filed Aug. 21, 2018.
- Co-pending U.S. Appl. No. 16/138,448, filed Sep. 21, 2018.
- Co-pending U.S. Appl. No. 16/144,832, filed Sep. 27, 2018.
- Co-pending U.S. Appl. No. 16/160,576, filed Oct. 15, 2018.
- Co-pending U.S. Appl. No. 16/160,719, filed Oct. 15, 2018.
- Co-pending U.S. Appl. No. 16/165,389, filed Oct. 19, 2018.
- Co-pending U.S. Appl. No. 16/170,980, filed Oct. 25, 2018.
- Delehanty, et al. Peptides for specific intracellular delivery and targeting of nanoparticles: implications for developing nanoparticle-mediated drug delivery. *Ther Deliv.* Sep. 2010;1(3):411-33.

US 10,227,648 B2

Page 14

(56)

References Cited

OTHER PUBLICATIONS

Epicentre., "EZ-Tn5™ Custom Transposome Construction Kits", <http://www.epicentre.com>, pp. 1-17, 2012.

Gao et al., Toehold of dsDNA Exchange Affects the Hydrogel Swelling Kinetic of a Polymer-dsDNA Hybrid Hydrogel, *Royal Soc. Chem.* 7:1741-1746 (Dec. 20, 2010).

Greenleaf, et al. Assaying the epigenome in limited numbers of cells. *Methods.* Jan. 15, 2015;72:51-6. doi: 10.1016/j.ymeth.2014.10.010. Epub Oct. 22, 2014.

"How many species of bacteria are there" (wisegeek.com; accessed Jan. 21, 2014).

Hu et al., Shape Controllable Microgel Particles Prepared by Microfluidic Combining External Crosslinking, *Biomicrofluidics* 6:26502 (May 18, 2012).

Lebedev, A. et al. "Hot Start PCR with heat-activatable primers: a novel approach for improved PCR performance" *NAR* (2008) 36(20):E131-1.

"List of sequenced bacterial genomes" (Wikipedia.com; accessed Jan. 24, 2014).

McGinnis, et al. Multi-seq: Scalable sample multiplexing for single-cell RNA sequencing using lipid-tagged indices. *bioRxiv* 387241; doi: <https://doi.org/10.1101/387241>.

"Meyer, et al., From micrograms to picograms: quantitative PCR reduces the material demands of high-throughput sequencing, *Nucleic Acids Research*, 2008, vol. 36, No. 1, 6 pages".

Savva, et al. The structural basis of specific base-excision repair by uracil-Dna glycosylase. *Nature.* Feb. 9, 1995;373(6514):487-93.

Zhang, et al. One-step fabrication of supramolecular microcapsules from microfluidic droplets. *Science.* Feb. 10, 2012;335(6069):690-4. doi: 10.1126/science.1215416.

Zhang, et al. Reconstruction of DNA sequencing by hybridization. *Bioinformatics.* Jan. 2003;19(1):14-21.

Co-pending U.S. Appl. No. 16/196,684, filed Nov. 20, 2018.

Co-pending U.S. Appl. No. 16/206,168, filed Nov. 30, 2018.

Co-pending U.S. Appl. No. 16/212,441, filed Dec. 6, 2018.

Jin, et al. Genome-wide detection of DNase I hypersensitive sites in single cells and FFPE tissue samples. *Nature.* Dec. 3, 2015;528(7580):142-6. doi: 10.1038/nature15740.

Margulies 2005 Supplementary methods (Year: 2005).

Thaxton, C.S. et al. "A Bio-Bar-Code Assay Based Upon Dithiothreitol Oligonucleotide Release" *Anal Chem* (2005) 77:8174-8178.





FIG. 1



U.S. Patent

Mar. 12, 2019

Sheet 3 of 8

US 10,227,648 B2




Fig. 3

U.S. Patent

Mar. 12, 2019

Sheet 4 of 8

US 10,227,648 B2






Fig. 4



A: CviQI	G/TAC
B: BfaI	C/TAG
C: HinP1I	G/CGC
D: CviAII	C/ATG
E: TaqαI	T/CGA
F: MseI	T/TAA
G: MspI	C/CGG

Fig. 5

**Fig. 6**

	4 Cutter	6 Cutter
Pair 1	MspI C/CGG	NarI GG/CGCC
Pair 2	Bfal C/TAG	NdeI CA/TATG
Pair 3	HinP1I G/CGC	Clal AT/CGAT
Pair 4	MseI T/TAA	NdeI CA/TATG
Pair 5	CviQI G/TAC	NdeI CA/TATG
Pair 6	TaqøI T/CGA	AclI AA/CGTT

Fig. 7A

	4 Cutter	6 Cutter
Pair 1	RsaI GT/AC	PmeI GTTT/AAAC
Pair 2	AluI AG/CT	EcoRV GAT/ATC
Pair 3	BstUI CG/CG	PmeI GTTT/AAAC
Pair 4	DpnI GA/TC	StuI AGG/CCT
Pair 5	HaeIII GG/CC	PmeI GTTT/AAAC
Pair 6	HpyCH4V TG/CA	SfoI GGC/GCC

Fig. 7B




Fig. 8

US 10,227,648 B2

1

**METHODS AND SYSTEMS FOR
PROCESSING POLYNUCLEOTIDES****CROSS-REFERENCE**

This application is a continuation application of U.S. application Ser. No. 14/104,650 filed Dec. 12, 2013, which claims priority to U.S. Provisional Patent Application No. 61/737,374, filed Dec. 14, 2012, which applications are entirely incorporated herein by reference.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Jan. 14, 2014, is named 43487-703.201_SL.txt and is 4,650 bytes in size.

BACKGROUND

The processing of polynucleotides and polynucleotide fragments is a critical aspect of a wide variety of technologies, including polynucleotide sequencing. Polynucleotide sequencing continues to find more widespread use in medical applications such as genetic screening and genotyping of tumors. Many polynucleotide sequencing methods rely on sample processing techniques solely utilizing random fragmentation of polynucleotides. Such random, uncontrolled fragmentation can introduce several problems in downstream processing. For example, these methods may produce fragments with large variation in length, including a large number or fraction of sequences that are too long to be sequenced accurately. This results in a loss of sequence information. Current methods of processing may also damage polynucleotides, resulting in incorrect sequence information, and/or the loss of sequence information. These, and other, problems may be significantly amplified by relatively minor operator variability. Thus, there is a significant need for improved methods that provide better control over all aspects of polynucleotide fragmentation and processing. In particular, there is need for polynucleotide processing methods that consistently provide fragments of appropriate size and composition for any downstream application, including sequencing.

SUMMARY**I. Non-Overlapping Fragmentation**

This disclosure provides methods, compositions, systems, and devices for processing polynucleotides. In one example, a method provided herein comprises: (a) providing a target polynucleotide; (b) fragmenting said target polynucleotide to generate a plurality of non-overlapping first polynucleotide fragments; (c) partitioning said first polynucleotide fragments to generate partitioned first polynucleotide fragments, wherein at least one partition of said partitioned first polynucleotide fragments comprises a first polynucleotide fragment with a unique sequence within said at least one partition; and (d) fragmenting said partitioned first polynucleotide fragments, to generate a plurality of non-overlapping second polynucleotide fragments.

In some of the methods provided in this disclosure, a third and fourth set of polynucleotide fragments are generated by performing the method described above and additionally performing a method comprising: (a) fragmenting said target

2

polynucleotide to generate a plurality of non-overlapping third polynucleotide fragments; (b) partitioning said third polynucleotide fragments to generate partitioned third polynucleotide fragments, wherein at least one partition of said partitioned third polynucleotide fragments comprises a third polynucleotide fragment with a unique sequence within said at least one partition; and (c) fragmenting said partitioned third polynucleotide fragments to generate a plurality of non-overlapping fourth polynucleotide fragments.

The third polynucleotide fragments may overlap with the first polynucleotide fragments. The fourth polynucleotide fragments may overlap with the second polynucleotide fragments.

The target polynucleotide may be, for example, DNA, RNA, cDNA, or any other polynucleotide.

In some cases, at least one of the first, second, third, and fourth polynucleotide fragments are generated by an enzyme. The enzyme may be a restriction enzyme. The restriction enzyme used to generate the first polynucleotide fragments may be different from the restriction enzyme used to generate the third polynucleotide fragments. The restriction enzyme used to generate the second polynucleotide fragments may be different from the restriction enzyme used to generate the fourth polynucleotide fragments. The restriction enzymes may have a recognition site of at least about six nucleotides in length.

The fragments can be of a variety of lengths. For example, the first and/or third polynucleotide fragments may have a median length of least about 10,000 nucleotides. The second or fourth polynucleotide fragments may have a median length of less than about 200 nucleotides.

The fragments can be attached to barcodes. For example, the second polynucleotide fragments and/or the fourth polynucleotide fragments may be attached to barcodes, to generate barcoded second and/or fourth polynucleotide fragments. The barcodes may be polynucleotide barcodes. The attachment of the barcodes to the polynucleotide fragments may be performed using an enzyme. The enzyme may be a ligase. The barcoded fragments may be pooled. Unpooled or pooled barcoded fragments may be sequenced.

In some cases, one or more steps of the methods described in this disclosure may be performed within a device. The device may comprise at least one well. The well may be a microwell. Any of the partitioning steps described in this disclosure may be performed by dispensing into a microwell.

The microwell (or well) may comprise reagents. These reagents may be any reagent, including, for example, barcodes, enzymes, adapters, and combinations thereof. The reagents may be physically separated from a polynucleotide sample placed in the microwell. This physical separation may be accomplished by containing the reagents within a microcapsule that is placed within a microwell. The physical separation may also be accomplished by dispensing the reagents in the microwell and overlaying the reagents with a layer that is, for example, dissolvable, meltable, or permeable prior to introducing the polynucleotide sample into the microwell. This layer may be, for example, an oil, wax, membrane, or the like. The microwell may be sealed at any point, for example after addition of the microcapsule, after addition of the reagents, or after addition of either of these components plus a polynucleotide sample.

Partitioning may also be performed by a variety of other means, including through the use of fluid flow in microfluidic channels, by emulsification, using spotted arrays, by surface acoustic waves, and by piezoelectric droplet generation.

US 10,227,648 B2

3

Additional methods of fragmenting nucleic acids that are compatible with the methods provided herein include mechanical disruption, sonication, chemical fragmentation, treatment with UV light, and heating, and combinations thereof. These methods may be used to fragment, for example, the partitioned first or third polynucleotide fragments described above.

Partitioning may be done at any time. For example, the first polynucleotide fragments and/or the third polynucleotide fragments may each be further partitioned into two or more partitions before further processing.

Pseudo-Random Fragmentation

This disclosure provides methods for pseudo-random fragmentation of polynucleotides. In some cases, such methods comprise: (a) providing a target polynucleotide; (b) fragmenting said target polynucleotide to generate a plurality of first polynucleotide fragments; (c) partitioning said first polynucleotide fragments to generate partitioned first polynucleotide fragments, such that at least one partition comprises a first polynucleotide fragment with a unique sequence within said at least one partition; and (d) fragmenting said partitioned first polynucleotide fragments with at least one restriction enzyme in at least one partition, to generate a plurality of second polynucleotide fragments, wherein said partitioned first polynucleotide fragment is fragmented with at least two restriction enzymes across all partitions.

In some cases, at least two restriction enzymes are disposed within the same partition. In some cases, at least two restriction enzymes are disposed across a plurality of different partitions.

The pseudo-random fragmentation methods can be performed in order to yield fragments of a certain size. In some cases, at least about 50% of the nucleotides within a target polynucleotide are within about 100 nucleotides of a restriction site of a restriction enzyme used to perform pseudo-random fragmentation. In some cases, at most about 25% of the nucleotides within a target polynucleotide are within about 50 nucleotides of a restriction site of a restriction enzyme used to perform pseudo-random fragmentation. In some cases, at most about 10% of the nucleotides within a target polynucleotide are more than about 200 nucleotides from a restriction site a restriction enzyme used to perform pseudo-random fragmentation.

A polynucleotide may be treated with two or more restriction enzymes concurrently or sequentially.

The pseudo-randomly fragmented polynucleotides may be attached to barcodes, to generate barcoded polynucleotide fragments. The barcoded polynucleotides may be pooled and sequenced.

The number of partitions holding the partitioned first polynucleotide fragments may be at least about 1,000 partitions. The volume of these partitions may be less than about 500 nanoliters.

Each enzyme may occupy an equivalent number of partitions, or each enzyme may occupy a different number of partitions.

III. Restriction Enzyme-Mediated Recycling

This disclosure provides methods for recycling certain unwanted reaction side products back into starting materials that can be used to generate a desired product. In some cases, these methods comprise: (a) providing a first polynucleotide, a second polynucleotide, a first restriction enzyme, and a second restriction enzyme, wherein said first polynucleotide comprises a target polynucleotide or a fragment thereof; and

4

(b) attaching said first polynucleotide to said second polynucleotide, to generate a polynucleotide product, wherein said first restriction enzyme cuts a polynucleotide generated by attachment of said first polynucleotide to itself, said second restriction enzyme cuts a polynucleotide generated by attachment of said second polynucleotide to itself, and neither said first restriction enzyme nor said second restriction enzyme cuts said polynucleotide product.

The first polynucleotide may be generated in the same reaction volume as the polynucleotide product, or in a different reaction volume. The target polynucleotide may be, for example, a fragment of genomic DNA.

The second polynucleotide may be generated in the same reaction volume as the polynucleotide product, or in a different reaction volume. The second polynucleotide may be, for example, a barcode or an adapter.

The first restriction enzyme may have a recognition site of at most about four nucleotides in length. The second restriction enzyme may have a recognition site of at least about six nucleotides in length. The first restriction enzyme may have a recognition site of about four nucleotides in length. The second restriction enzyme may have a recognition site of at least about five nucleotides in length.

The first and second restriction enzymes may generate ligation compatible ends. These ends may have single-stranded overhangs (i.e., "sticky ends") or be blunt. The sticky ends may match in sequence and orientation, to allow ligation. The attachment step may be performed by ligation.

The sequence 5' to the ligation compatible end generated by the first restriction enzyme may be different from the sequence 5' to the ligation compatible end generated by the second restriction enzyme. This will ensure that the desired product cannot be re-cut by either restriction enzyme.

The sequence 3' to the ligation compatible end generated by the first restriction enzyme may be different from the sequence 3' to the ligation compatible end generated by the second restriction enzyme. This will ensure that the desired product cannot be re-cut by either restriction enzyme. Given the criteria provided throughout this specification, one of ordinary skill in the art will recognize that many pairs of enzymes are suitable for use with this method.

The recycling may provide increased yield of the desired product, for example at least about 75% (w/w).

Also provided by this disclosure is a polynucleotide fragment generated by any of the methods provided herein, devices for performing the methods provided herein, and systems for performing the methods provided herein.

The methods provided in this disclosure (and portions thereof) may also be used with each other. For example, the non-overlapping fragmentation methods may be used alone and/or with the pseudo-random fragmentation methods and/or with the restriction enzyme-mediated recycling methods. Likewise, the pseudo-random fragmentation methods may be used alone and/or with the non-overlapping fragmentation methods and/or with the restriction enzyme-mediated recycling methods. Similarly, the restriction enzyme-mediated recycling methods may be used alone and/or with the non-overlapping fragmentation methods and/or with the pseudo-random fragmentation methods.

Additional aspects and advantages of the present disclosure will become readily apparent to those skilled in this art from the following detailed description, wherein only illustrative embodiments of the present disclosure are shown and described. As will be realized, the present disclosure is capable of other and different embodiments, and its several details are capable of modifications in various obvious respects, all without departing from the disclosure. Accord-

US 10,227,648 B2

5

ingly, the drawings and description are to be regarded as illustrative in nature, and not as restrictive.

INCORPORATION BY REFERENCE

All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.

BRIEF DESCRIPTION OF THE DRAWINGS

The novel features of methods, compositions, systems, and devices of this disclosure are set forth with particularity in the appended claims. A better understanding of the features and advantages of this disclosure will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the methods, compositions, systems, and devices of this disclosure are utilized, and the accompanying drawings of which:

FIG. 1 is a schematic representation of overlapping and non-overlapping deoxyribonucleic acid (DNA) fragments.

FIG. 2 is a schematic representation of methods of generating non-overlapping DNA fragments for DNA sequencing. FIG. 2 discloses SEQ ID NOS 8-10, respectively, in order of appearance.

FIG. 3 shows a distribution of DNA fragment size after simulating generation of 1 Mbp random DNA sequences followed by cutting the sequences with a 6Mer cutter, StuI (AGG/CCT).

FIG. 4 shows a distribution of DNA fragment size after simulating generation of 1 Mbp random DNA sequences followed by cutting the sequences with a 4Mer cutter, CviQI (G/TAC).

FIG. 5 shows a distribution of DNA fragment size after simulating the generation of a 1 Mbp random DNA sequence followed by cutting the sequences with seven 4Mer cutters: (1) CviQI (G/TAC), (2) BfaI (C/TAG), (3) HinfI (G/CGC), (4) CviAII (C/ATG), (5) TaqαI (T/CGA), (6) MseI (T/TAA), and (7) MspI (C/CGG).

FIG. 6 shows the generation of unwanted byproducts ("Side products") during ligation of adapters to genomic DNA fragments and the recycling of the unwanted byproducts into starting materials ("Genomic DNA", "Adapter 1", and "Adapter 2") by paring of appropriate restriction enzymes (here, MspI and NarI). FIG. 6 discloses SEQ ID NOS 11 and 11-13, respectively, in order of appearance.

FIG. 7A shows exemplary 4Mer cutter and 6Mer cutter pairs generating sticky ends.

FIG. 7B shows exemplary 4Mer cutter and 6Mer cutter pairs generating blunt ends.

FIG. 8 shows a capsule containing reagents for barcoding of polynucleotide fragments in a microwell (left) and a microwell containing reagents for barcoding of polynucleotide fragments dispensed in a microwell and sealed to prevent evaporation (right).

DETAILED DESCRIPTION

While various embodiments of the invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions may occur to those skilled in the art without depart-

6

ing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed.

This disclosure provides methods, compositions, systems, and devices for processing polynucleotides. Applications include processing polynucleotides for polynucleotide sequencing. Polynucleotides sequencing includes the sequencing of whole genomes, detection of specific sequences such as single nucleotide polymorphisms (SNPs) and other mutations, detection of nucleic acid (e.g., deoxyribonucleic acid) insertions, and detection of nucleic acid deletions.

Utilization of the methods, compositions, systems, and devices described herein may incorporate, unless otherwise indicated, conventional techniques of organic chemistry, polymer technology, microfluidics, molecular biology and recombinant techniques, cell biology, biochemistry, and immunology. Such conventional techniques include microwell construction, microfluidic device construction, polymer chemistry, restriction digestion, ligation, cloning, polynucleotide sequencing, and polynucleotide sequence assembly. Specific, non-limiting, illustrations of suitable techniques are described throughout this disclosure. However, equivalent procedures may also be utilized. Descriptions of certain techniques may be found in standard laboratory manuals, such as *Genome Analysis: A Laboratory Manual Series (Vols. I-IV)*, *Using Antibodies: A Laboratory Manual*, *Cells: A Laboratory Manual*, *PCR Primer: A Laboratory Manual*, and *Molecular Cloning: A Laboratory Manual* (all from Cold Spring Harbor Laboratory Press), and "Oligonucleotide Synthesis: A Practical Approach" 1984, IRL Press London, all of which are herein incorporated in their entirety by reference for all purposes.

I. Definitions

The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting.

As used herein, the singular forms "a," "an," and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise. Furthermore, to the extent that the terms "including," "includes," "having," "has", "with", "such as", or variants thereof, are used in either the specification and/or the claims, such terms are not limiting and are intended to be inclusive in a manner similar to the term "comprising".

The term "about," as used herein, generally refers to a range that is 15% greater than or less than a stated numerical value within the context of the particular usage. For example, "about 10" would include a range from 8.5 to 11.5.

The term "barcode", as used herein, generally refers to a label that may be attached to a polynucleotide, or any variant thereof, to convey information about the polynucleotide. For example, a barcode may be a polynucleotide sequence attached to all fragments of a target polynucleotide contained within a particular partition. This barcode may then be sequenced with the fragments of the target polynucleotide. The presence of the same barcode on multiple sequences may provide information about the origin of the sequence. For example, a barcode may indicate that the sequence came from a particular partition and/or a proximal region of a genome. This may be particularly useful when several partitions are pooled before sequencing.

The term "bp," as used herein, generally refers to an abbreviation for "base pairs".

US 10,227,648 B2

7

The term “Mer,” as used herein to refer to restriction enzymes, generally refers to the number of nucleotides in one strand of a restriction enzyme’s recognition site. For example, the enzyme CviQI has a recognition site of GTAC (4 nucleotides on one strand) and is thus referred to as a “4Mer cutter.” The enzyme StuI has a recognition site of AGGCCT (6 nucleotides on one strand) and is thus referred to as a “6Mer cutter.”

The term “microwell,” as used herein, generally refers to a well with a volume of less than 1 mL. Microwells may be made in various volumes, depending on the application. For example, microwells may be made in a size appropriate to accommodate any of the partition volumes described herein.

The terms “non-overlapping” and “overlapping,” as used to refer to polynucleotide fragments, generally refer to a collection of polynucleotide fragments without overlapping sequence or with overlapping sequence, respectively. By way of illustration, consider a hypothetical partition containing three copies of a genome (FIG. 1, top set of sequences). This genome may be fragmented randomly (e.g., by shearing in a pipette) or non-randomly (e.g., by digesting with a rare cutter). Fragmenting randomly produces overlapping sequences (second set of sequences from top in FIG. 1, “Fragmented randomly to generate overlap”), because each copy of the genome is cut at different positions. After sequencing of the fragments (which provides “sequence contigs”), this overlap may be used to determine the linear order of the fragments, thereby enabling assembly of the entire genomic sequence. By contrast, fragmenting by digesting with a rare cutter produces non-overlapping fragments, because each copy of the (same) genome is cut at the same position (third set of sequences from the top in FIG. 1, “Fragmented non-randomly using RE-1 to generate non-overlapping fragments”). After sequencing these fragments, it may be difficult to deduce their linear order due to the lack of overlap between the fragments. However, as described in this disclosure, the linear order may be determined by, for example, fragmenting the genome using a different technique. The fourth set of sequences from the top of FIG. 1 demonstrates the use of a second rare-cutter enzyme to generate a second set of non-overlapping fragments (“Fragmented non-randomly using RE-2 to generate non-overlapping fragments”). Because two different enzymes, for example, are used to generate the two sets of non-overlapping fragments, there is overlap between the fragments generated with the first rare-cutter enzyme (RE-1) and the fragments generated with the second rare-cutter enzyme (RE-2). This overlap may then be used to assemble the linear order of the sequences, and therefore the sequence of the entire genome.

The term “partition,” as used herein, may be a verb or a noun. When used as a verb (e.g., “partitioning”), the term refers to the fractionation of a substance (e.g., a polynucleotide) between vessels that can be used to sequester one fraction from another. Such vessels are referred to using the noun “partition.” Partitioning may be performed, for example, using microfluidics, dilution, dispensing, and the like. A partition may be, for example, a well, a microwell, a droplet, a test tube, a spot, or any other means of sequestering one fraction of a sample from another. In the methods and systems described herein, polynucleotides are often partitioned into microwells.

The terms “polynucleotide” or “nucleic acid,” as used herein, are used herein to refer to biological molecules comprising a plurality of nucleotides. Exemplary polynucle-

8

otides include deoxyribonucleic acids, ribonucleic acids, and synthetic analogues thereof, including peptide nucleic acids.

The term “rare-cutter enzyme,” as used herein, generally refers to an enzyme with a recognition site that occurs only rarely in a genome. The size of restriction fragments generated by cutting a hypothetical random genome with a restriction enzyme may be approximated by 4^N , where N is the number of nucleotides in the recognition site of the enzyme. For example, an enzyme with a recognition site consisting of 7 nucleotides would cut a genome once every 4⁷ bp, producing fragments of about 16,384 bp. Generally rare-cutter enzymes have recognition sites comprising 6 or more nucleotides. For example, a rare cutter enzyme may have a recognition site comprising or consisting of 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 nucleotides. Examples of rare-cutter enzymes include NotI (GCGGCCGC), XmaII (CGGCCG), SstII (CCGCGG), SalI (GTCGAC), NruI (TCGCGA), NheI (GCTAGC), Nb.BbvCI (CCTCAGC), BbvCI (CCTCAGC), AscI (GGCGCGCC), AsiSI (GC-GATCGC), FseI (GGCCGGCC), PacI (TTAATTA), PmeI (GTTTAAAC), SbfI (CCTGCAGG), SgrAI (CRCCG-GYG), SwaI (ATTTAAAT), BspQI (GCTCTTC), SapI (GCTCTTC), SfiI (GGCCNNNNNGGCC (SEQ ID NO: 1)), CspCI (CAANNNNNGTGG (SEQ ID NO: 2)), AbsI (CCTCGAGG), CciNI (GCGGCCGC), FspAI (RTGCG-CAY), MauBI (CGCGCGCG), MreI (GCCTGGCG), MssI (GTTTAAAC), PaeI (GGCGCGCC), RgaI (GC-GATCGC), RgiI (GGCCGGCC), SdaI (CCTGCAGG), SfaI (GCGATCGC), SgfI (GCGATCGC), SgrDI (CGTC-GACG), SgsI (GGCGCGCC), SmlI (ATTTAAAT), SrfI (GCCCCGGC), Sse2321 (CGCCGGCG), Sse83871 (CCT-GCAGG), LguI (GCTCTTC), PciSI (GCTCTTC), AarI (CACCTGC), AjuI (GAANNNNNNNTTGG (SEQ ID NO: 3)), AoiI (GAACNNNNNNNTCC (SEQ ID NO: 4)), BarI (GAAGNNNNNNNTAC (SEQ ID NO: 5)), PpiI (GAACNNNNNNCTC (SEQ ID NO: 6)), PsrI (GAACNNNNNNNTAC (SEQ ID NO: 7)), and others.

The term “target polynucleotide,” as used herein, generally refers to a polynucleotide to be processed. For example, if a user intends to process genomic DNA into fragments that may be sequenced, the genomic DNA would be the target polynucleotide. If a user intends to process fragments of a polynucleotide, then the fragments of the polynucleotide may be the target polynucleotide.

II. Non-Overlapping Fragmentation

This disclosure provides methods, compositions, systems, and devices for the generation of non-overlapping polynucleotide fragments. These fragments may be useful for downstream analyses such as DNA sequencing. For example, with reference to FIG. 2, a target polynucleotide **101**, such as genomic DNA, may be fragmented to generate a plurality of non-overlapping first polynucleotide fragments **102**. This fragmentation may be performed, for example, by digesting the target polynucleotide with a rare-cutter enzyme (e.g., rare-cutter enzyme 1), or an artificial restriction DNA cutter (ARCUT; Yamamoto et al., *Nucleic Acids Res.*, 2007, 35(7), e53). The first polynucleotide fragments may then be partitioned, such that at least one partition **103** comprises a first polynucleotide fragment with a unique sequence within that partition and, optionally, an additional first polynucleotide fragment with a different sequence **104**. The partitioned first polynucleotide fragments may then be further fragmented to produce a plurality of non-overlapping second polynucleotide fragments **105**. This fragmentation may be

US 10,227,648 B2

9

performed, for example, by enzymatic digestion, exposure to ultraviolet (UV) light, ultrasonication, and/or mechanical agitation. The second polynucleotide fragments may be of a size that is appropriate for DNA sequencing, i.e., a size that enables a DNA sequencer to obtain accurate sequence data for the entire fragment.

In order to facilitate DNA sequence assembly, the second fragments may be attached to a barcode, which may be attached to all of the second fragments disposed in a particular partition. The barcode may be, for example, a DNA barcode. With continued reference to FIG. 2, after attachment of the barcode, the barcoded fragments may be pooled into a partition comprising pooled, barcoded sequences 106. Three barcodes are depicted as [1], [2], and [3] in 106. The pooled fragments may be sequenced.

Certain methods of genome sequence assembly rely on the presence of overlapping fragments in order to generate higher order sequence data (e.g., whole genome sequences) from sequenced fragments. The methods, compositions, systems, and devices provided herein may also be used to provide overlapping fragments. For example, with continued reference to FIG. 2, fragments overlapping with the first and second fragments described above may be generated by generating a plurality of non-overlapping third polynucleotide fragments from the target polynucleotide 107. The third polynucleotide fragments may be generated, for example, by digesting the target polynucleotide 101 with a rare-cutter enzyme (e.g., rare-cutter enzyme 2; or ARCUT) that is different from the rare-cutter enzyme used to generate the first polynucleotide fragments. If rare-cutter enzymes 1 and 2 are chosen to cut the target polynucleotide sequence at different positions, the third polynucleotide fragments and the first polynucleotide fragments will overlap. The third polynucleotide fragments may then be processed as described above for the first polynucleotide fragments.

Specifically, the third polynucleotide fragments may be partitioned such that at least one partition 108 comprises a third polynucleotide fragment with a unique sequence within that partition and, optionally, an additional third polynucleotide fragment with a different sequence 109. These partitioned fragments may then be further fragmented to produce a plurality of non-overlapping fourth polynucleotide fragments 110. The fourth polynucleotide fragments and the second polynucleotide fragments may overlap. As for the second polynucleotide fragments, the fourth polynucleotide fragments may be generated by, for example, enzymatic digestion, exposure to ultraviolet (UV) light, ultrasonication, and/or mechanical agitation. The fourth fragments may be of a size that is appropriate for DNA sequencing, i.e., a size that enables a DNA sequencer to obtain accurate sequence data for the entire fragment.

In order to facilitate DNA sequencing, the fourth fragments may be attached to a barcode, which may be attached to all of the fourth fragments disposed in a particular partition. The barcode may be, for example, a DNA barcode. After attachment of the barcode, the barcoded fragments may be pooled, into a partition comprising pooled, barcoded, sequences 111. Three barcodes are depicted as [4], [5], and [6] in 111. The pooled fragments may be sequenced. The overlap between the sequences of the second fragments and the fourth fragments may be used to assemble higher order sequences, such whole genome sequences.

The steps described above may be performed using a variety of techniques. For example, certain steps of the methods may be performed in a device comprising microwell chambers (microwells), for example a microfluidic device. These microwells may be connected to each other, or

10

to a source of reagents, by channels. The first and third fragments may be generated outside of the device and then introduced into the device (or separate devices) for further processing. Partitioning of the first and third fragments may be accomplished using fluidic techniques. Generation of the second and fourth fragments may then occur within the microwells of the device or devices. These microwells may contain reagents for barcoding of the second and fourth fragments, such as DNA barcodes, ligase, adapter sequences, and the like. Microwells may feed or be directed into a common outlet, so that barcoded fragments may be pooled or otherwise collected into one or more aliquots which may then be sequenced.

In another example, the entire process could be performed within a single device. For example, a device could be split into two sections. A first section may comprise a partition comprising rare-cutter enzyme 1 (generating first polynucleotide fragments) and a second section may comprise a partition comprising rare-cutter enzyme 2 (generating third polynucleotide fragments). An aliquot of the target polynucleotide sequence may be placed into each of these partitions. Following digestion, the enzyme may be inactivated and the samples may be partitioned, fragmented, barcoded, pooled, and sequenced as described above. For convenience, this example has been described using rare-cutter enzymes as the means of generating the first and third fragments. However, this is not intended to be limiting, here or anywhere else in this disclosure. One of ordinary skill in the art will readily recognize that other means of generating non-overlapping, or predominantly non-overlapping, fragments would be just as suitable as the use of rare-cutter enzymes.

III. Pseudo-Random Fragmentation

This disclosure also provides methods, compositions, systems, and devices for fragmenting polynucleotides in a pseudo-random manner. This may be performed by treating partitioned polynucleotides with more than one restriction enzyme. For example, polynucleotides partitioned into microwells may be treated with combinations of restriction enzymes. Within each partition containing a particular combination of enzymes, the cutting is defined and predictable. However, across all of the partitions (through the use of multiple combinations of restriction enzymes in different partitions), the polynucleotide fragments generated approximate those obtained from methods of random fragmentation. However, these polynucleotide fragments are generated in a much more controlled manner than random fragments generated by methods known in the art (e.g., shearing). The partitioned, pseudo-randomly fragmented polynucleotides may be barcoded, as described throughout this disclosure, pooled, and sequenced. The pseudo-random fragmentation methods may be used with the non-overlapping fragmentation methods described herein, or with any other method described herein such as the high yield adapter/barcode attachment method. Pseudo-random fragmentation may occur by exposing a polynucleotide to multiple enzymes simultaneously, sequentially, or simultaneously and sequentially.

Thus, this disclosure provides methods and systems for processing polynucleotides comprising generating pseudo-random fragments of said polynucleotides. These pseudo random fragments are generated by treating a polynucleotide with more than one restriction enzyme. For example, a polynucleotide may be treated with about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 45,

US 10,227,648 B2

11

45, 50, or more restriction enzymes. A polynucleotide may be treated with at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 45, 45, 50, or more restriction enzymes. A polynucleotide may be treated with at least 2 but fewer than 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 45, 45, or 50 restriction enzymes. A polynucleotide may be treated with about 2-4, 4-6, 6-8, 8-10, 10-12, 12-14, 14-16, 16-18, 18-20, 20-25, 25-30, 35-40, 40-45, or 45-50 restriction enzymes.

The restriction enzymes may be chosen in order to maximize the number or fraction of fragments that will provide accurate sequencing data, based on the size of the fragments generated by the pseudo-random fragmentation. For present day sequencing technology, accuracy degrades beyond a read length of about 100 nucleotides. Therefore, fragments of about 200 or fewer nucleotides generally provide the most accurate sequence data since they can be sequenced from either end. Fragments below about 50 nucleotides are generally less desirable because, although the produce accurate sequencing data, they underutilize the read length capacity of current sequencing instruments which are capable of 150 to 200 base reads. Fragments of about 200 to about 400 nucleotides may be sequenced with systematic errors introduced as the read length increases beyond the initial 100 bases from each end. Sequence information from fragments greater than about 400 nucleotides is typically completely lost for those bases greater than 200 bases from either end. One of skill in the art will recognize that sequencing technology is constantly advancing and that the ability to obtain accurate sequence information from longer fragments is also constantly improving. Thus, the pseudo-random fragmentation methods presented herein may be used to produce optimal fragment lengths for any sequencing method.

In some cases, fragments may be defined by the distance of their component nucleotides from a restriction site (measured in nucleotides). For example, each nucleotide within a polynucleotide fragment generated by the pseudo-random fragmentation method may be less than about 10, 50, 75, 100, 125, 150, 175, 200, 250, 300, 350, 400, 550, 600, 1000, 5000, 10000, or 100000 nucleotides from the restriction site of an enzyme to which the polynucleotide is exposed. Each nucleotide within a polynucleotide fragment may be about 10, 50, 75, 100, 125, 150, 175, 200, 250, 300, 350, 400, 550, 600, 1000, 5000, 10000, or 100000 nucleotides from the restriction site of an enzyme to which the polynucleotide is exposed. Each nucleotide within a polynucleotide fragment may be at least about 10, 50, 75, 100, 125, 150, 175, 200, 250, 300, 350, 400, 550, 600, 1000, 5000, 10000, or 100000 nucleotides from the restriction site of an enzyme to which the polynucleotide is exposed.

In some cases, at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%, of the nucleotides comprising a target polynucleotide sequence are within about 10, 50, 75, 100, 125, 150, 175, 200, 250, 300, 350, 400, 550, 600, 1000, 5000, 10000, or 100000 nucleotides from the restriction site of an enzyme to which the polynucleotide is exposed. All combinations of these percentages and polynucleotide lengths are contemplated.

In some cases, at less than about 1%, 5%, 10%, 25%, 30%, 35%, 40%, 45%, or 50% of the nucleotides comprising a target polynucleotide sequence are within about 1, 5, 10, 50, 200, 250, 300, 350, 400, 550, 600, 1000, 5000, 10000, or 100000 nucleotides from the restriction site of an enzyme

12

to which the polynucleotide is exposed. All combinations of these percentages and polynucleotide lengths are contemplated.

The pseudo-random fragmentation methods may be used to obtain fragments of about 10 to 50 nucleotides, 46 to 210 nucleotides, 50 to 250 nucleotides, 250 to 400 nucleotides, 400 to 550 nucleotides, 550 to 700 nucleotides, 700 to 1000 nucleotides, 1000 to 1300 nucleotides, 1300 to 1600 nucleotides, 1600 to 1900 nucleotides, 1900 to 2200 nucleotides, or 2200 to 3000 nucleotides. The pseudo-random fragmentation methods may be used to obtain fragments with a mean or median of about 40 nucleotides, 60 nucleotides, 80 nucleotides, 100 nucleotides, 120 nucleotides, 130 nucleotides, 140 nucleotides, 160 nucleotides, 180 nucleotides, 200 nucleotides, 250 nucleotides, 300 nucleotides, 400 nucleotides, 500 nucleotides, 600 nucleotides, 700 nucleotides, 800 nucleotides, 900 nucleotides, 1000 nucleotides, 1200 nucleotides, 1400 nucleotides, 1600 nucleotides, 1800 nucleotides, 2000 nucleotides, 2500 nucleotides, 3000 nucleotides, or more. The pseudo-random fragmentation methods may be used to obtain fragments with a mean or median of at least about 40 nucleotides, 60 nucleotides, 80 nucleotides, 100 nucleotides, 120 nucleotides, 130 nucleotides, 140 nucleotides, 160 nucleotides, 180 nucleotides, 200 nucleotides, 250 nucleotides, 300 nucleotides, 400 nucleotides, 500 nucleotides, 600 nucleotides, 700 nucleotides, 800 nucleotides, 900 nucleotides, 1000 nucleotides, 1200 nucleotides, 1400 nucleotides, 1600 nucleotides, 1800 nucleotides, 2000 nucleotides, 2500 nucleotides, 3000 nucleotides, or more. The pseudo-random fragmentation methods may be used to obtain fragments with a mean or median of less than about 40 nucleotides, 60 nucleotides, 80 nucleotides, 100 nucleotides, 120 nucleotides, 130 nucleotides, 140 nucleotides, 160 nucleotides, 180 nucleotides, 200 nucleotides, 250 nucleotides, 300 nucleotides, 400 nucleotides, 500 nucleotides, 600 nucleotides, 700 nucleotides, 800 nucleotides, 900 nucleotides, 1000 nucleotides, 1200 nucleotides, 1400 nucleotides, 1600 nucleotides, 1800 nucleotides, 2000 nucleotides, 2500 nucleotides, or 3000 nucleotides.

In some examples, the pseudo-random fragmentation methods provided herein are used to generate fragments wherein a particular percentage (or fraction) of the fragments generated fall within any of the size ranges described herein. For example, about 0%, 2%, 4%, 6%, 8%, 10%, 12%, 14%, 16%, 18%, 20%, 22%, 24%, 26%, 28%, 30%, 32%, 34%, 36%, 38%, 40%, 42%, 44%, 46%, 48%, 50%, 52%, 54%, 56%, 58%, 60%, 62%, 64%, 66%, 68%, 70%, 72%, 74%, 76%, 78%, 80%, 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, or 100% of the fragments generated may fall within any of the size ranges described herein.

In some examples multiple 4Mer cutters may be used to provide a distribution of about 18% of fragments of about 50 nucleotides or less, about 38% of fragments of about 200 nucleotides or less, about 25% of fragments between about 200 and about 400 nucleotides, and about 37% of fragments greater than about 400 nucleotides (e.g., see FIG. 4).

Additionally, the pseudo-random fragmentation method may be designed to minimize the percentage of fragments greater than a certain number of nucleotides in length, in order to minimize the loss of sequence information. For example, the method may be designed to yield less than about 0.1%, 0.5%, 1%, 2%, 5%, 10%, 20%, or 50% fragments greater than 100 nucleotides. The method may be designed to yield less than about 0.1%, 0.5%, 1%, 2%, 5%, 10%, 20%, or 50% fragments greater than 150 nucleotides. The method may be designed to yield less than about 0.1%,

US 10,227,648 B2

13

0.5%, 1%, 2%, 5%, 10%, 20%, or 50% fragments greater than 200 nucleotides. The method may be designed to yield less than about 0.1%, 0.5%, 1%, 2%, 5%, 10%, 20%, or 50% fragments greater than 300 nucleotides, and so on. As the ability of sequencing technologies to accurately read long DNA fragments increases, the pseudo-random fragmentation methods of the invention may be used to generate sequences suitable for any chosen read length.

Enzymes for use with the pseudo-random fragmentation method described herein may be chosen, for example, based on the length of their recognition site and their compatibility with certain buffer conditions (to allow for combination with other enzymes). Enzymes may also be chosen so that their cutting activity is methylation insensitive, or sensitive to methylation. For example, restriction enzymes with shorter recognition sites generally cut polynucleotides more frequently. Thus, cutting a target polynucleotide with a 6Mer cutter will generally produce more large fragments than cutting the same polynucleotide with a 4Mer cutter (e.g., compare FIGS. 3 and 4). Cutting a target polynucleotide with a plurality of enzymes (e.g. 2, 3, 4, 5, 6, 7, or more) may produce a greater number or fraction of fragments in the optimal size range for DNA sequencing than cutting with a single enzyme (see FIG. 5). Any restriction enzyme may be used with this method. Many are named in this specification, but others are known in the art.

This disclosure also provides methods of selecting a plurality of enzymes for pseudo-random fragmentation of a polynucleotide sequence. For example, a target polynucleotide may be exposed separately to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 restriction enzymes. The size distribution of the target polynucleotide fragments is then determined, for example, by electrophoresis. The combination of enzymes providing the greatest number of fragments that are capable of being sequenced can then be chosen. The method can also be carried out in silico.

The enzymes may be disposed within the same partition, or within a plurality of partitions. For example, any of the plurality of enzyme number described herein may be disposed within a single partition, or across partitions. For example, a polynucleotide may be treated with about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 45, 45, 50, or more restriction enzymes in the same partition, or across partitions. A polynucleotide may be treated with at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 45, 45, 50, or more restriction enzymes in the same partition, or across partitions. A polynucleotide may be treated with at least 2 but fewer than 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 45, 45, or 50 restriction enzymes in the same partition, or across partitions. A polynucleotide may be treated with about 2-4, 4-6, 6-8, 8-10, 10-12, 12-14, 14-16, 16-18, 18-20, 20-25, 25-30, 35-40, 40-45, or 45-50 restriction enzymes in the same partition, or across partitions.

The distribution of the restriction enzymes among the partitions will vary depending on the restriction enzymes, the target polynucleotide, and the desired fragment size. In some cases, each restriction enzyme may be distributed across an equivalent number of partitions, so that the number of partitions occupied by each restriction enzyme is equivalent. For example, if 10 restriction enzymes are used in a device containing 1,000 partitions, each enzyme may be present in 100 partitions. In other cases, each restriction enzyme may be distributed across a non-equivalent number of partitions, so that the number of partitions occupied by each restriction enzyme is not equivalent. For example, if 10

14

restriction enzymes are used in a device containing 1,000 partitions, enzymes 1-8 may be present in 100 partitions each, enzyme 9 may be present in 50 partitions, and enzyme 10 may be present in 150 partitions. Placement of restriction enzymes in an unequal number of partitions may be beneficial, for example, when an enzyme generates a desired product at a low yield. Placing this low-yield enzyme in more partitions will therefore expose more of the target polynucleotide to the enzyme, increasing the amount of the desired product (e.g., fragment of a certain size or composition) that can be formed from the enzyme. Such an approach may be useful for accessing portions of a target polynucleotide (e.g., a genome) that are not cut by enzymes producing polynucleotide fragments at a higher yield. The restriction site and efficiency of an enzyme, composition of the target polynucleotide, and efficiency and side-products generated by the enzyme may all be among the factors considered when determining how many partitions should receive a particular enzyme.

In some cases, different numbers of restriction enzymes may be used in a single partition and across all partitions. For example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 45, 45, or 50 restriction enzymes or more may be used in each partition, while 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 45, 45, or 50 restriction enzymes or more may be used across all partitions. All combinations of these numbers are included within the invention. Non-limiting specific examples include the use of 1 restriction enzyme per partition and 2, 3, 4, 5, 6, 7, 8, 9, or 10 restriction enzymes across all partitions; 2 restriction enzymes per partition and 3, 4, 5, 6, 7, 8, 9, or 10 restriction enzymes across all partitions; 3 restriction enzymes per partition and 4, 5, 6, 7, 8, 9, or 10 restriction enzymes across all partitions; 4 restriction enzymes per partition and 5, 6, 7, 8, 9, or 10 restriction enzymes across all partitions; 5 restriction enzymes per partition and 6, 7, 8, 9, or 10 restriction enzymes across all partitions; 6 restriction enzymes per partition and 7, 8, 9, or 10 restriction enzymes across all partitions; 7 restriction enzymes per partition and 8, 9, or 10 restriction enzymes across all partitions; 8 restriction enzymes per partition and 9 or 10 restriction enzymes across all partitions; and 9 restriction enzymes per partition and 10 or more restriction enzymes across all partitions.

In some cases, at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 45, 45, or 50 restriction enzymes or more may be used in each partition, while at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 45, 45, or 50 restriction enzymes or more may be used across all partitions. All combinations of these numbers are included within the invention. Non-limiting specific examples include the use of at least 1 restriction enzyme per partition and at least 2, 3, 4, 5, 6, 7, 8, 9, or 10 restriction enzymes across all partitions; at least 2 restriction enzymes per partition and at least 3, 4, 5, 6, 7, 8, 9, or 10 restriction enzymes across all partitions; at least 3 restriction enzymes per partition and at least 4, 5, 6, 7, 8, 9, or 10 restriction enzymes across all partitions; at least 4 restriction enzymes per partition and at least 5, 6, 7, 8, 9, or 10 restriction enzymes across all partitions; at least 5 restriction enzymes per partition and at least 6, 7, 8, 9, or 10 restriction enzymes across all partitions; at least 6 restriction enzymes per partition and at least 7, 8, 9, or 10 restriction enzymes across all partitions; at least 7 restriction enzymes per partition and at least 8, 9, or 10 restriction enzymes across all partitions; at least 8 restriction enzymes per partition and at least 9 or 10 restriction enzymes across all

US 10,227,648 B2

15

partitions; and at least 9 restriction enzymes per partition and at least 10 or more restriction enzymes across all partitions.

In some cases, at most 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 45, 45, or 50 restriction enzymes or more may be used in each partition, while at most 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 45, 45, or 50 restriction enzymes or more may be used across all partitions. All combinations of these numbers are included within the invention. Non-limiting specific examples include the use of at most 1 restriction enzyme per partition and at most 2, 3, 4, 5, 6, 7, 8, 9, or 10 restriction enzymes across all partitions; at most 2 restriction enzymes per partition and at most 3, 4, 5, 6, 7, 8, 9, or 10 restriction enzymes across all partitions; at most 3 restriction enzymes per partition and at most 4, 5, 6, 7, 8, 9, or 10 restriction enzymes across all partitions; at most 4 restriction enzymes per partition and at most 5, 6, 7, 8, 9, or 10 restriction enzymes across all partitions; at most 5 restriction enzymes per partition and at most 6, 7, 8, 9, or 10 restriction enzymes across all partitions; at most 6 restriction enzymes per partition and at most 7, 8, 9, or 10 restriction enzymes across all partitions; at most 7 restriction enzymes per partition and at most 8, 9, or 10 restriction enzymes across all partitions; at most 8 restriction enzymes per partition and at most 9 or 10 restriction enzymes across all partitions; and at most 9 restriction enzymes per partition and at most 10 or more restriction enzymes across all partitions.

In some cases, at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 45, 45, or 50 restriction enzymes or more may be used in each partition, while at most 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 45, 45, or 50 restriction enzymes or more may be used across all partitions. All combinations of these numbers are included within the invention. Non-limiting specific examples include the use of at least 1 restriction enzyme per partition and at most 2, 3, 4, 5, 6, 7, 8, 9, or 10 restriction enzymes across all partitions; at least 2 restriction enzymes per partition and at most 3, 4, 5, 6, 7, 8, 9, or 10 restriction enzymes across all partitions; at least 3 restriction enzymes per partition and at most 4, 5, 6, 7, 8, 9, or 10 restriction enzymes across all partitions; at least 4 restriction enzymes per partition and at most 5, 6, 7, 8, 9, or 10 restriction enzymes across all partitions; at least 5 restriction enzymes per partition and at most 6, 7, 8, 9, or 10 restriction enzymes across all partitions; at least 6 restriction enzymes per partition and at most 7, 8, 9, or 10 restriction enzymes across all partitions; at least 7 restriction enzymes per partition and at most 8, 9, or 10 restriction enzymes across all partitions; at least 8 restriction enzymes per partition and at most 9 or 10 restriction enzymes across all partitions; and at least 9 restriction enzymes per partition and at most 10 or more restriction enzymes across all partitions.

In some cases, at most 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 45, 45, or 50 restriction enzymes or more may be used in each partition, while at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 45, 45, or 50 restriction enzymes or more may be used across all partitions. All combinations of these numbers are included within the invention. Non-limiting specific examples include the use of at most 1 restriction enzyme per partition and at least 2, 3, 4, 5, 6, 7, 8, 9, or 10 restriction enzymes across all partitions; at most 2 restriction enzymes per partition and at least 3, 4, 5, 6, 7, 8, 9, or 10 restriction enzymes across all partitions; at most

16

3 restriction enzymes per partition and at least 4, 5, 6, 7, 8, 9, or 10 restriction enzymes across all partitions; at most 4 restriction enzymes per partition and at least 5, 6, 7, 8, 9, or 10 restriction enzymes across all partitions; at most 5 restriction enzymes per partition and at least 6, 7, 8, 9, or 10 restriction enzymes across all partitions; at most 6 restriction enzymes per partition and at least 7, 8, 9, or 10 restriction enzymes across all partitions; at most 7 restriction enzymes per partition and at least 8, 9, or 10 restriction enzymes across all partitions; at most 8 restriction enzymes per partition and at least 9 or 10 restriction enzymes across all partitions; and at most 9 restriction enzymes per partition and at least 10 or more restriction enzymes across all partitions.

IV. Restriction Enzyme-Mediated Recycling

As described throughout this disclosure, certain methods of the invention involve the addition of barcodes, adapters, or other sequences to fragmented target polynucleotides. Barcodes may be polynucleotide barcodes, which may be ligated to the fragmented target polynucleotides or added via an amplification reaction. As described throughout this disclosure, fragmentation of target polynucleotides may be performed using one or more restriction enzymes contained within a partition (e.g., a microwell) where the fragmentation is performed. The partition may also contain a polynucleotide barcode and a ligase, which enables the attachment of the barcode to the fragmented polynucleotide. In some cases, an adapter may be used to make a fragmented target polynucleotide compatible for ligation with a barcode. The presence of adapters, fragmented target polynucleotide, barcodes, restriction enzymes, and ligases in the same partition may lead to the generation of undesirable side products that decrease the yield of a desired end product. For example, self-ligation may occur between adapters, target polynucleotide fragments, and/or barcodes. These self-ligations reduce the amount of starting material and decrease the yield of the desired product, for example, a polynucleotide fragment properly ligated to a barcode and/or adapter.

This disclosure provides methods, compositions, systems, and devices for addressing this problem and increasing the yield of a desired product. The problem is addressed by pairing a first restriction enzyme and a second restriction enzyme. The two restriction enzymes create compatible termini upon cutting, but each enzyme has a different recognition sequence.

Ligation of two pieces of DNA generated after cutting with the first restriction enzyme will regenerate the recognition site for the first restriction enzyme, allowing the first restriction enzyme to re-cut the ligated DNA. Likewise, ligation of two pieces of DNA generated after cutting with the second restriction enzyme will regenerate the recognition site for the second restriction enzyme, allowing the second restriction enzyme to re-cut the ligated DNA. However, ligation of one piece of DNA generated after cutting with the first restriction enzyme and one piece of DNA generated after cutting with the second restriction enzyme will result in ligated DNA that is unrecognizable (and therefore uncuttable) by both the first and second enzymes. The result is that any multimers of fragmented target polynucleotides are re-cut and any multimers of adapter (or other molecules, e.g., barcodes) are also re-cut. However, when a fragmented target polynucleotide is properly ligated to an adapter (or barcode), the restriction sites for both enzymes are not present and the correctly ligated molecule may not be re-cut by either enzyme.

US 10,227,648 B2

17

An example of this method is illustrated in FIG. 6, and additional pairs of enzymes that may be used with the method are provided in FIGS. 7A-7B. Any pair of enzymes may be used, so long as they meet the following criteria: (1) the enzymes should create identical, or at least similar, ligatable termini upon cutting; and (2) the enzymes should have different recognition sequences. The enzymes may be selected to avoid or minimize cutting of certain polynucleotide sequences such as barcodes, adapters, and other polynucleotide components of a sample processing or preparation platform. The enzymes may be selected for methylation insensitivity or methylation sensitivity. The enzymes may also be selected to be active under a single set of environmental conditions, such as buffer conditions, temperature, etc. Minimizing the cutting of barcodes and adapters may be accomplished by pairing certain enzymes with certain barcodes and/or adapters.

This method may be used to increase the yield of any of the barcoding methods described herein. The regeneration of the starting materials (e.g., fragmented target polynucleotide, adapters, and barcodes) allows these starting materials another opportunity to form the desired products (i.e., fragmented target polynucleotides ligated to barcodes, optionally with adapters). This greatly increases the yield of the reaction and therefore decreases the amount of starting material required to produce the necessary amount of the desired products while limiting the amount of undesirable side products and lost sequence information.

The methods described above may be used to achieve about 75%, 85%, 95%, 96%, 97%, 98%, 99%, or 99.5% yield (w/w). The methods may be used to achieve at least about 75%, 85%, 95%, 96%, 97%, 98%, 99%, or 99.5% yield (w/w).

The methods described above may use, for example, a pair of restriction enzyme selected from the group consisting of MspI-NarI, BfaI-NarI, BfaI-NdeI, HinPII-Clal, MseI-NdeI, CviQI-NdeI, TaqAI-AclI, RsaI-PmeI, AluI-EcoRV, BstUI-PmeI, DpnI-StuI, HaeIII-PmeI, and HpyCH4V-SfoI. This list of enzymes is provided for purposes of illustration only, and is not meant to be limiting.

The methods described above may generally use any two enzymes that create ligatable termini upon cutting but that have different recognition sequences. However, the method is not limited to ligation. For example, multimers formed after amplification of side products formed by association of compatible ends could also be re-cut using the methods described above.

More than one pair of enzymes may also be used. The number of pairs of enzymes chosen will vary depending on the number of undesirable side products formed in a reaction. For example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or more pairs of enzymes may be used. Treatment of a polynucleotide with the enzymes may be sequential, simultaneous, or both.

V. Preparation of Target Polynucleotides

Target polynucleotides processed according to the methods provided in this disclosure may be DNA, RNA, peptide nucleic acids, and any hybrid thereof, where the polynucleotide contains any combination of deoxyribo- and ribonucleotides. Polynucleotides may be single stranded or double stranded, as specified, or contain portions of both double stranded or single stranded sequence. Polynucleotides may contain any combination of nucleotides, including uracil, adenine, thymine, cytosine, guanine, inosine, xanthine, hypoxanthine, isocytosine, isoguanine and any

18

nucleotide derivative thereof. As used herein, the term "nucleotide" may include nucleotides and nucleosides, as well as nucleoside and nucleotide analogs, and modified nucleotides, including both synthetic and naturally occurring species. Target polynucleotides may be cDNA, mitochondrial DNA (mtDNA), messenger RNA (mRNA), ribosomal RNA (rRNA), transfer RNA (tRNA), nuclear RNA (nRNA), small interfering RNA (siRNA), small nuclear RNA (snRNA), small nucleolar RNA (snoRNA), small Cajal body-specific RNA (scaRNA), microRNA (miRNA), double stranded (dsRNA), ribozyme, riboswitch or viral RNA. Target polynucleotides may be contained on a plasmid, cosmid, or chromosome, and may be part of a genome. In some cases, a target polynucleotide may comprise one or more genes and/or one or more pseudogenes. A pseudogene generally refers to a dysfunctional relative of a gene that has lost its protein coding ability and/or is otherwise no longer expressed in the cell.

Target polynucleotides may be obtained from a sample using any methods known in the art. A target polynucleotide processed as described herein may be obtained from whole cells, cell preparations and cell-free compositions from any organism, tissue, cell, or environment. In some instances, target polynucleotides may be obtained from bodily fluids which may include blood, urine, serum, lymph, saliva, mucosal secretions, perspiration, or semen. In some instances, polynucleotides may be obtained from environmental samples including air, agricultural products, water, and soil. In other instances polynucleotides may be the products of experimental manipulation including, recombinant cloning, polynucleotide amplification (as generally described in PCT/US99/01705), polymerase chain reaction (PCR) amplification, purification methods (such as purification of genomic DNA or RNA), and synthesis reactions.

Genomic DNA may be obtained from naturally occurring or genetically modified organisms or from artificially or synthetically created genomes. Target polynucleotides comprising genomic DNA may be obtained from any source and using any methods known in the art. For example, genomic DNA may be isolated with or without amplification. Amplification may include PCR amplification, multiple displacement amplification (MDA), rolling circle amplification and other amplification methods. Genomic DNA may also be obtained by cloning or recombinant methods, such as those involving plasmids and artificial chromosomes or other conventional methods (see Sambrook and Russell, *Molecular Cloning: A Laboratory Manual*, cited supra.) Polynucleotides may be isolated using other methods known in the art, for example as disclosed in *Genome Analysis: A Laboratory Manual Series* (Vols. I-IV) or *Molecular Cloning: A Laboratory Manual*. If the isolated polynucleotide is an mRNA, it may be reverse transcribed into cDNA using conventional techniques, as described in Sambrook and Russell, *Molecular Cloning: A Laboratory Manual*, cited supra.

Target polynucleotides may also be isolated from "target organisms" or "target cells". The terms "target organism" and "target cell" refer to an organism or cell, respectively, from which target polynucleotides may be obtained. Target cells may be obtained from a variety of organisms including human, mammal, non-human mammal, ape, monkey, chimpanzee, plant, reptilian, amphibian, avian, fungal, viral or bacterial organisms. Target cells may also be obtained from a variety of clinical sources such as biopsies, aspirates, blood, urine, formalin fixed embedded tissues, and the like. Target cells may comprise a specific cell type, such as a somatic cell, germline cell, wild-type cell, cancer or tumor cells, or diseased or infected cell. A target cell may refer to

US 10,227,648 B2

19

a cell derived from a particular tissue or a particular locus in a target organism. A target cell may comprise whole intact cells, or cell preparations.

Target polynucleotides may also be obtained or provided in specified quantities. Amplification may be used to increase the quantity of a target polynucleotide. Target polynucleotides may be quantified by mass. For example, target polynucleotides may be provided in a mass ranging from about 1-10, 10-50, 50-100, 100-200, 200-1000, 1000-10000 ng. Target polynucleotides may be provided in a mass of at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 50, 100, 500, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 6500, 7000, 7500, 8000, 8500, 9000, 9500, or 10000 ng. Target polynucleotides may be provided in a mass of less than about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 50, 100, 500, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 6500, 7000, 7500, 8000, 8500, 9000, 9500, or 10000 ng.

Target polynucleotides may also be quantified as "genome equivalents." A genome equivalent is an amount of polynucleotide equivalent to one haploid genome of an organism from which the target polynucleotide is derived. For example, a single diploid cell contains two genome equivalents of DNA. Target polynucleotides may be provided in an amount ranging from about 1-10, 10-50, 50-100, 100-1000, 1000-10000, 10000-100000, or 100000-1000000 genome equivalents. Target polynucleotides may be provided in an amount of at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 50, 100, 500, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 6500, 7000, 7500, 8000, 8500, 9000, 9500, 10000, 20000, 30000, 40000, 50000, 60000, 70000, 80000, 90000, 100000, 200000, 300000, 400000, 500000, 600000, 700000, 800000, 900000, or 1000000 genome equivalents. Target polynucleotides may be provided in an amount less than about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 50, 100, 500, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 6500, 7000, 7500, 8000, 8500, 9000, 9500, 10000, 20000, 30000, 40000, 50000, 60000, 70000, 80000, 90000, 100000, 200000, 300000, 400000, 500000, 600000, 700000, 800000, 900000, or 1000000 genome equivalents.

Target polynucleotide may also be quantified by the amount of sequence coverage provided. The amount of sequence coverage refers to the average number of reads representing a given nucleotide in a reconstructed sequence. Generally, the greater the number of times a region is sequenced, the more accurate the sequence information obtained. Target polynucleotides may be provided in an amount that provides a range of sequence coverage from about 0.1X-10X, 10X-50X, 50X-100X, 100X-200X, or 200X-500X. Target polynucleotide may be provided in an amount that provides at least about 0.1X, 0.2X, 0.3X, 0.4X, 0.5X, 0.6X, 0.7X, 0.8X, 0.9X, 1.0X, 5X, 10X, 25X, 50X, 100X, 125X, 150X, 175X, or 200X sequence coverage. Target polynucleotide may be provided in an amount that provides less than about 0.2X, 0.3X, 0.4X, 0.5X, 0.6X, 0.7X, 0.8X, 0.9X, 1.0X, 5X, 10X, 25X, 50X, 100X, 125X, 150X, 175X, or 200X sequence coverage.

VI. Fragmentation of Target Polynucleotides

Fragmentation of polynucleotides is used as a step in a variety of processing methods described herein. The size of the polynucleotide fragments, typically described in terms of length (quantified by the linear number of nucleotides per

20

fragment), may vary depending on the source of the target polynucleotide, the method used for fragmentation, and the desired application. Moreover, while certain methods of the invention are illustrated using a certain number of fragmentation steps, the number of fragmentation steps provided is not meant to be limiting, and any number of fragmentation steps may be used. For example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or more fragmentation steps may be used.

Fragments generated using the methods described herein may be about 1-10, 10-20, 20-50, 50-100, 50-200, 100-200, 200-300, 300-400, 400-500, 500-1000, 1000-5000, 5000-10000, 10000-100000, 100000-250000, or 250000-500000 nucleotides in length. Fragments generated using the methods described herein may be at least about 10, 20, 100, 200, 300, 400, 500, 1000, 5000, 10000, 100000, 250000, 500000, or more nucleotides in length. Fragments generated using the methods described herein may be less than about 10, 20, 100, 200, 300, 400, 500, 1000, 5000, 10000, 100000, 250000, 500000, nucleotides in length.

Fragments generated using the methods described herein may have a mean or median length of about 1-10, 10-20, 20-50, 50-100, 50-200, 100-200, 200-300, 300-400, 400-500, 500-1000, 1000-5000, 5000-10000, 10000-100000, 100000-250000, or 250000-500000 nucleotides. Fragments generated using the methods described herein may have a mean or median length of at least about 10, 20, 100, 200, 300, 400, 500, 1000, 5000, 10000, 100000, 250000, 500000, or more nucleotides. Fragments generated using the methods described herein may have a mean or median length of less than about 10, 20, 100, 200, 300, 400, 500, 1000, 5000, 10000, 100000, 250000, 500000, nucleotides.

Numerous fragmentation methods are described herein and known in the art. For example, fragmentation may be performed through physical, mechanical or enzymatic methods. Physical fragmentation may include exposing a target polynucleotide to heat or to UV light. Mechanical disruption may be used to mechanically shear a target polynucleotide into fragments of the desired range. Mechanical shearing may be accomplished through a number of methods known in the art, including repetitive pipetting of the target polynucleotide, sonication and nebulization. Target polynucleotides may also be fragmented using enzymatic methods. In some cases, enzymatic digestion may be performed using enzymes such as using restriction enzymes.

While the methods of fragmentation described in the preceding paragraph, and in some paragraphs of the disclosure, are described with reference to "target" polynucleotides, this is not meant to be limiting, above or anywhere else in this disclosure. Any means of fragmentation described herein, or known in the art, can be applied to any polynucleotide used with the invention. In some cases, this polynucleotide may be a target polynucleotide, such as a genome. In other cases, this polynucleotide may be a fragment of a target polynucleotide which one wishes to further fragment. In still other cases, still further fragments may be still further fragmented. Any suitable polynucleotide may be fragmented according to the methods described herein.

A fragment of a polynucleotide generally comprises a portion of the sequence of the targeted polynucleotide from which the fragment was generated. In some cases, a fragment may comprise a copy of a gene and/or pseudogene, including one included in the original target polynucleotide. In some cases, a plurality of fragments generated from fragmenting a target polynucleotide may comprise fragments that each comprise a copy of a gene and/or pseudogene.

US 10,227,648 B2

21

Restriction enzymes may be used to perform specific or non-specific fragmentation of target polynucleotides. The methods of the present disclosure may use one or more types of restriction enzymes, generally described as Type I enzymes, Type II enzymes, and/or Type III enzymes. Type II and Type III enzymes are generally commercially available and well known in the art. Type II and Type III enzymes recognize specific sequences of nucleotide base pairs within a double stranded polynucleotide sequence (a "recognition sequence" or "recognition site"). Upon binding and recognition of these sequences, Type II and Type III enzymes cleave the polynucleotide sequence. In some cases, cleavage will result in a polynucleotide fragment with a portion of overhanging single stranded DNA, called a "sticky end." In other cases, cleavage will not result in a fragment with an overhang, creating a "blunt end." The methods of the present disclosure may comprise use of restriction enzymes that generate either sticky ends or blunt ends.

Restriction enzymes may recognize a variety of recognition sites in the target polynucleotide. Some restriction enzymes ("exact cutters") recognize only a single recognition site (e.g., GAATTC). Other restriction enzymes are more promiscuous, and recognize more than one recognition site, or a variety of recognition sites. Some enzymes cut at a single position within the recognition site, while others may cut at multiple positions. Some enzymes cut at the same position within the recognition site, while others cut at variable positions.

The present disclosure provides method of selecting one or more restriction enzymes to produce fragments of a desired length. Polynucleotide fragmentation may be simulated in silico, and the fragmentation may be optimized to obtain the greatest number or fraction of polynucleotide fragments within a particular size range, while minimizing the number or fraction of fragments within undesirable size ranges. Optimization algorithms may be applied to select a combination of two or more enzymes to produce the desired fragment sizes with the desired distribution of fragments quantities.

A polynucleotide may be exposed to two or more restriction enzymes simultaneously or sequentially. This may be accomplished by, for example, adding more than one restriction enzyme to a partition, or by adding one restriction enzyme to a partition, performing the digestion, deactivating the restriction enzyme (e.g., by heat treatment) and then adding a second restriction enzyme. Any suitable restriction enzyme may be used alone, or in combination, in the methods presented herein.

Fragmenting of a target polynucleotide may occur prior to partitioning of the target polynucleotide or fragments generated from fragmenting. For example, genomic DNA (gDNA) may be fragmented, using, for example, a restriction enzyme, prior to the partitioning of its generated fragments. In another example, a target polynucleotide may be entered into a partition along with reagents necessary for fragmentation (e.g., including a restriction enzyme), such that fragmentation of the target polynucleotide occurs within the partition. For example, gDNA may be fragmented in a partition comprising a restriction enzyme, and the restriction enzyme is used to fragment the gDNA.

In some cases, a plurality of fragments may be generated prior to partitioning, using any method for fragmentation described herein. Some or all of the fragments of the plurality, for example, may each comprise a copy of a gene and/or a pseudogene. The fragments can be separated and partitioned such that each copy of the gene or pseudogene is located in a different partition. Each partition, for example,

22

can comprise a different barcode sequence such that each copy of the gene and/or pseudogene can be associated with a different barcode sequence, using barcoding methods described elsewhere herein. Via the different barcode sequences, each gene and/or pseudogene can be counted and/or differentiated during sequencing of the barcoded fragments. Any sequencing method may be used, including those described herein.

For example, using restriction enzymes, genomic DNA (gDNA) can be fragmented to generate a plurality of non-overlapping fragments of the gDNA. At least some of the fragments of the plurality may each comprise a copy of a gene and/or a pseudogene. The fragments may be separated and partitioned such that each copy of the gene or pseudogene is located in a different partition. Each partition, for example, can comprise a different barcode sequence such that each copy of the gene and/or pseudogene may be barcoded with a different barcode sequence. Via the different barcode sequences, the genes and/or pseudogenes may be counted and or differentiated after sequencing of the bar-coded fragments. Any sequencing method may be used, including those described herein.

IV. Partitioning of Polynucleotides

As described throughout the disclosure, certain methods, systems, and compositions of the disclosure may utilize partitioning of polynucleotides into separate partitions (e.g., microwells, droplets of an emulsion). These partitions may be used to contain polynucleotides for further processing, such as, for example, cutting, ligating, and/or barcoding.

Any number of devices, systems or containers may be used to hold, support or contain partitions of polynucleotides and their fragments. In some cases, partitions are formed from droplets, emulsions, or spots on a substrate. Weizmann et al. (Nature Methods, 2006, Vol. 3 No. 7 pages 545-550). Suitable methods for forming emulsions, which can be used as partitions or to generate microcapsules, include the methods described in Weitz et al. (U.S. Pub. No. 2012/0211084). Partitions may also be formed through the use of wells, microwells, multi-well plates, and microwell arrays. Partitioning may be performed using piezoelectric droplet generation (e.g., Bransky et al., *Lab on a Chip*, 2009, 9, 516-520). Partitioning may be performed using surface acoustic waves (e.g., Demirci and Montesano, *Lab on a Chip*, 2007, 7, 1139-1145).

Such partitions may be pre-loaded with reagents to perform a particular reaction. For example, a capsule containing one or more reagents may be placed within a microwell. After adding a polynucleotide sample to the well, the capsule may be made to release its contents. The contents of the capsule may include, for example, restriction enzymes, ligases, barcodes, and adapters for processing the polynucleotide sample placed in the microwell.

In some cases, such partitions may be droplets of an emulsion. For example, a droplet of an emulsion may be an aqueous droplet in an oil phase. The droplet may comprise, for example, one or more reagents (e.g., restriction enzymes, ligases, polymerases, reagents necessary for nucleic acid amplification (e.g., primers, DNA polymerases, dNTPs, buffers)), a polynucleotide sample, and a barcode sequence. In some cases, the barcode sequence, polynucleotide sample, or any reagent may be associated with a solid surface within a droplet. In some cases, the solid surface is a bead. In some cases, the bead is a gel bead (see e.g., Agresti et al., U.S. Patent Publication No. 2010/0136544). In some cases the droplet is hardened into a gel bead (e.g., via polymerization).

US 10,227,648 B2

23

Polynucleotides may be partitioned using a variety of methods. For example, polynucleotides may be diluted and dispensed across a plurality of partitions. A terminal dilution of a medium comprising polynucleotides may be performed such that the number of partitions or wells exceeds the number of polynucleotides. The ratio of the number of polynucleotides to the number of partitions may range from about 0.1-10, 0.5-10, 1-10, 2-10, 10-100, 100-1000, or more. The ratio of the number of polynucleotides to the number of partitions may be about 0.1, 0.5, 1, 2, 4, 8, 10, 20, 50, 100, or 1000. The ratio of the number of polynucleotides to the number of partitions may be at least about 0.1, 0.5, 1, 2, 4, 8, 10, 20, 50, 100, or 1000. The ratio of the number of polynucleotides to the number of partitions may be less than about 0.1, 0.5, 1, 2, 4, 8, 10, 20, 50, 100, or 1000.

The number of partitions employed may vary depending on the application. For example, the number of partitions may be about 5, 10, 50, 100, 250, 500, 750, 1000, 1500, 2000, 2500, 5000, 7500, or 10,000, or more. The number of partitions may be at least about 5, 10, 50, 100, 250, 500, 750, 1000, 1500, 2000, 2500, 5000, 7500, or 10,000, or more. The number of partitions may be less than about 5, 10, 50, 100, 250, 500, 750, 1000, 1500, 2000, 2500, 5000, 7500, or 10,000.

The volume of the partitions may vary depending on the application. For example, the volume of the partitions may be about 1000 μ L, 900 μ L, 800 μ L, 700 μ L, 600 μ L, 500 μ L, 400 μ L, 300 μ L, 200 μ L, 100 μ L, 50 μ L, 25 μ L, 10 μ L, 5 μ L, 1 μ L, 900 nL, 800 nL, 700 nL, 600 nL, 500 nL, 400 nL, 300 nL, 200 nL, 100 nL, 50 nL, 25 nL, 10 nL, or 5 nL. The volume of the partitions may be at least about 1000 μ L, 900 μ L, 800 μ L, 700 μ L, 600 μ L, 500 μ L, 400 μ L, 300 μ L, 200 μ L, 100 μ L, 50 μ L, 25 μ L, 10 μ L, 5 μ L, 1 μ L, 900 nL, 800 nL, 700 nL, 600 nL, 500 nL, 400 nL, 300 nL, 200 nL, 100 nL, 50 nL, 25 nL, 10 nL, or 5 nL. The volume of the partitions may be less than about 1000 μ L, 900 μ L, 800 μ L, 700 μ L, 600 μ L, 500 μ L, 400 μ L, 300 μ L, 200 μ L, 100 μ L, 50 μ L, 25 μ L, 10 μ L, 5 μ L, 1 μ L, 900 nL, 800 nL, 700 nL, 600 nL, 500 nL, 400 nL, 300 nL, 200 nL, 100 nL, 50 nL, 25 nL, 10 nL, or 5 nL.

Particular polynucleotides may also be targeted to specific partitions. For example, in some cases, a capture reagent such as an oligonucleotide probe may be immobilized in a partition to capture specific polynucleotides through hybridization.

Polynucleotides may also be partitioned at a particular density. For example, polynucleotides may be partitioned such that each partition contains about 1-5, 5-10, 10-50, 50-100, 100-1000, 1000-10000, 10000-100000, or 100000-1000000 polynucleotides per well. Polynucleotides may be partitioned so that each partition contains about 1, 5, 10, 50, 100, 1000, 10000, 100000, 1000000 or more polynucleotides per well. Polynucleotides may be partitioned so that each partition contains less than about 1, 5, 10, 50, 100, 1000, 10000, 100000, or 1000000 polynucleotides per well. Polynucleotides may be partitioned so that each partition contains at least about 1, 5, 10, 50, 100, 1000, 10000, 100000, or 1000000 polynucleotides per well.

Polynucleotides may be partitioned such that at least one partition comprises a polynucleotide sequence with a unique sequence compared to all other polynucleotide sequences contained within the same partition. This may be true for about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or more of the partitions. This may be true for less than about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or more of the partitions. This may be true for more than about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or more of the partitions.

24

V. Barcoding

Downstream applications, for example DNA sequencing, may rely on the barcodes to identify the origin of a sequence and, for example, to assemble a larger sequence from sequenced fragments. Therefore, it may be desirable to add barcodes to the polynucleotide fragments generated by the methods described herein. Barcodes may be of a variety of different formats, including polynucleotide barcodes. Depending upon the specific application, barcodes may be attached to polynucleotide fragments in a reversible or irreversible manner. Barcodes may also allow for identification and/or quantification of individual polynucleotide fragments during sequencing.

Barcodes may be loaded into partitions so that one or more barcodes are introduced into a particular partition. Each partition may contain a different set of barcodes. This may be accomplished by directly dispensing the barcodes into the partitions, enveloping the barcodes (e.g., in a droplet of an emulsion), or by placing the barcodes within a container that is placed in a partition (e.g., a microcapsule).

For example, a population of microcapsules may be prepared such that a first microcapsule in the population comprises multiple copies of identical barcodes (e.g., polynucleotide bar codes, etc.) and a second microcapsule in the population comprises multiple copies of a barcode that differs from the barcode within the first microcapsule. In some cases, the population of microcapsules may comprise multiple microcapsules (e.g., greater than about 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 100, 500, 1000, 5000, 10000, 100000, 1000000, 10000000, 100000000, or 1000000000 microcapsules), each containing multiple copies of a barcode that differs from that contained in the other microcapsules. In some cases, the population may comprise greater than about 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 100, 500, 1000, 5000, 10000, 100000, 1000000, 10000000, or 1000000000 microcapsules with identical sets of barcodes. In some cases, the population may comprise greater than about 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 100, 500, 1000, 5000, 10000, 100000, 1000000, 10000000, or 1000000000 microcapsules, wherein the microcapsules each comprise a different combination of barcodes. For example, in some cases the different combinations overlap, such that a first microcapsule may comprise, e.g., barcodes A, B, and C, while a second microcapsule may comprise barcodes A, B, and D. In another example, the different combinations do not overlap, such that a first microcapsule may comprise, e.g., barcodes A, B, and C, while a second microcapsule may comprise barcodes D, E, and F. The use of microcapsules is, of course, optional. All of the combinations described above, and throughout this disclosure, may also be generated by dispensing barcodes (and other reagents) directly into partitions (e.g., microwells).

The barcodes may be loaded into the partitions at an expected or predicted ratio of barcodes per species to be barcoded (e.g., polynucleotide fragment, strand of polynucleotide, cell, etc.). In some cases, the barcodes are loaded into partitions such that more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50, 100, 500, 1000, 5000, 10000, or 200000 barcodes are loaded per species. In some cases, the barcodes are loaded in the partitions so that less than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50, 100, 500, 1000, 5000, 10000, or 200000 barcodes are loaded per species. In some cases, the average number of barcodes loaded per species is less than,

US 10,227,648 B2

25

or greater than, about 0.0001, 0.001, 0.01, 0.1, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50, 100, 500, 1000, 5000, 10000, or 200000 barcodes per species.

When more than one barcode is present per polynucleotide fragment, such barcodes may be copies of the same barcode, or multiple different barcodes. For example, the attachment process may be designed to attach multiple identical barcodes to a single polynucleotide fragment, or multiple different barcodes to the polynucleotide fragment.

The methods provided herein may comprise loading a partition (e.g., a microwell, droplet of an emulsion) with the reagents necessary for the attachment of barcodes to polynucleotide fragments. In the case of ligation reactions, reagents including restriction enzymes, ligase enzymes, buffers, adapters, barcodes and the like may be loaded into a partition. In the case of barcoding by amplification, reagents including primers, DNA polymerases, dNTPs, buffers, barcodes and the like may be loaded into a partition. As described throughout this disclosure, these reagents may be loaded directly into the partition, or via a container such as a microcapsule. If the reagents are not disposed within a container, they may be loaded into a partition (e.g., a microwell) which may then be sealed with a wax or oil until the reagents are used.

Barcodes may be ligated to a polynucleotide fragment using sticky or blunt ends. Barcoded polynucleotide fragments may also be generated by amplifying a polynucleotide fragment with primers comprising barcodes.

Barcodes may be assembled combinatorially, from smaller components designed to assemble in a modular format. For example, three modules, 1A, 1B, and 1C may be combinatorially assembled to produce barcode 1ABC. Such combinatorial assembly may significantly reduce the cost of synthesizing a plurality of barcodes. For example, a combinatorial system consisting of 3 A modules, 3 B modules, and 3 C modules may generate $3^3=27$ possible barcode sequences from only 9 modules.

VI. Microcapsules and Microwell Capsule Arrays

Microcapsules and microwell capsule array (MCA) devices may be used to perform the polynucleotide processing methods described herein. MCA devices are devices with a plurality of microwells. Microcapsules are introduced into these microwells, before, after, or concurrently with the introduction of a sample.

Microwells may comprise free reagents and/or reagents encapsulated in microcapsules. Any of the reagents described in this disclosure may be encapsulated in a microcapsule, including any chemicals, particles, and elements suitable for sample processing reactions involving a polynucleotide. For example, a microcapsule used in a sample preparation reaction for DNA sequencing may comprise one or more of the following reagents: enzymes, restriction enzymes (e.g., multiple cutters), ligase, polymerase, fluorophores, oligonucleotide barcodes, adapters, buffers, dNTPs, ddNTPs and the like.

Additional exemplary reagents include: buffers, acidic solution, basic solution, temperature-sensitive enzymes, pH-sensitive enzymes, light-sensitive enzymes, metals, metal ions, magnesium chloride, sodium chloride, manganese, aqueous buffer, mild buffer, ionic buffer, inhibitor, enzyme, protein, polynucleotide, antibodies, saccharides, lipid, oil, salt, ion, detergents, ionic detergents, non-ionic detergents, oligonucleotides, nucleotides, deoxyribonucleotide triphosphates (dNTPs), dideoxyribonucleotide triphosphates (ddNTPs), DNA, RNA, peptide polynucleotides, comple-

26

mentary DNA (cDNA), double stranded DNA (dsDNA), single stranded DNA (ssDNA), plasmid DNA, cosmid DNA, chromosomal DNA, genomic DNA, viral DNA, bacterial DNA, mtDNA (mitochondrial DNA), mRNA, rRNA, tRNA, nRNA, siRNA, snRNA, snoRNA, scaRNA, microRNA, dsRNA, ribozyme, riboswitch and viral RNA, polymerase, ligase, restriction enzymes, proteases, nucleases, protease inhibitors, nuclease inhibitors, chelating agents, reducing agents, oxidizing agents, fluorophores, probes, chromophores, dyes, organics, emulsifiers, surfactants, stabilizers, polymers, water, small molecules, pharmaceuticals, radioactive molecules, preservatives, antibiotics, aptamers, and pharmaceutical drug compounds.

In some cases, a microcapsule comprises a set of reagents that have a similar attribute (e.g., a set of enzymes, a set of minerals, a set of oligonucleotides, a mixture of different bar-codes, a mixture of identical bar-codes). In other cases, a microcapsule comprises a heterogeneous mixture of reagents. In some cases, the heterogeneous mixture of reagents comprises all components necessary to perform a reaction. In some cases, such mixture comprises all components necessary to perform a reaction, except for 1, 2, 3, 4, 5, or more components necessary to perform a reaction. In some cases, such additional components are contained within a different microcapsule or within a solution within a partition (e.g., microwell) of the device.

In some cases, only microcapsules comprising reagents are introduced. In other cases, both free reagents and reagents encapsulated in microcapsules are loaded into the device, either sequentially or concurrently. In some cases, reagents are introduced to the device either before or after a particular step. In some cases, reagents and/or microcapsules comprising reagents are introduced sequentially such that different reactions or operations occur at different steps. The reagents (or microcapsules) may be also be loaded at steps interspersed with a reaction or operation step. For example, microcapsules comprising reagents for fragmenting polynucleotides (e.g., restriction enzymes) may be loaded into the device, followed by loading of microcapsules comprising reagents for ligating bar-codes and subsequent ligation of the bar-codes to the fragmented molecules.

Microcapsules may be pre-formed and filled with reagents by injection. For example, the picoinjection methods described in Abate et al. (Proc. Natl. Acad. Sci. U.S.A., 2010, 107(45), 19163-19166) and Weitz et al. (U.S. Pub. No. 2012/0132288) may be used to introduce reagents into the interior of microcapsules described herein. These methods can also be used to introduce a plurality of any of the reagents described herein into microcapsules.

Microcapsules may be formed by any emulsion technique known in the art. For example, the multiple emulsion technique of Weitz et al. (U.S. Pub. No. 2012/0211084) may be used to form microcapsules (or partitions) for use with the methods disclosed herein.

VII. Polynucleotide Sequencing

Generally, the methods and compositions provided herein are useful for preparation of polynucleotide fragments for downstream applications such as sequencing. Sequencing may be performed by any available technique. For example, sequencing may be performed by the classic Sanger sequencing method. Sequencing methods may also include: high-throughput sequencing, pyrosequencing, sequencing-by-synthesis, single-molecule sequencing, nanopore sequencing, sequencing-by-ligation, sequencing-by-hybridization, RNA-Seq (Illumina), Digital Gene Expression (He-

licos), next generation sequencing, single molecule sequencing by synthesis (SMSS) (Helicos), massively-parallel sequencing, clonal single molecule Array (Solexa), shotgun sequencing, Maxim-Gilbert sequencing, primer walking, and any other sequencing methods known in the art.

In some cases varying numbers of fragments are sequenced. For example, in some cases about 30%-90% of the fragments are sequenced. In some cases, about 35%-85%, 40%-80%, 45%-75%, 50%-70%, 55%-65%, or 50%-60% of the fragments are sequenced. In some cases, at least about 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the fragments are sequenced. In some cases less than about 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the fragments are sequenced.

In some cases sequences from fragments are assembled to provide sequence information for a contiguous region of the original target polynucleotide that is longer than the individual sequence reads. Individual sequence reads may be about 10-50, 50-100, 100-200, 200-300, 300-400, or more nucleotides in length.

The identities of the barcode tags may serve to order the sequence reads from individual fragments as well as to differentiate between haplotypes. For example, during the partitioning of individual fragments, parental polynucleotide fragments may be separated into different partitions. With an increase in the number of partitions, the likelihood of a fragment from both a maternal and paternal haplotype contained in the same partition becomes negligibly small. Thus, sequence reads from fragments in the same partition may be assembled and ordered.

VIII. Polynucleotide Phasing

This disclosure also provides methods and compositions to prepare polynucleotide fragments in such a manner that may enable phasing or linkage information to be generated. Such information may allow for the detection of linked genetic variations in sequences, including genetic variations (e.g., SNPs, mutations, indels, copy number variations, transversions, translocations, inversions, etc.) that are separated by long stretches of polynucleotides. The term "indel" refers to a mutation resulting in a colocalized insertion and deletion and a net gain or loss in nucleotides. A "microindel" is an indel that results in a net gain or loss of 1 to 50 nucleotides. These variations may exist in either a cis or trans relationship. In a cis relationship, two or more genetic variations exist in the same polynucleotide or strand. In a trans relationship, two or more genetic variations exist on multiple polynucleotide molecules or strands.

Methods provided herein may be used to determine polynucleotide phasing. For example, a polynucleotide sample (e.g., a polynucleotide that spans a given locus or loci) may be partitioned such that at most one molecule of polynucleotide is present per partition (e.g., microwell). The polynucleotide may then be fragmented, barcoded, and sequenced. The sequences may be examined for genetic variation. The detection of genetic variations in the same sequence tagged with two different bar codes may indicate that the two genetic variations are derived from two separate strands of DNA, reflecting a trans relationship. Conversely, the detection of two different genetic variations tagged with the same bar codes may indicate that the two genetic variations are from the same strand of DNA, reflecting a cis relationship.

Phase information may be important for the characterization of a polynucleotide fragment, particularly if the polynucleotide fragment is derived from a subject at risk of,

having, or suspected of having a particular disease or disorder (e.g., hereditary recessive disease such as cystic fibrosis, cancer, etc.). The information may be able to distinguish between the following possibilities: (1) two genetic variations within the same gene on the same strand of DNA and (2) two genetic variations within the same gene but located on separate strands of DNA. Possibility (1) may indicate that one copy of the gene is normal and the individual is free of the disease, while possibility (2) may indicate that the individual has or will develop the disease, particularly if the two genetic variations are damaging to the function of the gene when present within the same gene copy. Similarly, the phasing information may also be able to distinguish between the following possibilities: (1) two genetic variations, each within a different gene on the same strand of DNA and (2) two genetic variations, each within a different gene but located on separate strands of DNA.

IX. Sequencing Polynucleotides from Small Numbers of Cells

Methods provided herein may also be used to prepare polynucleotide contained within cells in a manner that enables cell-specific information to be obtained. The methods enable detection of genetic variations (e.g., SNPs, mutations, indels, copy number variations, transversions, translocations, inversions, etc.) from very small samples, such as from samples comprising about 10-100 cells. In some cases, about 1, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 cells may be used in the methods described herein. In some cases, at least about 1, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 cells may be used in the methods described herein. In other cases, at most about 5, 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 cells may be used in the methods described herein.

In an example, a method comprises partitioning a cellular sample (or crude cell extract) such that at most one cell (or extract of one cell) is present per partition, lysing the cells, fragmenting the polynucleotides contained within the cells by any of the methods described herein, attaching the fragmented polynucleotides to barcodes, pooling, and sequencing.

As described elsewhere herein, the barcodes and other reagents may be contained within a microcapsule. These microcapsules may be loaded into a partition (e.g., a microwell) before, after, or concurrently with the loading of the cell, such that each cell is contacted with a different microcapsule. This technique may be used to attach a unique barcode to polynucleotides obtained from each cell. The resulting tagged polynucleotides may then be pooled and sequenced, and the barcodes may be used to trace the origin of the polynucleotides. For example, polynucleotides with identical barcodes may be determined to originate from the same cell, while polynucleotides with different barcodes may be determined to originate from different cells.

The methods described herein may be used to detect the distribution of oncogenic mutations across a population of cancerous tumor cells. For example, some tumor cells may have a mutation, or amplification, of an oncogene (e.g., HER2, BRAF, EGFR, KRAS) in both alleles (homozygous), others may have a mutation in one allele (heterozygous), and still others may have no mutation (wild-type). The methods described herein may be used to detect these differences, and also to quantify the relative numbers of homozygous, heterozygous, and wild-type cells. Such information may be used, for example, to stage a particular cancer and/or to monitor the progression of the cancer and its treatment over time.

In some examples, this disclosure provides methods of identifying mutations in two different oncogenes (e.g., KRAS and EGFR). If the same cell comprises genes with both mutations, this may indicate a more aggressive form of cancer. In contrast, if the mutations are located in two different cells, this may indicate that the cancer is more benign, or less advanced.

X. Analysis of Gene Expression

Methods of the disclosure may be applicable to processing samples for the detection of changes in gene expression. A sample may comprise a cell, mRNA, or cDNA reverse transcribed from mRNA. The sample may be a pooled sample, comprising extracts from several different cells or tissues, or a sample comprising extracts from a single cell or tissue.

Cells may be placed directly into an partition (e.g., a microwell) and lysed. After lysis, the methods of the invention may be used to fragment and barcode the polynucleotides of the cell for sequencing. Polynucleotides may also be extracted from cells prior to introducing them into a partition used in a method of the invention. Reverse transcription of mRNA may be performed in a partition described herein, or outside of such a partition. Sequencing cDNA may provide an indication of the abundance of a particular transcript in a particular cell over time, or after exposure to a particular condition.

The methods presented throughout this disclosure provide several advantages over current polynucleotide processing methods. First, inter-operator variability is greatly reduced. Second, the methods may be carried out in microfluidic devices, which have a low cost and can be easily fabricated. Third, the controlled fragmentation of the target polynucleotides allows the user to produce polynucleotide fragments with a defined and appropriate length. This aids in partitioning the polynucleotides and also reduces the amount of sequence information loss due to the present of overly-large fragments. The methods and systems also provide a facile workflow that maintains the integrity of the processed polynucleotide. Additionally, the use of restriction enzymes enables the user to create DNA overhangs ("sticky ends") that may be designed for compatibility with adapters and/or barcodes.

EXAMPLES

Example 1: Generation of Non-Overlapping DNA Fragments for Sequencing

This example demonstrates a method for the generation of non-overlapping DNA fragments suitable for DNA sequencing and other downstream applications. An implementation of this method is schematically illustrated in FIG. 2.

With reference to FIG. 2, a target polynucleotide **101**, genomic DNA, is fragmented with the enzyme NotI, to generate a plurality of non-overlapping first polynucleotide fragments **102**. The first polynucleotide fragments are partitioned into separate microwells **103** in a microdevice such that each microwell comprises a plurality of fragments, but only a single fragment with a particular sequence **104**. The left-hand side of FIG. 2 illustrates three microwells (one is labeled **103**), each containing three exemplary unique fragments **104**, corresponding to the first polynucleotide fragments **102**. Referring again to the left-hand side of FIG. 2, the left-most well contains fragments A1, B2, and C3, the

middle well contains fragments B1, A2, and A3, and the right-most well contains fragments C1, C2, and B3.

The partitioned fragments are then further fragmented, to generate a plurality of non-overlapping second polynucleotide fragments **105**. Referring again to the left-hand side of FIG. 2, each member of the second polynucleotide fragments is designated by its first fragment identifier (e.g., A1, B2, etc.), followed by a "-1" or a "-2". For example, first fragment A1 is fragmented to produce second fragments A1-1 and A1-2. First fragment B2 is fragmented to produce second fragments B2-1 and B2-2, and so on. For the sake of simplicity, only two second fragments are shown for each first fragment. This is, of course, not meant to be limiting, as any number of fragments may be generated at any step of the process.

The second set polynucleotide fragments are barcoded, and the barcoded sequences are pooled. Referring to the lower left-hand side of FIG. 2, the labels [1], [2], and [3] represent three different barcode sequences used to label the second fragments **105**. The labeled sequences are designated **106**. Optionally, adapter sequences (not shown) are used to make the second fragments **105** compatible for ligation with the barcodes. The barcoding is performed while the fragments are still partitioned, before pooling. The pooled barcoded sequences are then sequenced.

With continued reference to FIG. 2, the methods described above are then repeated, using a second rare cutter enzyme, XmaII to digest the genomic DNA and generate a plurality of non-overlapping third polynucleotide fragments **107**. The third polynucleotide fragments and the first polynucleotide fragments are overlapping, because they are generated with different rare-cutter enzymes that cut the target polynucleotides at different sites. The third polynucleotide fragments are partitioned into separate microwells **108** in a microdevice such that each microwell comprises a plurality of fragments, but only a single fragment with a particular sequence **109**. The right-hand side of FIG. 2 illustrates three microwells (one is labeled **108**), each containing three exemplary unique fragments **109**, corresponding to the third polynucleotide fragments **107**. Referring again to the right-hand side of FIG. 2, the left-most well contains fragments D1, E2, and F3, the middle well contains fragments E1, D2, and D3, and the right-most well contains fragments F1, F2, and E3.

With continued reference to FIG. 2, The partitioned fragments are then further fragmented, to generate a plurality of non-overlapping fourth polynucleotide fragments **110**. The fourth polynucleotide fragments and the second polynucleotide fragments are overlapping, because they are generated by fragmenting the third and first fragments, respectively, which were generated with rare-cutter enzymes that cut the target polynucleotide at different sites, as described above. Referring again to the right-hand side of FIG. 2, each member of the fourth set of polynucleotide fragments is designated by its third fragment identifier (e.g., D1, E2, etc.), followed by a "-1" or a "-2". For example, third fragment D1 is fragmented to produce fourth fragments D1-1 and D1-2. Third fragment E2 is fragmented to produce fourth fragments E2-1 and E2-2, and so on. For the sake of simplicity, only two fourth fragments are shown for each third fragment. This is, of course, not meant to be limiting, as any number of fragments may be generated.

The fourth polynucleotides fragments are barcoded, and the barcoded sequences are pooled. Referring to the lower right-hand side of FIG. 2, the numbers [4], [5], and [6] represent three different barcode sequences used to label the fourth fragments **110**. The labeled sequences are designated

US 10,227,648 B2

31

111. Optionally, adapter sequences (not shown) are used to make the fourth fragments 110 compatible for ligation with the barcodes. The barcoding is performed while the fragments are still partitioned, before pooling. The pooled bar-coded sequences are then sequenced.

The example above describes sequencing the barcoded second fragments separately from the barcoded fourth fragments. The barcoded second fragments and the barcoded fourth fragments may also be combined, and the combined sample may be sequenced. One or more steps of the process may be carried out in a device. The steps carried out in a device may be carried out in the same device or in different devices.

After sequencing, sequence contigs are assembled and the overlapping sequences between the second fragments and the fourth fragments are used to assemble the sequence of the genome.

Example 2: Pseudo-Random Fragmentation of Polynucleotides

A simulation was performed to evaluate the size distribution of fragments generated by a 6Mer cutter (StuI), a 4Mer cutter (CviQI), and two to seven 4Mer cutters. Random 1 Mbp DNA sequences were generated in silico and cuts were simulated based on the occurrence of the recognition sites for each of the restriction enzymes within the random sequences.

FIG. 3 shows the size distribution of a random 1 Mbp DNA sequence cut with the 6Mer cutter StuI (AGG/CCT). Fragments less than about 50 nucleotides were designated as “low yield,” because they underutilize the read length capacity of sequencing instruments. Fragments less than about 200 nucleotides were designated as fragments likely to provide the most accurate data from today’s sequencing technology. As described throughout this disclosure, this size range is in no way meant to be limiting, and the methods exemplified here, and described throughout this disclosure, may be used to generate fragments of any size range. Fragments from about 200 to about 400 nucleotides typically produce sequence data with systematic error for bases more than 100 bases from either fragment end. Fragments of more than about 400 nucleotides typically do not produce any useful sequence information for bases further than 200 bases from a fragment end, using today’s sequencing technologies. However, this is expected to change, and the methods presented herein can be used to generate sequences of this size or larger.

As shown in FIG. 3, 3 of 271 fragments (1.5%) were considered low yield since they were 50 bases or smaller. Fourteen fragments (5%) were considered high accuracy since they were 200 bases or smaller (i.e., each base of the fragment is within 100 bases of a restriction site and could be sequenced with high accuracy). Eleven fragments (4%) were between 200 and 400 bases and would generate data that is both accurate (0-100 bases from each end) and inaccurate (100-200 bases from each end). The remaining 246 fragments (91%) were greater than 400 bases and would generate accurate (0-100), inaccurate (100-200) and no (>200 bases from a restriction site) sequence data. Overall only 5% of the 1 Mbp random sequence was within 100 bases from a restriction site and would generate accurate sequence data.

FIG. 4 shows the results from a second simulation using the 4Mer cutter CviQI (G/TAC), instead of StuI (the 6Mer cutter described above) to simulate cutting a random 1 Mbp DNA sequence. As shown in FIG. 4, the use of a restriction

32

enzyme with a shorter recognition site results in more cuts, and the size distribution of the fragments is therefore shifted toward a smaller size range. In particular, as shown in FIG. 4, 18% of fragments were considered low yield since they were 50 bases or smaller. Thirty-eight percent of fragments were considered high accuracy since they were 200 bases or smaller (i.e., each base of the fragment was within 100 bases of a restriction site and could be sequenced with high accuracy). Twenty five percent of fragments were between 200 and 400 bases and would generate data that is both accurate (0-100 bases from each end) and inaccurate (100-200 bases from each end). The remaining fragments (37%) were greater than 400 bases and would generate accurate (0-100), inaccurate (100-200) and no (>200 bases from a restriction site) sequence data. Overall 56% of the 1 Mbp random sequence was within 100 bases from a restriction site and would generate accurate sequence data. Therefore, cutting the randomly generated 1 Mbp DNA sequence with CviQI resulted in a higher percentage of fragments with nucleotides within 100 nucleotides of a restriction site than cutting with StuI (i.e., 56% vs. 5%, respectively). Cutting with CviQI is therefore expected to provide more fragments that may be fully sequenced.

Next, simulated cuts were made in a random 1 Mbp DNA sequence using combinations of one to seven different 4Mer cutters. The 4Mer cutters were: (A) CviQI (G/TAC); (B) BfaI (C/TAG); (C) HinfI (G/CGC); (D) CviAII (C/ATG); (E) TaqAI (T/CGA); (F) MseI (T/TAA); and (G) MspI (C/CGG). The results of these simulations are shown in FIG. 5. As shown in FIG. 5, increasing the number of 4Mer cutter enzymes, from one to seven, increases the number of fragments with nucleotides within 100 nucleotides of a restriction site. Therefore, cutting the randomly generated 1 Mbp DNA sequence with more than one 4Mer cutter results in more fragments that may be fully sequenced than cutting with a single 4Mer cutter.

The number of enzymes used to cut a sequence can be chosen so that a particular fraction of a target nucleotide (e.g., a genomic) sequence within 100 nucleotides of a restriction enzyme is achieved. For example, the fraction of a random genome within 100 nucleotides of a restriction site for a 4Mer cutter is equal to $1-0.44^x$, where x is the number of independent 4Mer cutters. Similarly, the fraction of a random genome within 100 nucleotides of a restriction site for a 5Mer cutter is equal to $1-0.25^x$, where x is the number of independent 5Mer cutters. For a 6Mer cutter, the fraction of a random genome within 100 nucleotides of a restriction site is equal to $1-0.95^x$, where x is the number of independent 6Mer cutters.

Table 1 shows the percentage of sequences with a length greater than 100 nucleotides for each of the seven enzymatic treatments described above. These sequences are considered those likely to result in missing data. Increasing the number of enzymes decreases the percentage of sequences greater than 100 nucleotides. The number of enzymes and their restriction site recognition length may be chosen in order to minimize the loss of sequence information from sequences greater than 100 nucleotides from a restriction site while also minimizing the generation of sequences less than 50 nucleotides, which are undesirable because they underutilize the read length capacity of sequencing instruments. The presence of these fragments may be minimized or avoided by selecting restriction enzymes that cut more rarely but at the potential price of reduced sequencing coverage of the DNA (i.e., more fragments may have bases >100 bases from a restriction site). These fragments may also be physically removed by a size selection step. Since these fragments are

US 10,227,648 B2

33

small and some fraction of the bases represented in the small fragments may be covered in larger fragments from other enzymes, the effect on coverage would likely be minimal.

The exemplary 4Mer cutter methods presented herein are optimized to provide fragments compatible with current DNA sequencing technology, which may achieve accurate read lengths up to about 100 nucleotides from the terminus of a fragment. One of ordinary skill in the art will readily recognize that other restriction enzymes (e.g., 5Mer cutters, 6Mer cutters, etc.) would be suitable for DNA sequencing technologies capable of accurately reading larger fragments of DNA (e.g., 300-400, or more nucleotides). The methods presented in this disclosure are, of course generalizable, and may be used to obtain DNA fragments of any size distribution compatible with present or future sequencing technology.

TABLE 1

Percentage of random 1Mbp sequence more than 100 nucleotides from any restriction site. The letters in the first row refer to treatment with the following enzymes: (A) CviQI (G/TAC); (B) BfaI (C/TAG); (C) HinfI (G/CGC); (D) CviAII (C/ATG); (E) TaqOI (T/CGA); (F) MseI (T/TAA); and (G) MspI (C/CGG).						
A	AB	ABC	ABCD	ABCDE	ABCDEF	ABCDEFG
44.2%	20.1%	9.3%	4.2%	1.7%	0.6%	0.3%

Example 3: High Yield Adapter Ligation by Restriction Enzyme-Mediated Recycling of Undesirable Side Products

As described elsewhere herein, many downstream applications of the polynucleotide processing methods provided herein may utilize polynucleotide barcodes. An adapter may be used to provide compatible ends for the attachment of a barcode to a polynucleotide fragment (e.g., by ligation or PCR). In these cases, the desired products may be, for example:

[B]-[TPF]-[B], or

[B]-[A]-[TPF]-[A]-[B], where

[B] represents a barcode, [A] represents an adapter, and [TPF] represents a target polynucleotide fragment. However, in some cases, undesirable side products may form, for example, from the self ligation of barcodes, adapters, and/or target polynucleotide fragments. This example demonstrates one solution to this potential problem.

FIG. 6 shows a schematic of an implementation of the method described in this example. In the example shown in FIG. 6, three polynucleotide starting materials (Genomic DNA; Adapter 1; and Adapter 2) and three enzymes (MspI; NarI; and DNA Ligase) are contained within a partition. The restriction enzyme MspI (C/CGG) recognizes the CCGG sequence occurring within the Genomic DNA sequence and cuts the Genomic DNA sequence to generate a fragment of genomic DNA. If the reaction proceeds as intended, the fragment of genomic DNA is then ligated to Adapter 1 and Adapter 2, to generate a fragment of genomic DNA flanked by ligated adapters (FIG. 6, lower-left). This fragment with ligated adapters may then be ligated to DNA barcodes, which may also be present within the same partition (not shown).

However, the reaction described above may also result in several unwanted side products, including multimers produced by self-ligation of the fragmented genomic DNA and adapters (or other molecules, such as barcodes, which are not shown). For the sake of simplicity, FIG. 6 illustrates this concept by showing only self-ligation of fragmented genomic DNA and adapters.

34

One unwanted side product is a multimer of genomic DNA fragments. This may occur, for example, if genomic DNA fragments with compatible ends are ligated to each other after cutting. In FIG. 6, cutting of Genomic DNA with MspI generates compatible ends that may be ligated by the ligase present in the partition. Similarly, Adapter 1 and Adapter 2, as shown, have compatible ligatable ends, and may also be ligated to form multimers.

As indicated in FIG. 6, one solution to this problem is to pair one enzyme (in this example, MspI) with a second enzyme (in this example, NarI). In this example, MspI re-cuts genomic DNA multimers produced by self-ligation of genomic DNA fragments. Therefore, MspI recycles unwanted genomic DNA fragment multimers back into genomic DNA fragments, which may then be correctly ligated to the adapters. Similarly, NarI cuts multimers of

Adapter 1 and Adapter 2 into monomers of Adapter 1 and monomers of Adapter 2, which may then be correctly ligated to genomic DNA fragments. This recycles unwanted adapter multimers back into the desired starting materials of Adapter 1 and Adapter 2.

The enzymes are chosen such that the desired product (i.e., the genomic DNA fragment with adapters on each end) does not contain a recognition site for either enzyme. Therefore, the product will not be re-cut by any enzyme contained within the partition. This process increases the yield of the desired product, while minimizing the number of unwanted side products and reducing the amount of starting material required to produce a desired amount of a product. As described in this disclosure, a pair of enzymes may be chosen so that one enzyme recognizes one undesirable side-product and regenerates a starting material and another recognizes another undesirable side product and regenerates another starting material, but neither enzyme recognizes the desired product. This can be done for an unlimited number of side products.

In general, one strategy for selecting such pairs is to choose two enzymes that create identical (or similar, ligatable) termini after cutting, but have recognition sequences of different lengths. FIG. 7 shows examples of such pairs of enzymes. The enzymes provided in FIG. 7A provide sticky ends, while those provided in FIG. 7B provide blunt ends.

The exemplary embodiment shown in FIG. 6 uses Genomic DNA and two adapters (Adapter 1 and Adapter 2) as starting materials. Therefore, in this embodiment, MspI is used not only to regenerate genomic DNA fragments after self-ligation, but also to generate the genomic DNA fragments in the first place, from Genomic DNA. Of course, this is optional, as one may introduce pre-fragmented genomic DNA into the partition and the method is still applicable.

Similarly, the embodiment shown in FIG. 6 shows two separate adapter molecules as starting materials. Adapter molecules may also be provided as a single polynucleotide sequence which is then cut by an enzyme contained within the partition (in this example, NarI) to generate ligation

US 10,227,648 B2

35

compatible ends for attachment to the fragmented genomic DNA. The method is also applicable to other polynucleotides described throughout this disclosure and to methods of attachment based on techniques other than ligation (e.g., attachment of an adapter or a barcode by PCR).

Pseudo-complimentary nucleotides that preferentially bind natural nucleotides over themselves (e.g., *Biochemistry* (1996) 35, 11170-11176; *Nucleic Acids Research* (1996) 15, 2470-2475), may also be used to minimize or avoid the formation of certain multimers, for example adapter-adapter multimers and barcode-barcode multimers. If adapters and/or barcodes (and/or other polynucleotides) are synthesized using pseudo-complimentary nucleotides, they will prefer to hybridize with naturally occurring polynucleotide fragments (e.g., genomic DNA fragments) rather than themselves, therefore leading to a higher yield of the desired product.

Example 4: Provision of Reagents in Microcapsules and Directly in Microwells

As described throughout this disclosure, the polynucleotide processing methods described herein may involve the treatment of partitioned polynucleotides with a variety of reagents. These reagents may include, for example, restriction enzymes, ligases, phosphatases, kinases, barcodes, adapters, or any other reagent useful in polynucleotide processing or in a downstream application, such as sequencing. FIG. 8 shows two exemplary methods of providing reagents. On the left-hand side of FIG. 8, reagents are provided within a microcapsule. The microcapsule that is shown in FIG. 8 has an outer shell ("3"), an intermediate non-aqueous layer ("2") and an inner aqueous drop contained within the intermediate non-aqueous layer ("1ABC+RE"). This droplet is made by a water-oil-water emulsion technique followed by polymerization of the outermost water layer ("3") to form a shell. Reagents are contained within the inner aqueous phase of the capsule. The left-hand side of FIG. 8 shows an exemplary embodiment with four reagents contained within the aqueous phase of the capsule, namely three barcode reagents (1A, 1B, and 1C), and a restriction enzyme ("RE"). The embodiment shown is merely exemplary. The reagents may be located in any part of the capsule.

The capsule is dispensed into a partition (e.g., a microwell). A target polynucleotide and a ligase are then added to

36

the partition. The capsule is made to release its contents by exposure to a stimulus, such as a change in temperature, a solvent, or stirring. The restriction enzyme fragments the target polynucleotide and the ligase attaches the barcode reagents to the target polynucleotide fragments generated by the restriction enzyme.

The restriction digestion and ligation may proceed according to any of the methods described herein, for example by non-overlapping fragmentation techniques, by pseudo-random fragmentation methods, and/or by pairing of restriction enzymes to recycle unwanted side products into new starting products (e.g., target polynucleotide fragments and barcodes). Adapters may also be included within the microcapsule. The barcodes shown in FIG. 8 are modular. For example, barcode components 1A, 1B, and 1C may ligate to form barcode: [1A]-[1BH1C].

The right-hand side of FIG. 8 shows the same reagents dispensed into a microwell, followed by sealing with sealant (e.g., a wax or oil), to prevent evaporation before use. This approach may be substituted for the approach described above, where the reagents are placed within microcapsules. Both approaches are used to produce partitions (e.g., microwells) pre-loaded with reagents for DNA fragmentation and barcoding. In order to fragment and barcode DNA using reagents dispensed within a microwell, a user unseals a partition, and introduces a target polynucleotide and a ligase (or any other reagents applicable for the method the user is conducting). As described above, the restriction enzyme fragments the target polynucleotide and the ligase attaches the barcode reagents to the target polynucleotide fragments generated by the restriction enzyme. Of course, both approaches may be combined by placing certain reagents in the microwell and others in the microcapsule.

While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 13

<210> SEQ ID NO 1

<211> LENGTH: 13

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic oligonucleotide

<220> FEATURE:

<221> NAME/KEY: modified_base

<222> LOCATION: (5)..(9)

<223> OTHER INFORMATION: a, c, t, g, unknown or other

<400> SEQUENCE: 1

ggccnnnnng gcc

13

<210> SEQ ID NO 2

<211> LENGTH: 12

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

US 10,227,648 B2

37

38

-continued

```

<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      oligonucleotide
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (4)..(8)
<223> OTHER INFORMATION: a, c, t, g, unknown or other

<400> SEQUENCE: 2

caannnnngt gg                                     12

<210> SEQ ID NO 3
<211> LENGTH: 14
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      oligonucleotide
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (4)..(10)
<223> OTHER INFORMATION: a, c, t, g, unknown or other

<400> SEQUENCE: 3

gaannnnnnn ttgg                                    14

<210> SEQ ID NO 4
<211> LENGTH: 13
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      oligonucleotide
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (5)..(10)
<223> OTHER INFORMATION: a, c, t, g, unknown or other

<400> SEQUENCE: 4

gaacnnnnnn tcc                                     13

<210> SEQ ID NO 5
<211> LENGTH: 13
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      oligonucleotide
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (5)..(10)
<223> OTHER INFORMATION: a, c, t, g, unknown or other

<400> SEQUENCE: 5

gaagnnnnnn tac                                     13

<210> SEQ ID NO 6
<211> LENGTH: 12
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      oligonucleotide
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (5)..(9)
<223> OTHER INFORMATION: a, c, t, g, unknown or other

<400> SEQUENCE: 6

gaacnnnnnc tc                                      12

```

US 10,227,648 B2

39

40

-continued

```

<210> SEQ ID NO 7
<211> LENGTH: 13
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      oligonucleotide
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (5)..(10)
<223> OTHER INFORMATION: a, c, t, g, unknown or other

<400> SEQUENCE: 7

gaacnnnnnn tac                                     13

<210> SEQ ID NO 8
<211> LENGTH: 11
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      oligonucleotide

<400> SEQUENCE: 8

atcctttaag c                                       11

<210> SEQ ID NO 9
<211> LENGTH: 11
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      oligonucleotide

<400> SEQUENCE: 9

ggatcaagct a                                       11

<210> SEQ ID NO 10
<211> LENGTH: 11
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      oligonucleotide

<400> SEQUENCE: 10

aaattcggc a                                       11

<210> SEQ ID NO 11
<211> LENGTH: 28
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      oligonucleotide
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (1)..(5)
<223> OTHER INFORMATION: a, c, t, g, unknown or other
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (10)..(19)
<223> OTHER INFORMATION: a, c, t, g, unknown or other
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (24)..(28)
<223> OTHER INFORMATION: a, c, t, g, unknown or other

<400> SEQUENCE: 11

nnnnnccggn nnnnnnnnnc cggnnnnn                                     28

```

US 10,227,648 B2

41

42

-continued

```

<210> SEQ ID NO 12
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      oligonucleotide
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (1)..(5)
<223> OTHER INFORMATION: a, c, t, g, unknown or other
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (12)..(16)
<223> OTHER INFORMATION: a, c, t, g, unknown or other

```

```

<400> SEQUENCE: 12

```

```

nnnnnnggcgc cnnnnn

```

16

```

<210> SEQ ID NO 13
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      oligonucleotide
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (1)..(5)
<223> OTHER INFORMATION: a, c, t, g, unknown or other
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (11)..(20)
<223> OTHER INFORMATION: a, c, t, g, unknown or other
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (26)..(30)
<223> OTHER INFORMATION: a, c, t, g, unknown or other

```

```

<400> SEQUENCE: 13

```

```

nnnnnnggcgg nnnnnnnnnn cgcnnnnnn

```

30

What is claimed is:

1. A system for nucleic acid processing, comprising: a microwell array comprising 1,000 microwells configured to partition a plurality of polynucleotide molecules, a plurality of beads, and a plurality of barcode molecules in the 1,000 microwells of the microwell array, wherein the plurality of barcode molecules comprises a plurality of barcode sequences that are different across the 1,000 microwells, and wherein a microwell of the microwell array comprises: (i) a polynucleotide molecule from the plurality of polynucleotide molecules; and (ii) a barcode molecule from the plurality of barcode molecules, wherein the barcode molecule is attached to a bead from the plurality of beads and comprises a barcode sequence from the plurality of barcode sequences.
2. The system of claim 1, further comprising a sequencer that generates sequences of the plurality of polynucleotide molecules or derivatives thereof.
3. The system of claim 1, wherein the plurality of beads is a plurality of solid particles.
4. The system of claim 1, wherein the plurality of beads is a plurality of gel beads.
5. The system of claim 1, wherein the microwell comprises a cell comprising the polynucleotide molecule from the plurality of polynucleotide molecules.

40

6. The system of claim 1, wherein the microwell comprises a reducing agent.

45

7. The system of claim 1, wherein the barcode molecule comprises a sequence complementary to a sequence of the polynucleotide molecule.

50

8. The system of claim 1, wherein the plurality of polynucleotide molecules comprises polynucleotide molecules with overlapping sequences.

55

9. The system of claim 1, wherein the microwell comprises an antibody.

60

10. The system of claim 1, wherein the microwell comprises multiple barcode molecules from the plurality of barcode molecules, wherein the multiple barcode molecules comprise the barcode molecule.

65

11. The system of claim 10, wherein each of the multiple barcode molecules comprises the barcode sequence.

12. The system of claim 1, wherein the 1,000 microwells are a subset of microwells of the microwell array.

70

13. The system of claim 12, wherein at least one microwell of the microwell array does not include a barcode molecule from the plurality of barcode molecules or a polynucleotide molecule from the plurality of polynucleotide molecules.

75

14. The system of claim 1, wherein the microwell of the microwell array is configured to accommodate a volume of less than about 500 nanoliters (nL).

80

15. The system of claim 1, wherein the microwell array comprises at least 5,000 microwells.

US 10,227,648 B2

43

16. A system for nucleic acid processing, comprising:
 a microwell array comprising a plurality of microwells
 configured to partition a plurality of beads and a
 plurality of cells;
 wherein the plurality of microwells comprises 1,000
 microwells;
 wherein a microwell of the plurality of microwells is
 configured to accommodate a volume of less than about
 5 nanoliters (nL); and
 wherein the system is configured to partition the plurality
 of cells, the plurality of beads, and a plurality of
 barcode molecules into the plurality of microwells such
 that the plurality of barcode molecules comprises a
 plurality of barcode sequences that are different across
 microwells of the microwell array, and wherein the
 microwell is configured to comprise: (a) a cell of the
 plurality of cells; and (b) a bead of the plurality of
 beads.

17. The system of claim 16, wherein the plurality of
 barcode molecules is attached to the plurality of beads.

18. The system of claim 17, wherein the bead of (b) is
 attached to a barcode molecule of the plurality of barcode
 molecules and comprises a barcode sequence that is different
 from barcode sequences of other barcode molecules attached
 to other beads in the microwells.

19. The system of claim 16, further comprising a
 sequencer that generates sequences of the plurality of bar-
 code molecules or derivatives thereof.

20. The system of claim 16, wherein the plurality of beads
 is a plurality of solid particles.

21. The system of claim 16, wherein the plurality of beads
 is a plurality of gel beads.

22. The system of claim 16, wherein the microwell further
 comprises a reducing agent.

23. The system of claim 16, wherein the microwell of the
 microwell array comprises an antibody.

24. The system of claim 16, wherein the microwell array
 comprises 10,000 microwells and wherein the microwell is
 configured to comprise: (a) the cell of the plurality of cells;
 and (b) the bead of the plurality of beads.

25. The assay of claim 16, wherein at least one microwell
 of the plurality of microwells does not include a barcode
 molecule from the plurality of barcode molecules or a cell
 from the plurality of cells.

26. A microwell array, comprising:
 a plurality of microwells comprising a plurality of cells
 and a plurality of beads;
 wherein the plurality of beads comprises a plurality of
 barcode molecules;
 wherein the plurality of microwells comprises 1,000
 microwells;
 wherein the plurality of barcode molecules comprise a
 plurality of barcode sequences that are different across
 the 1,000 microwells;
 wherein a microwell of the plurality of microwells is
 configured to accommodate a volume of less than about
 5 nanoliters; and
 wherein the microwell comprises: (a) a cell of the plu-
 rality of cells; and (b) a bead of the plurality of beads,
 wherein the bead is attached to a barcode molecule of
 the plurality of barcode molecules.

27. The microwell array of claim 26, wherein the barcode
 molecule attached to the bead of (b) comprises a barcode

44

sequence that is different from barcode sequences of barcode
 molecules attached to other beads in microwells of the
 plurality of microwells.

28. The microwell array of claim 26, wherein the plurality
 of beads is a plurality of solid particles.

29. The microwell array of claim 26, wherein the plurality
 of beads is a plurality of gel beads.

30. The microwell array of claim 26, wherein the microw-
 ell comprises a reducing agent.

31. The microwell array of claim 26, wherein the microw-
 ell comprises an antibody.

32. The microwell array of claim 26, wherein at least one
 microwell does not include a barcode molecule from the
 plurality of barcode molecules or a cell from the plurality of
 cells.

33. The microwell array of claim 26, wherein the plurality
 of microwells comprises 10,000 microwells and wherein the
 microwell comprises: (a) a cell of the plurality of cells; and
 (b) a bead of the plurality of beads.

34. The system of claim 1, wherein the polynucleotide
 molecule does not include a barcode sequence, and wherein
 the polynucleotide molecule is hybridized to the barcode
 molecule.

35. The system of claim 1, wherein the bead in the
 microwell is not attached to an amplification product of the
 polynucleotide molecule.

36. The system of claim 18, wherein the cell comprises a
 plurality of polynucleotide molecules, and wherein the bar-
 code sequence comprises a sequence that is complementary
 to a sequence of a polynucleotide of the plurality of poly-
 nucleotide molecules.

37. The system of claim 14, wherein the microwell is
 configured to accommodate a volume of less than about 200
 nL.

38. The system of claim 37, wherein the microwell is
 configured to accommodate a volume of less than about 100
 nL.

39. The system of claim 38, wherein the microwell is
 configured to accommodate a volume of less than about 50
 nL.

40. The system of claim 39, wherein the microwell is
 configured to accommodate a volume of less than about 25
 nL.

41. The system of claim 40, wherein the microwell is
 configured to accommodate a volume of less than about 10
 nL.

42. The system of claim 41, wherein the microwell is
 configured to accommodate a volume of less than about 5
 nL.

43. The system of claim 15, wherein the microwell array
 comprises 2,500 microwells.

44. The system of claim 43, wherein the microwell array
 comprises 5,000 microwells.

45. The system of claim 44, wherein the microwell array
 comprises 7,500 microwells.

46. The system of claim 45, wherein the microwell array
 comprises 10,000 microwells.

47. The system of claim 16, wherein the microwell
 comprises the cell of the plurality of cells and the bead of the
 plurality of beads.

* * * * *